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The value of knowledge
Peter is a clinical research manager at a pharmaceutical company and his
current job is to set up a clinical development program for a new promising
antipsychotic drug. His plan is to perform phase i studies in healthy volun-
teers (single ascending dose/multiple ascending dose/drug metabolism
studies/food interaction), followed by phase ii trials in well defined small
groups of patients to select the optimal dose which he intends to use in the
large phase iii trials.
John just started working at the same company after having worked as an
academic neurologist and he is unsure if the drug will penetrate the brain.
Therefore, he has suggested adding a brain imaging study with positron
emission tomography (pet) study immediately after the first study in man.
This will require the development of a special radioactive labelled molecule
and may delay the project by more than a year. John and Peter have discus-
sed this with their manager. They have a short meeting about this during
which the research director shows a spreadsheet (table 1).
table 1 Project valuation by Net Present Value (npv)
Peter’s plan (xM$)
Out 1 2 4 20 30 40 0 0 0
In 0 0 0 0 0 0 100 100 300
Balance -1 -2 -4 -20 -30 -40 100 100 300
John’s plan (xM$)
Out 1 2 2 4 20 30 40 0 0 0
In 0 0 0 0 0 0 0 100 100 300
Balance -1 -2 -2 -4 -20 -30 -40 100 100 300
Net Present Value ( npv)
Peter’s plan (xM$) 241
John’s plan (xM$) 226
Difference (xM$) 15
“Sorry John but as you can see there is no chance we will do this. Delaying
the project will not only cost us two million dollars extra, but worse, you
reduce the value of our project by 15 million. I know that the board is unlikely
to allocate enough priority to this project so we probably have to cancel 
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it altogether. Anyway, we will have to assess the efficacy of the new drug 
in the phase ii studies in the patients. Also, John, please remember that we
are a commercial company. Our job is to make money -not write interesting
papers. With a planned yearly turnover of about 500 million dollars this is
what I see as the cost of a year’s delay!”
John feels there is something wrong with the logic of this reasoning and
ponders two possible scenarios. Of course the drug may be developed
according to Peter’s plan, but what if the drug does not penetrate the blood
brain barrier? In that case the first indication of this will only come in
expensive phase ii or iii trials.
table 2 Recalculation of the plans for the scenario that the drug does not penetrate 
the brain.
Peter’s plan (xM$)
Out 1 2 4 20 30 40 0 0 0
In 0 0 0 0 0 0 0 0 0
Balance -1 -2 -4 -20 -30 -40 0 0 0
John’s plan (xM$)
Out 1 2 2 4 0 0 0 0 0 0
In 0 0 0 0 0 0 0 0 0 0
Balance -1 -2 -2 -4 0 0 0 0 0 0
Net Present Value (npv)
Peter’s plan (xM$) (74)
John’s plan (xM$) (8)
Difference (xM$) (66)
John wants to convince his boss that in the latter case, his development plan
would have saved considerably more resources than Peter’s. While the initial
value of his plan was lower according to his boss’s estimation, he feels the
project valuation did not adequately value the contents of his program or 
the value of the early discontinuation of the development. He is not quite
sure why the calculation of the Net Present Value of his plan does not seem
to reflect exactly what he sees as value. He manages to get his manager’s
spreadsheet and recalculates it for the situation that the project is discon-
tinued after Phase iii for Peter’s plan because the drug is not effective in
schizophrenia. In John’s plan the pet study may have given unequivocal
evidence that the drug does not get into the brain and the project is stopped
immediately after the pet study (Table 2). To his surprise this shows a very
different picture. Now the value of both projects is negative because there 
is no income anymore but Peter’s plan produces much more negative value
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than his does! John goes back to the research director and presents this
again. “John, my dear fellow, you seem to be making an academic exercise
out of everything you do! I do not rate the probability that this happens very
high. You would be best advised to just do what you are paid for- show that
our new drugs work in patients.”
John is disappointed. His boss obviously judges the probability of certain
scenarios differently, but why? It surely can’t be as black-and-white as this?
How can he find a way to communicate with his colleagues about these
matters? John leaves the office and wonders how he can express all these
different facts so that his point does become clear -he has never been the
type that gives up easily.
Problem with modern drug 
development
Every year 200.000 compounds are examined on potential medicinal
properties worldwide. About twenty new drugs are introduced every year.
This implies that one in ten thousand compounds make it through the drug
development program. The discovery and development of new medicines is
an expensive and time-consuming process. It takes an average of 12-15 years
to discover and develop a new medicine. Most of that time is spent testing
the drug to make sure it is safe. The average cost of bringing one new
medicine to market in 1990 was estimated at $500 million. The Tufts
University Center for the Study of Drug Development found that the time
from synthesis of a new drug to marketing approval has increased over time.
While in the 1960s the approximate time from synthesis to approval was
about 8 years, this has increased to 14.2 years in the 1990s. Recent figures
show that although pharmaceutical companies spend more on research 
and development of new drugs, the number of new compounds launched
decreases (Figure 1). There is no denying that many of the diseases that
fuelled the enormous explosion in profit and turnover of the pharmaceutical
industry in the 1980’s and 90’s (like asthma and gastric ulcers) are now well
controlled and this reduces the potential added value of any new treatment.
Furthermore, the many diseases that remain inadequately treated are
chronic with complex pathophysiology and difficult outcome measurements.
Good examples are neuro-psychiatric diseases or cancer. Therefore, pharma-
ceutical companies need to rely on a few highly successful products to fund
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that it is increasingly difficult to develop new drugs for the treatment of the
complex diseases that remain inadequately treated. To limit the costs of 
drug development it pays to discontinue failures as early as possible.
figure 1 Growing drug development costs and declining number of registrations of new 
drugs
In order to cope with this changing perspective, several attempts are made to
optimise the development of new drugs:
Target optimisation
Several individual approaches are introduced to optimise the process of
identifying new lead compounds both in quantity and selectivity:
• Computer aided drug design
The use of computational techniques to design and optimise molecular
targets has increased the number of new chemical entities (nce’s).
Furthermore, the selectivity of the nce’s is enhanced by evaluating and
optimising the binding affinity to selected targets in situ.
• Combinatorial chemistry
Combinatorial chemistry techniques (often automated using synthesis
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robots) have facilitated and increased the number of synthesised nce’s with 
potential biological activity.
• High throughput screening
The increased number of synthesised compounds is easily screened using
molecular biological techniques usually referred to as high throughput
screening. This usually implies that several hundreds of related compounds
can be simultaneously screened for activity at receptor level using
fluorescent activation markers. Therefore, the most potent compounds at
receptor level can be selected from the wide range of available compounds.
• Genomics
The availability of the human genome has generated a wealth of new possi-
bilities for new drug targets. New insights to the origin of complex diseases
are under investigation. Furthermore, gene chips are available to evaluate the
effects of new drugs at dna/rna/protein production level providing more
detailed knowledge on the mechanism of action of new and existing drugs.
There is no doubt that these approaches are producing many molecules that
bind to biological targets. However, for these to be successful as medicines
much more is needed. New drug targets do not necessarily mean that the
relation of these to disease is well understood and realising this understan-
ding may be very time consuming. An immediate payback of these
techniques is therefore not expected.
Process optimisation
Optimisation of the discovery of new drugs is complemented by optimisation
of the development process. 
• Optimisation of resources 
Pharmaceutical companies have merged in an effort to increase the company’s
pipeline of new investigational drugs and to combine expertise on different indi-
cation areas as well as reduce overhead costs. This has largely failed from this
point of view. The percentage of turnover spent on research and development
has remained constant for companies before and after mergers. This gives no
indication of any economy of scale. Clearly there may have been other advanta-
ges of the increased market share that are beyond the scope of this paper.
• Rigorous selection of investigational new drugs
Identifying and stopping development of drugs that will fail to reach
registration as soon as possible once it has entered the clinical development
phase is highly rewarding. For this reason, more and more effort is put in early
selection of the compounds.
ref. 4
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• Inclusion of biomarkers for effects in an early phase
Part of the early selection and cost reduction is the inclusion of biomarkers at
an early stage and introduction of early proof of principle or proof of concept
studies.
• Project value estimation and portfolio analysis
In order to select the most profitable project within a company’s pipeline,
each project is valuated in advance, usually using Net Present Value (npv;
see box 1) calculations. The highest npv is achieved by projects with the
highest estimated market value combined with the lowest development
costs and shortest time to registration. Throughout the development process
the milestones to monitor the project progress are usually defined by the
classical development phases 1 (small healthy volunteer studies on safety,
kinetics and tolerability), 2 (small patient population studies on mechanism
of action and therapeutic window) and 3 (large multi centre trials to confirm
efficacy and safety). A description of these clinical phases by the us Food 
and Drug Administration (fda) is given in box 2.
Because Peter’s program optimised many procedural aspects of the
development including time and costs, his project had a high npv as
estimated by his boss. John assumed that the bottleneck for the potential
antipsychotic could be the penetration in the brain and he proposed to spend
additional time and money to get an early confirmation of the critical
question. Subsequently, the npv of his project was lower than Peter’s but 
it was unclear to them how to value the early increase of critical knowledge.
For some reason they communicated about procedural aspects but seemed
to lack a device to communicate about the content of their project. Whilst
the procedural aspects were covered by numbers any discussion about the
probabilities of certain events occurring was done intuitively.
Improving the discovery or the process has not resolved the main problem of
the apparent slack in drug innovation. One of the matters that has not been
dealt with is the integration of both procedural and knowledge aspects of
drug development. We therefore postulate a question-based approach to
drug development that integrates the two into a comprehensive concept.
Question-based development (QBD)
During the classical phases 1 to 3 (and 4), a number of generic questions
need to be answered (Figure 2). The detailed questions have to be deter-
mined on a case-by-case basis but the questions groups may give some
structure to the list.
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1 Does the biologically active compound/active metabolites get to
the site of action?
This main generic question contains several issues that need to be deter-
mined such as absorption, distribution, metabolism and excretion of the
drug. Not only the parent compound, but also any possible active metabo-
lites should be included in answering this question. Additional items can 
be relevant for certain drugs such as ability to penetrate the blood-brain-
barrier for cns active drugs. Unexpected biologically active metabolites 
can be formed in vivo, or unexpected sites of action can be discovered, 
which should be incorporated in this main question as soon as observed.
2 Does the compound cause its intended pharmacological /
functional effect(s)?
Answering this question includes the demonstration of the mechanism of
action of the investigational drug. For example a new drug for hyperlipidemia
will at least have to reduce the plasma cholesterol in a dose or plasma
concentration dependent manner.
3 Does the compound have beneficial effects on the disease 
or its pathophysiology?
This question reflects the question traditionally answered in the classical
phase 3 studies to establish the effects on the disease but also the alteration
of other physiological systems resulting in clinical side-effects. 
4 What is the therapeutic window of the new drug?
The therapeutic window of each investigational drug needs to be established
in order to select the optimal dose that is clinically efficacious at tolerated
levels. This question includes important sub-questions: Which dose regimen
will keep the drug’s concentration within the therapeutic window? What is
the optimal dosing interval relative to the intended indication (chronicity of
intended drug exposure)? Can controlled drug delivery improve the product’s
action? What is the forgiveness of the product (i.e. the difference between
the product’s post-dose duration of effective therapeutic action and the
recommended interval between doses)?
5 How do the sources of variability in drug response in the target
population affect the development of the product?
The sources of variability in drug response have been defined as: Dose
(formulations and compliance), Pharmacokinetics (absorption, distribution,
metabolism and elimination), Pharmacodynamics (sensitivity, maximum
response) and other (disease, other drugs, circadian rhythms). The main
question should include: Are there any specific factors in the target
population that may affect dosage? A general sub-question can be: is there
any food-interaction with this compound? But also more drug/population
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target population may require extra drug interaction studies.
Ethnopharmacological issues and pharmacogenomics can play a key role in
some development programs (e.g. for introduction of a ‘western’ drug in
Japan).
figure 2 Schematic representation of the course of action of drugs (from administration 
to effects) and the questions from the question-based development plan
One question can be concealed in several studies and one study can provide
partial answers to multiple questions. However, when a project is monitored
by its progression through the traditional phases, little is learned about what
questions are actually being answered. Managers will have to assume this is
being done adequately. The first time the answers are sometimes critically
examined is by the regulatory authority that has to give approval for
marketing. Extreme disappointments and losses can occur in such cases. 
In 2002 the company Bristol Myers Squibb paid several billion dollars for 
a small biotech company Imclone with an interesting anticancer agent
(Erbitux). A fee of 200 million dollars was paid when the dossier was sent 
15 introduction and outline of this thesis – chapter 1
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to the fda who subsequently judged the data to be insufficient. The details
will probably never be known but the questions lingers how experienced drug
developers at bms were able to miss something that was found after review
of the dossier by the fda.
The question-based approach is designed to make the central issue in drug
development projects explicit rather than implicit. This central issue can be
described concisely as “Are all the relevant questions asked and answered
adequately?” If so, a regulatory authority can confidently give market
authorisation. During the development period, managers can monitor the
progress of the study by the questions that are answered and the length of
the remaining list. Obviously, it remains important to answer these questions
as rapidly and as cheaply as possible, but the tools for doing so should be in
place in any sensible company.
qbd assumes that the costs of an answer and the probability an answer 
can be given adequately can be estimated. These probabilities and costs 
can be estimated using either expert opinions or historical data. Subsequent
sensitivity analysis can reveal the relative impact of the estimations on the
project value. Each set of probabilities and costs (combined with market
value) will have its own optimal priority sequence. Therefore, early evaluation
figure 3 Question-based drug development plan
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studies on the most critical questions are highly rewarding, since these
prevent expenditure on projects that are unlikely to produce a positive cash
flow. npv analysis just indicates that such evaluation studies only cost time
and money. npv calculation inadequately values the increases in knowledge.
The option-based theory takes such probabilities of success into account.
However, this method is rarely used and if so, it uses the classical phases of
drug development as decision points (or knots in the project’s decision tree).
These phase definitions are not relevant as drug development targets but are
merely classifications based on the type and number of patients involved in
such studies. 
We therefore propose a question-based approach that uses decision points
that are relevant to the development of knowledge in the drug development 
process (the five standard questions). The question-based approach now 
moves one closer to an adequate reflection of true risks and values of the
uncertainties that are faced during the development of a new drug. 
Additionally, the question-based approach can demonstrate how the project
value varies with increased knowledge generated by early evaluation studies.
The unique combination of probabilities on successfully answering the
question in combination with the costs (and market value) determines 
the optimal development strategy that varies for each drug. Furthermore, 
it displays the bottlenecks within the development and can contribute
substantially to the early discontinuation of failures. The estimation of the
market value of the new drug can be less accurate in this question-based
approach as long as the market value far outweighs the costs. As the
probability of successfully answering the questions is determined both by 
the compound’s potential and the availability of methods to demonstrate
effects, the question-based approach incorporates the value of both
knowledge about methodology and additional early evaluation studies
contrary to conventional npv calculations.
If John and Peter’s boss had used the question-based approach to develop
the antipsychotic drug, he would have estimated the probabilities and costs
of answering the questions. He would have wanted the input from his fellow
project team member’s (including pre-clinical scientists as well as John and
Peter) opinion on the compounds potential and the availability of adequate
methods to successfully answer the questions. Together, they might have
reached consensus that the ‘site of action’ question for the potential anti-
psychotic had the lowest probability of success and therefore, this question
would have required the highest priority in the program. The addition of
John’s suggested pet study combined with the ‘traditional’ phase i studies
would have adequately answered the ‘site of action’ question at the earliest
possible stage. The question-based approach to drug development is
especially valuable for stopping development of drugs that have a high
probability of failing by identifying the critical issues that will lead to the
discontinuation and dealing with these first. Early discussions about
probabilities are also an excellent device to promote communication about
critical issues within the project team and to higher management.
The decision analysis tree shown in figure 3 now shows Peter’s plan with 
the probabilities as estimated by the team. The input parameters for the
development plan are shown in table 3. The team has decided that the
overall probability the compound will make it to registration is comparable 
to the historical probability of a drugs making it through the clinical phases;
i.e., about 30%. They used the cost and payoff estimates from the npv
calculations: total development costs will be M$ 97 and the payoff will be 
M$ 500.
Decision analysis revealed that the estimated project value taken these
success probabilities into account would be M$ 90.1. According to the
original npv analysis, addition of the pet study according to John’s
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suggestion would increase the overall costs with M$ 2. A lively discussion
begins in the team how the input parameters will change if the pet study is
performed. One team member argues that the probability that too low a dose
will be selected for further development is substantially decreased if the pet
study is performed. The team agrees with the assumption that with this
study a dose can be found that shows minimum receptor occupancy. 
table 3 Input parameters for Peter’s development program
Parameter Value
Success action site 80%
Success pharmacological effect 75%
Success clinical efficacy 65%
Success therapeutic window 85%
Success population 90%
Costs action site 12 M$
Costs Pharmacological effect 19 M$
Costs Clinical effect 35 M$
Costs Clinical window 14 M$
Costs Population 17 M$
Estimated marketvalue 500 M$
According to the literature, lower than 90% occupancy can not have any
clinical effect. This consideration would increase the probability that clinical
effects will be observed with the selected dose and the successful defining 
of the therapeutic window will also be enhanced because the lower limit is
determined. The team does not want to be too optimistic towards
management so they decide to increase the estimated probabilities of
success on both the ‘clinical’ and the ‘window’ question both with only 
1%. The additional costs of the pet study are divided amongst the ‘clinical’
(M$ 36) and ‘window’ (M$ 15) questions. The project value is recalculated
and instead of the loss of M$ 15 according to the npv analysis, the estimated
value is increased with M$ 2.6 to M$ 92.7!!
John decides to investigate how much more costs can be introduced in
Peter’s plan if the success probabilities are affected more than the estimated
1%. He calculates the project value for a series of different success probability
combinations. He varies both the ‘clinical’ and the ‘window’ question up to 
± 10% of the base values. This two-way sensitivity analysis is displayed in
table 4. John realises that his gut feeling that Peter runs a higher risk to lose
relatively large amounts compared to his plan is confirmed by this analysis.
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John and Peter needed some time to explain their question based plan and
the decision analysis that demonstrated that an early pet study actually had
a high probability to be very cost effective. However, management agreed in
the end. It was agreed to add a question-based Gantt chart to the traditional
project and regularly review the progress in answering questions as well as
the conventional progress in the studies. 
table 4 Break-even table for success probabilities ‘clinical’ and ‘window’; the bold 
project value is the expected value for 1% increase in both probabilities
Success probability ‘window’
Success 0.77 0.79 0.81 0.83 0.84 0.86 0.88 0.89 0.91 0.93 0.95
probability 
‘clinical’
0.59 67 69 71 73 76 79 81 84 87 89 92
0.61 70 72 74 76 79 81 84 87 90 92 95
0.62 72 74 77 79 81 84 87 90 93 95 98
0.63 75 77 79 82 84 87 90 93 96 98 101
0.65 78 80 82 85 87 90 93 96 99 102 105
0.66 80 83 85 88 90 93 96 99 102 105 108
0.67 83 85 88 90 93 96 99 102 105 108 111
0.69 86 88 90 93 96 99 101 105 108 111 114
0.70 88 91 93 96 99 102 104 107 111 114 117
0.71 91 93 96 99 102 104 107 110 114 117 120
0.73 94 96 99 102 105 107 110 113 117 120 123
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box 1 net present value calculation
The Net Present Value (npv) of a project is calculated by adding the present value of all future
cash flows and subtracting the initial investments. The calculation of the present value is
performed by discounting the future cash flows with a percentage, which reflects the required
return of investment of the project according to the following formula:
n
npv = ∑ cf (t)
t=0 (1+i)t
Where
npv= Net Present Value; cf(t) = Cash flow in period t (including investments), incoming +,
outgoing –; t = Period; n = Number of periods; i = Required return of investment (or discount
factor)
The npv assumes an incremental cash flow. Therefore, the npv calculation compares 
the situation where the project is performed and the situation that results if the project 
is cancelled. If the npv of a project is positive, the project adds value to the company and 
is therefore worthwhile.
npv calculation requires the a priori determination of the required return of investment. 
This factor correlates with the risk associated with the investment in the project. The higher 
the risk of the investment, the higher the return of investment should be. Usually, the discount
factor is determined using the Weighted Average Cost of Capital:
mvd mve
wacc = Kd(1-Tc)[ ] + Ket d e t d e
Where
wacc = Weighted Average Cost of Capital; Kd = Interest rate; Ke = Treasury rate; 
Tc = Tax return; mvd = Market Value of Debt; mve = Market Value of Equity; 
tde = Total Debt and Equity = mvd + mve
box 2 phases in clinical drug development
phase i
Research using small groups of healthy volunteers. Traditionally, this phase mainly focuses on 
if the human body tolerates the new drug and on finding a dose where the level of tolerance is
acceptable. In general, this phase takes about 1 to 2 years. The centre for drug evaluation and
research of the United States Food and Drug Administration (fda) states:
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“Phase 1 includes the initial introduction of an investigational new drug into humans. These studies
are closely monitored and may be conducted in patients, but are usually conducted in healthy volun-
teer subjects. These studies are designed to determine the metabolic and pharmacologic actions of the
drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evi-
dence on effectiveness. During Phase 1, sufficient information about the drug’s pharmacokinetics and
pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid,
Phase 2 studies. Phase 1 studies also evaluate drug metabolism, structure-activity relationships, and
the mechanism of action in humans. These studies also determine which investigational drugs are
used as research tools to explore biological phenomena or disease processes. The total number of sub-
jects included in Phase 1 studies varies with the drug, but is generally in the range of twenty to eighty.”
phase ii
Research on a group of patients where the first proof for efficacy is established. More charac-
teristics of the nce are determined and a safe and well-tolerated dose is determined where 
the drug is efficacious. According to the fda:
“Phase 2 includes the early controlled clinical studies conducted to obtain some preliminary data 
on the effectiveness of the drug for a particular indication or indications in patients with the disease
or condition. This phase of testing also helps determine the common short-term side effects and risks
associated with the drug. Phase 2 studies are typically well-controlled, closely monitored, and con-
ducted in a relatively small number of patients, usually involving several hundred people.”
phase iii
The potential new drug is tested on thousands of patients in multi-centre research projects 
to investigate the side effects of the drug at a set dose in more detail. Furthermore, the efficacy
of the drug at the determined dose is compared to existing medication. Further research is
conducted to investigate possible side effects after long-term treatment and development 
of the drug for different indications is investigated. The fda describes:
“Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after prelimi-
nary evidence suggesting effectiveness of the drug has been obtained in Phase 2, and are intended 
to gather the additional information about effectiveness and safety that is needed to evaluate the
overall benefit-risk relationship of the drug. Phase 3 studies also provide an adequate basis for
extrapolating the results to the general population and transmitting that information in the
physician labelling. Phase 3 studies usually include several hundred to several thousand people.”
phase iv
The registered drug is monitored closely to examine the occurrence of unexpected side-effects
and interactions with other drugs.
22 a question based approach to drug development
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Outline of this thesis
As shown in the previous case study, changing the development plan from
phase/time oriented to question based can improve the insights on the
information that needs to be obtained and will help display the priorities
within the program. In conventional phase-based drug development, timing
is not the most important issue, as long as studies are performed rapidly. 
In this thesis, it is shown that the order in which studies are performed has 
a significant impact on the efficiency and quality of the drug development
process. The impact of this novel approach can best be demonstrated by
calculation of the financial consequences of resolving the right questions at
the right time, during the development of new compounds. This calculation
is based on the real-option theory, applied to drug development questions.
Simple decision analyses suffice to determine the best sequence of research
projects, and detailed pharmaco-economic models are unnecessary for this
purpose. The thesis also provides some examples of research projects that
were performed at different stages of drug development, with widely
different consequences for the values of the projects concerned.
This thesis consists of four main sections. 
section 1   Literature evaluation describes some examples of evaluating
existing biomarkers for clinical effects in healthy volunteers as helpful tools
for early phase drug development. A structural procedure was adopted to
evaluate the methods used in healthy volunteer trials using antipsychotics
(Chapter 2) and benzodiazepines (Chapter 3). The use of rem sleep reduction
as a frequently used method to evaluate the effects of antidepressants is
reviewed in Chapter 4.
section 2   Developing a new formulation describes four clinical studies
with rilmenidine -a centrally acting antihypertensive agent- that investigate
and define the optimal characteristics of sustained release rilmenidine
formulations. Chapter 5 investigates the in vivo properties of a sustained
release formulation in healthy volunteers. Furthermore, these in vivo
pharmacokinetic characteristics are related to the in vitro sustained release
properties. Chapter 6 defines the pharmacokinetic/pharmacodynamic
relationship between rilmenidine concentrations and the development 
of side effects in healthy volunteers. In Chapter 7, the pharmacokinetic /
pharmacodynamic relationship between rilmenidine concentrations and 
the reduction of blood pressure is investigated in mild to moderate hyper-
tensive patients. Finally, in Chapter 8 the effects of multiple doses of
sustained release formulations are investigated in mild to moderate
hypertensive patients.
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section 3   Bridging the gap to Japan exemplifies two ways of comparing
Japanese and Caucasian subjects with the aim of reliably extrapolating
clinical data from Caucasian subjects to Japanese subjects. Chapter 9
describes an interethnic comparative study between Japanese and Caucasian
volunteers. A Japanese study on the pharmacokinetic/pharmacodynamic
relationship of nitrazepam is repeated in Caucasian subjects matched for
gender, age and body size and the results are subsequently compared.
Chapter 10 describes a simultaneously performed bridging study on a new
oral contraceptive agent where the single dose and steady-state pharma-
cokinetics are compared between Caucasian female subjects and Japanese
female subjects.
section 4   Market advantage shows that early in the drug development
program a small study can be performed to investigate potential advantages
of newly developed agents over existing drugs. Chapter 11 describes a study
in healthy volunteers to compare two doses of a potential anxiolytic drug
with lorazepam and placebo to investigate the central nervous system effects
of the new agent.
Each section is concluded with a value estimation, which discusses the
impact of the presented studies on the drug development program using 
the question-based approach.
25 introduction and outline of this thesis – chapter 1
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Studies of novel antipsychotics in healthy volunteers are traditionally
concerned with kinetics and tolerability, but useful information may also be
obtained from biomarkers of clinical endpoints. A useful biomarker should
meet the following requirements: a consistent response across studies and
antipsychotics; a clear response of the biomarker to a therapeutic dose; a
dose-response relationship; a plausible relationship between biomarker,
pharmacology and pathogenesis. In the current review, all individual tests
found in studies of neuroleptics in healthy volunteers since 1966 were
progressively evaluated for compliance with these requirements. A MedLine
search yielded 65 different studies, investigating the effects of 23 different
neuroleptics on 101 different (variants of) neuropsychological tests, which
could be clustered into seven neuropsychological domains. Subjective and
objective measures of alertness, and of visual-visuomotor-auditory and
motor skills were most sensitive to antipsychotics, although over half of all
the studies failed to show statistically significant differences from placebo.
The most consistent effects were observed using prolactin response and
saccadic eye movements, where 96% and 83% of all studies resp. showed
statistically significant effects. The prolactin inducing dose equivalencies
relative to haloperidol of nineteen different antipsychotic agents correlated
with the lowest recommended daily maintenance dose (R2 = 0.52). This
relationship could reflect the clinical practice of aiming for maximum
tolerated levels, or it could represent a common basis behind prolactin
release and antipsychotic activity (probably D2-antagonism). The number 
of tests used in human psychopharmacology appears to be excessive. 
Future studies should look for the most specific and sensitive test within
each of the domains that are most susceptible to neuroleptics.
Introduction
There is a growing pressure on the drug development process to enhance 
the relevance of studies at all stages. Traditionally, phase 1 studies were
mainly concerned with kinetics and tolerability of a new compound in
healthy volunteers, but increasing efforts are now made to include potential
biomarkers of clinical endpoints. This approach is particularly useful in areas
where phase 2 studies are cumbersome, for practical or ethical reasons. 
This is the case for many neuropsychiatric indications, including psychosis
and schizophrenia. Patient studies can be complicated by factors associated
with the disease, such as concomitant or previous treatments, adaptation 
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of dose and duration of treatment to clinical responses, different types and
severity of psychopathology and overlap between symptoms and side effects
of treatment. Also, a heterogenic patient population may augment individual
variability for example due to differences in intelligence and motivational
aspects.
Studies in healthy volunteers lack most of these methodological and logistic
problems, but are faced with others. Healthy volunteers are usually studied
using single (ascending) doses, as opposed to chronic treatment in patients.
They obviously also lack the disease characteristics that serve to measure 
the treatment effects, although some studies use healthy subjects with
schizotypy-like personalities to approach clinical relevance. The information
derived from studies in healthy volunteers could also be enhanced with
appropriate biomarkers, which can be defined as indicators of biologic,
pathogenic or pharmacologic processes or responses to therapeutic
interventions.
Currently, no validated biomarkers for psychosis or antipsychotics are
available, but a useful marker should meet the following requirements:
1 a clear, consistent response across studies (from different groups) and
antipsychotics
2 a clear response of the biomarker to a therapeutic dose of the
antipsychotic
3 a dose (concentration)-response relationship
4 a plausible relationship between the biomarker, the pharmacology of the
antipsychotic and the pathogenesis of the disease.
In the current review, these requirements were used to evaluate all potential
biomarkers that have been used in healthy volunteer studies of antipsychotic
agents over the past 30 years.
Methods
Structured literature evaluation
An extensive MedLine search (keywords: (antipsychotic or neuroleptic) and
healthy) revealed a large number of individual tests, which differed widely in
their sensitivity and specificity for detection of central nervous system (cns)
drug effects, with a lack of standardisation between the studies even for the
ref. 1-4
31 section 1: literature evaluation – chapter 2
same tests. In addition, many studies used different antipsychotic dosages,
usually at single doses. A structured procedure was adopted in order to
obtain an overview. First, the results for all individual tests, drugs and
dosages were put into a database. Most studies used different tests, which
were all treated as independent measures of drug effect. The tests could 
then be roughly divided into neuropsychological/ motor skills, subjective
assessments, and neurophysiological and neuroendocrine measurements.
This approach allowed the preservation of individual study data in early
stages, followed by a progressive condensation of results in logical clusters.
The test results could not be recorded quantitatively, considering the large
diversity of methods, parameters and treatments. Instead, the ability of a 
test to show a statistically significant difference from placebo was scored 
as + (improvement/increase), = (no significant effect) or - (impairment /
decrease). Although statistical significance is not only determined by the 
test variance but also by other factors like group size, this approach at least
allowed an evaluation of the applicability of a test as a biomarker. No efforts
were made to further quantify the level of statistical significance. A more
quantitative approach was possible only for prolactin, where the peak
concentration relative to baseline could be determined from most studies.
The chance that a test will detect a difference from placebo is expected to
grow with increasing dose. To investigate this possibility, for each individual
neuroleptic and test it was determined whether the number of statistically
significant results increased with the dose. In this way, the most frequently
used tests and drug dosages could be compared for dose-dependency. In
many cases however, the number of tests or doses was too small to
determine a relationship. To obtain an overview of dose-effects across
neuroleptics, drug dosages were pooled into ‘lower’, ‘medium’ and ‘higher’
dosages. The ‘medium’ dose was determined as the lowest recommended
therapeutic starting dose, as shown in Table 1. If the starting dose could 
not be retrieved, half the lowest recommended maintenance dose was used.
The ‘lower’ and ‘higher’ doses were all dosages below or above this level.
This approach allowed the identification of tests showing a consistent
response across studies and antipsychotics, and those with a clear response
to a therapeutic dose of the antipsychotic (requirements 1 and 2 from the
introduction). All measurements fulfilling these criteria were further tested
for compliance with requirements 3 and 4: the existence of dose-response
relationship and the plausibility of a mechanistic relationship, by reference 
to the original publications and the neuropharmacological literature.
ref. 5-6
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table 1 prl-inducing dose equivalencies for prolactin release, therapeutic dose and 
receptor affinities for antipsychotic drugs. (See text for explanation of 
prl-inducing dose equivalence)
Drug Maintenance Reported prl-inducing D2 receptor 5-ht2/D2 
dose study dose affinity ratio *
(mg/day) range (mg) equivalencies Ki (nM)*
Amisulpride 300-1200 20-400 56.6
du -29895 ? 3-10 2
Remoxipride 60-300 0.5-150 9.29 272 >40
Sulpiride 100-200 100-400 97.8 31 40
Zetidoline 10-30 10-40 0.81
Raclopride 4-8 0.1-16 1.72 7.0 1429
Mazapertine ? 5-50 -
Zotepine 50-300 25-100 17.2 13 0.07
Pimozide 2-6 2-6 7.89 1.2 5
Setoperone 15-120 5-40 14
Olanzapine 5-20 3-5 -
Clozapine 150-300 12.5-50 309 152 0.02
Risperidone 4-8 1-2 0.1 3.1 0.05
Chlorpromazine 75-300 25-100 39.6 19 0.14
Prochlorperazine 25-50 2.5-5 8.3 3.1 2.4
Trifluoperazine 20-30 4 5.1 4.3 2
Perphenazine 16-64 1 2 6.5 0.66
Haloperidol 4-10 0.25-10 1.11 1.2 2.3
Fluphenazine 2.5-5 0.35 1.89 1.9 1.8
Thiotixene 20-30 0.25-0.5 0.56 2.5 39
Thiethylperazine 10 10 4.37 4.5 11
Molindone 30-100 5 1.13 25 94
Thioridazine 200-800 10-75 - 16 0.26
*Leysen et al. Psychopharmacology (Berl) 1993; 112:40-54
Neuropsychological/motor skill
In the first phase of the literature review, tests from different studies were
only grouped if they were equal as judged from name and description or
literature reference (e.g. all Digit Symbol Substitution Tests (dsst)), but all
variants or related forms of the tests (dcct, sdst etc.) were treated
separately.
ref. 49
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table 2 Progressive condensation of all reported tests; from test to cluster to domain











Simple reaction (conflict task)






Visual search Complex info process
Time estimation

















Continuous attention Other vigilance











Introductory conditioning Learning Memory
Delayed word recall
Delayed word recognition
Delayed picture recognition Delayed recall






















Performance time (Delayed word recogn.)
Performance time (Nummeric working memory)
Performance time (Digit vigilance)
Performance time (Rapid info processing)
Performance time (Delayed picture recognition)







sdstart Visual, visuomotor and auditory

















Hand arm lateral reach coordination
Visual arm random reach
Motor contr.&coord.
Motor behaviour Motorcontrol
35 section 1: literature evaluation – chapter 2
Next, all tests that could be regarded as variants from a basic form were
clustered as indicated in Table 2. Thus, all tests determining the ability to
discriminate flash- or flicker frequencies were grouped as ‘flicker discrimi-
nation’. These data were used to determine the consistency of results within
test clusters and to identify potential dose-effects.
Although many different methods are used to evaluate the functional effects
of neuroleptics, most actually measure a limited number of core features.
Neuropsychological/ motor skills-tests can be categorised according to a
catalogue of neurocognitive tests (attention, executive etc.), as presented in
Table 2. This catalogue divides tests according to different neuropsychologi-
cal domains, assuming that the results of each test are mainly determined 
by one of these domains. To determine the domains that are most affected
by neuroleptics in healthy subjects, all tests within a neurocognitive domain
were bundled. The number of statistically significant differences from
placebo was scored and compared to the total number of studies within the
domain.
Subjective assessments
For the subjective assessments, most individual scales corresponded to
individual lines for the subscales ‘alertness’, ‘mood’ and ‘calmness’, proposed
by Norris and applied to cns-drug evaluation by Bond and Lader. Other
scales could be grouped under ‘anxiety’, ‘subjective (psychotropic) drug
effects’ and ‘(extrapyramidal) side effects’.
Neurophysiological assessments
electroencephalography (eeg)   eeg is sensitive to a wide
range of centrally active substances, although the exact mechanism is hardly
ever known. eeg-studies differ in numbers of leads or technical settings, but
they usually report effects per eeg-frequency band, which are divided into
delta (0.5-3.5 Hz), theta (3.5-7.5 Hz), alpha (7.5-11.5 Hz) and beta (above 11.5
Hz; sometimes subdivided into beta 1 (11.5-30Hz) and beta 2 (above 30 Hz)).
In the current review, statistically significant differences from placebo were
scored for the four major frequency bands.
eye movements   Smooth pursuit and saccadic eye movements have
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movements provide information on the sedative properties of antipsychotic
drugs. These effects are not specific for a class of drugs, but rather quantify
sleep/wake transition. Although there are different techniques to measure
eye movements, most studies report peak velocity for visually guided
saccades or sometimes anti-saccades (where subjects are instructed to 
look away from the target). Smooth pursuit eye movements are reported 
as deviations from the time that the eyes closely followed the target.
Statistically significant differences from placebo were reported, and dose-
response relationships were investigated for consistent responses.
evoked potentials   Schizophrenic patients exhibit abnormalities 
in event related potentials (erp) that are postulated to reflect characteristic
changes in stimulus discriminability and decision making. Typically, these
consist of a reduction in the amplitude and a prolongation of the latency of
the P300 component.
There were not enough healthy volunteer studies to warrant (semi-)
quantitative evaluation of these tests, but the results are described because
of the apparent relevance of this method in schizophrenia research.
Neuroendocrine assessments
prolactin (prl)   Neuroendocrine tests and particularly the prl
response to antipsychotic agents have been reviewed in several publications.
prl response to antipsychotics is clinically related to hyperprolactinemia and
is therefore thought undesirable during drug development. However, the
prolactin response to antipsychotics is a direct consequence of dopamine
antagonism, since pituitary prl secretion is inhibited by dopamine.
Dopamine antagonism is one of the core characteristics of antipsychotic
agents, and abnormal dopamine activity is a widely accepted central
pathophysiological abnormality in psychosis. The prl-response to
neuroleptics is frequently studied in healthy volunteers, and usually the
maximum prl-response is reported. This response is determined by the 
dose of a neuroleptic, and by its prl-inducing potency. The value of prolactin
as a biomarker would be particularly large, if for a range of neuroleptics the
prl-inducing potencies were closely related to the therapeutic doses. Such 
a comparison can only be made directly on the basis of well-defined prl-
inducing potencies determined from complete dose-response relationships
for each neuroleptic. The literature did not provide this information for most
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dose range, as described in the results-section. Therefore, an alternative
approach was chosen where the prl-inducing potency of each neuroleptic
was expressed relative to this haloperidol dose-response curve. Neuroleptic
doses that caused a larger prl-response than observed with haloperidol
were not plotted on this reference curve; i.e. data were not extrapolated
beyond the extent of the curve. In this way, for each neuroleptic dose an
equipotent haloperidol dose could be determined, that would theoretically
cause the same peak prl-response. Next, each dose was normalised to
haloperidol 1 mg, and the mean of these values was calculated per
neuroleptic. This constituted a prl-inducing dose equivalence (relative to
haloperidol) for each neuroleptic.
To examine the value of prolactin release as a biomarker for therapeutic
efficacy, these mean prl-inducing dose equivalencies were compared to 
the lowest recommended daily therapeutic maintenance doses (see Table 1).
The relationships of individual prl-inducing dose equivalencies with some
key pharmacological features for the antipsychotics (D2 affinity (Ki) and 5-
ht/D2 antagonism ratio) were examined. The Ki values (Table 1) were
assessed using the same methods, allowing inter-drug comparison.
cortisol and growth hormone (gh)   5-ht agonists and
antagonists have been found to have an effect on plasma cortisol and growth
hormone levels, but the data are inconclusive. These hormones have been
used to evaluate antipsychotic drug action on serotonergic function,
particularly 5-ht2 which may play a role in the mechanism of action of
atypical neuroleptics. The number of studies was too low to allow any
quantitative analysis. The statistically significant differences from placebo
were reported.
Statistical evaluation
To allow the calculation of average responses with confidence intervals 
for binomial proportions, responses were coded as follows. Impairment /
decrease was coded as 0, no change was coded as 0.5 and improvement /
increase was coded as 1. A cumulated response code was calculated by
multiplying the number of occurrences for each response by the coding, and
adding this over the 3 responses. A proportion was calculated by dividing the
cumulated response code by the total number of responses. This yields an
average response between 0 (impairment/decrease) and 1 (improvement /
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proportions were calculated using the cumulated response code and the
total number of responses. Exact confidence intervals were calculated using
sas for Windows V6.12 with the Exactpci V1.2 procedure provided by sas Inc,
(sas Institute Inc, Cary, nc).
Results
The literature search yielded 65 different studies, published since 1966.
These studies investigated 23 different neuroleptic agents, with 2.2 doses per
study on average. Olanzapine was only given at slightly subtherapeutic
dosages and mazapertine was not registered, but 76% of the doses of all
other agents were at ‘medium’ or ‘higher’ levels. Thus, most studies were
able to comply with the requirement that a useful biomarker should respond
to therapeutic doses. Eighteen studies were solely devoted to haloperidol,
and 12 studies used haloperidol as a reference for other neuroleptics. 
On average, there were 17 healthy participants (range 5-110) per study.
Neuropsychological/motor skill
There were 101 different test-(variants), as shown in Table 2; 51 of these 
were used only once. Six tests were used more than ten times: critical flicker
fusion (32 times), choice reaction times (32x), finger tapping (18x), time
estimation (15x), simple reaction times (15x) and dsst (14x). At least 33% 
of all tests that were used twice or more (by different groups) showed
statistically non-significant or conflicting differences between neuroleptics
and placebo. For the five most frequently used test, these percentages were
53%, 47%, 39%, 53%, 40% and 43%, respectively. 
Fifteen individual tests showed statistically significant impairment in all
cases (100%), but nine of these were only used once (one dose of one
antipsychotic), and the six other tests were only used by a single research
group: alphabetic cross-out (8x), wire maze tracing (3x), Pauli test (3x),
delayed picture recognition (2x), delayed word recognition (2x), and
performance time for digit vigilance (2x).
Subsequently, comparable tests or variants were clustered as shown in 
Table 2. Reaction times showed significant prolongation in 46% of the 52
times this method was used. Complex information processing tasks were
used 39 times, showing significant impairment in 46%. Flicker fusion was
ref. 2, 19, 47-48,
52-53, 55-107
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employed 38 times, demonstrating significant impairment in 45%. The 
21 dsst-like tests showed statistically significant impairment in 48%, 
no change in 48% and an improvement in 4%. Significant impairment on
search tasks was found in 70% of 20 cases. Medium or higher doses were
used in all cases except two. Manipulative motor tasks were performed 31
times, and showed significant impairment in 48%. A significant impairment
was found in 41% of the 34 times that eye hand co-ordination was studied.
Clustering of comparable tests thus did not increase the number of
significant results.
figure 1 The averaged significant effects of antipsychotics on neuropsychological 
domains, subjective assessment, neuroendocrine and neurophysiological 
parameters
impairment no effect improvement























However, the larger number of studies within clusters allowed a better
estimation of dose-dependency. In most cases, consideration of only
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‘medium’ or ‘higher’ doses did not appreciably increase the percentages of
significant results. Only flicker fusion and complex information processing
showed modest increases in the percentages of tests demonstrating
impairment, when the lower dosages were omitted (from 45% to 57%, and
from 46% to 51%, respectively).
No individual neuropsychological/motor skill-test or cluster of related test
variants showed a consistent response to antipsychotics, and this did not
improve to any extent when a dose-effect relationship was taken into
account. To evaluate which neuropsychological domains are most clearly
affected by neuroleptics in healthy volunteers, tests were categorised as
indicated in Table 2. The percentages of statistically significant test results
are presented in Figure 1. These results show that the most sensitive neuro-
psychological domains are attention, visual/auditory/visuomotor skills, and
motor function.
It was subsequently determined for these most sensitive areas, whether
there were systematic differences between effects of ‘classic’ (haloperidol,
thioridazine and chlorpromazine) and ‘atypical’ neuroleptics (all others -see
Table 1). In addition, an overview was obtained for differences between
individual agents, although this effort was restricted by the limited number
of assessments per drug. Such differences did not appear to exist. In each of
the most sensitive areas, at least 48% of the ‘atypical’ antipsychotics caused
impairment. Similar or even lower percentages were found for the ‘classical’
neuroleptics.
Subjective assessments
Thirty-one different subjective assessment scales were employed; five of
which only once. The scales used most often (by more than one research
group) were: simple visual analogue scales for alertness (17 times), mood
(13x) and attention (10x), and the combined scales from Bond & Lader (11x)
and the Von Zerssen Befindlichkeitsskala (10x). The latter test was most
consistent (significant results in 8 cases), but these were all from the same
group; the only other group using this method obtained non-significant
results. The other frequently used tests showed impairment in 38-59% 
of cases. Thus, none of the individual neuropsychological/motor skill tests 
or subjective assessments exhibited a consistent response across studies 
and antipsychotics. None of the subjective assessments showed an
improvement, except one positive mood change with 2 mg haloperidol.
ref. 70, 74, 107
ref. 82
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Assessments were clustered into scales for ‘alertness’ (57 measurements;
significant deterioration in 53%), ‘mood’ (28x; 50%), ‘calmness’ (16x; 19%),
‘anxiety’ (5x; 0%), ‘subjective (psychotropic) drug effects’ (14x; 57%) and
‘extrapyramidal side effects’ (21x; 29%). Most subjective assessments
showed indications for dose-dependency. After deletion of ‘lower’ doses,
scales for ‘alertness’ became significant in 64%, ‘mood’ in 70%, ‘calmness’
in 33%,‘subjective (psychotropic) drug effects’ in 80% and ‘extrapyramidal
side effects’ in 43%.
Neurophysiological parameters
electroencephalogram (eeg)   eeg was measured 17 times
employing six different antipsychotics. The observed trend is an increase in
delta (59%) and theta (65%) and a decrease in alpha (59%) and beta (29%)
frequencies, as shown in Figure 1. These effects can be observed with a
number of other psycho-active drugs and generally indicate sedation.
Consideration of only ‘medium’ and ‘higher’ doses did not appreciably
change these results.
eye movements   Saccadic eye movements were used more frequently
than smooth pursuit eye movements (18x vs 9x) (Figure 1). No more than
three different antipsychotics were evaluated by saccadic eye movement.
Saccadic peak velocity showed significant impairment compared to placebo 
in 83%. Only 56% of the smooth pursuit eye movement recordings showed
impairment (increased saccadic intrusions). These percentages increased
slightly to 85% and 57% after discarding the ‘lower’ doses. However the
effects of the neuroleptics on eye movements were found to be indistinguish-
able from the effects of benzodiazepines. Saccadic eye movements appear to
remain a sensitive nonspecific marker for the sedative properties of a drug.
evoked potentials   The effects of oral sulpiride 150 and 300 mg 
on erp’s have been studied recently in healthy volunteers. Sulpiride induced
an increase in P200 and P300 latencies. The amplitude response to sulpiride
of erp parameters was bidirectional; the amplitude of subjects with a high
initial value decreased while those with low initial values increased. It is
remarkable that comparable results were obtained with the dopamine
agonist bromocriptine. However, a recent study showed that the dopamine
agonist apomorphine (0.75 mg s.c.) had no effect on the P300. Assessing the
potential of erp as a biomarker is difficult. First of all, no clear quantitative
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symptomatology exists. Secondly, the relationship between the latency /
amplitude and stimulus perception/processing is speculative. Also, the 
P300 is markedly influenced by the subjective expectancy of a stimulus 
by an individual subject. Given that the effect of antipsychotic drugs on erp
in healthy volunteers has been assessed in very few studies, erp is as yet
unsuitable as a biomarker in the development of antipsychotic drugs.
Neuroendocrine parameters
prolactin (prl)   Plasma prolactin response to antipsychotic agents
was assessed 79 times using 21 different antipsychotics. Three statistically
non-significant responses were measured, for the lowest dose (0.1 mg po) 
of raclopride and for clozapine 12.5 and 50 mg. ‘Lower’ doses showed 96%
statistically significant prl responses. Consideration of only the ‘medium’
and ‘higher’ dosages increased these percentages to 97%. These uniform
prl responses allowed an examination of the relationship between prl
response and therapeutic effect of antipsychotics, as described in the
methods-section. The normalisation of different doses was accomplished by
reference to a logarithmic dose-response curve for haloperidol, constructed
using eleven haloperidol dosages reported in the literature (range 0.25-7 mg;
relative prl increase = 1.192Ln(dose) + 3.672; R2 = 0.70; see insert in Figure
2). This range of haloperidol doses caused peak prl-increases of 1.4-6.6
times baseline. All doses of the other neuroleptics that did not exceed the
maximum prl-increase observed with haloperidol were plotted on this
curve. For each neuroleptic, the geometric mean of the equivalent halope-
ridol-doses was calculated as a measure of prl-inducing dose equivalence.
Nineteen neuroleptic doses caused prl responses beyond the range of the
haloperidol reference line (range 7.6-10.6 times prl elevation). This
completely excluded mazapertine from the analysis, as well as several doses
of amisulpride, raclopride, remoxipride, risperidone, sulpiride and zetidoline.
The prl-inducing dose equivalencies and their concomitant lowest thera-
peutic maintenance doses are shown in Table 1 and Figure 2. The neurolep-
tics showed a good correlation between these two characteristics (R2 = 0.52,
p<0.001). Compounds to the right of haloperidol in the graph are less potent
prl-releasers than haloperidol, although higher doses may still cause more
prl-release. Clinically potent drugs with a minimal prl-releasing propensity
are expected in the lower right hand corner of the graph, which only includes
pimozide. There is no clear distinction between ‘classic’ and ‘atypical’
neuroleptics (e.g. clozapine).
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figure 2 prl-inducing dose equivalencies compared to lowest daily therapeutic 
maintenance dose for various antipsychotics (see text for explanation). 
Insert: reference curve for haloperidol dose (x-axis) and prl-increase relative 
to baseline (y-axis)
Prolactin release is generally attributed to inhibition of the D2-receptor,
whereas the antipsychotic effect may be more related to the ratio of 
5-ht2/D2-antagonism. This was further investigated by correlating these
parameters (shown in Table 1) with the therapeutic and prl-inducing 
dose equivalencies. There were no significant relationships between the 
ref. 48
ref. 109, 110
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5-ht2/D2-ratio and the prl-inducing dose equivalence (R2 = 0.05) or 
the therapeutic dose (R2 = 0.03). Weak correlations were found between 
D2-Ki-values and prl-release (R2 = 0.34, p<0.05) or the recommended
maintenance dose (R2 = 0.63, p<0.001).
cortisol and growth hormone (gh)   It seems that 5-ht
function is reflected by Cortisol and gh release; agonists elevate hormone
levels and antagonists reduce the hormone response. Decreased levels of
both hormones are expected after neuroleptics, since most antipsychotic
agents have some 5-ht antagonistic properties (particularly 5-ht2 and 5-
ht1A). Cortisol response to antipsychotic drugs was measured eleven times;
gh was evaluated in 18 instances. Significant changes from baseline were
rare. Cortisol levels were changed in only two studies with antipsychotics in
healthy volunteers. Only 11% of the gh responses to neuroleptics showed
significant decreases (2 out of 18). This percentage decreased if only
‘medium’ and ‘higher’ doses are taken into consideration. Decreased levels
from baseline of both hormones are difficult to measure due to detection
limits. Baseline levels can be increased using heat stress (cortisol) or exercise
(gh). Both methods were used once with neuroleptics and both yielded
significant decreases. For now, cortisol and gh responses are unreliable
biomarkers, but may become measures of 5-ht antagonism in studies using
baseline-induction techniques.
Discussion
The aim of this review was to evaluate the usefulness of methods used to
assess neuroleptic effects in healthy subjects. A striking number of different
neurocognitive tests was identified, and only very few methods were used
frequently enough to allow individual evaluation. Consequently, tests had 
to be grouped, to observe trends for relationships with neuroleptic effects.
Several different meaningful ways to group tests were used in this review,
although each method inevitably led to a loss of information. Even grouping
tests with the same name and/or description bypasses differences among
research groups or test variants. Some methods used by individual research
groups may have all the characteristics of ideal biomarkers, but this may
have been missed in this review. Some of these tests consistently showed
effects of different neuroleptics (e.g. alphabetic cross-out, wire maze tracing,
Pauli test), but it is difficult to evaluate their usefulness in drug development
if they are not generally applied, and more studies are needed to allow a
judgement on these tests.
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Even after clustering of comparable tests (dsst-like, flicker discrimination-
like etc, as shown in Table 2), most methods were still applied relatively
infrequently. Six of twenty test clusters were performed more than twenty
times, and the effects of neuroleptics were inconsistent in over half of these
cases. Thus, no single widely applied test or test-cluster appeared to stand
out. 
Despite the large number of test forms, most primarily address a single
neuropsychological function, or a limited number of functional domains
(Table 2). Therefore, tests were further grouped according to their primary
neuropsychological domain. This showed that certain functional and
subjective drug effects were more consistently affected by neuroleptics than
others (Figure 1), notably attention (dsst like, flicker discrimination and
search clusters), visual/auditory visuomotor responses (reaction time
cluster), motor skills (manipulative motor skill cluster), and subjective effects
(mood, alertness, and ‘drug effect’). Tests aiming for achievement, executive
function, memory, language and (extrapyramidal) side effects showed little or
no change, although they were used quite regularly. This information is
useful for planning future studies with neuroleptics in healthy subjects,
because it allows the targeted selection of a few specific tests within each
sensitive domain. Attention for instance is one of the most sensitive domains
to single dose neuroleptics, and some 24 different test clusters (or more than
fifty different individual tests) were used within this domain. Not all of these
tests have been systematically compared, but whenever comparisons were
made, saccadic eye movement (peak velocity) was the most sensitive
measure of alertness/attention caused by a wide range of drugs or
circumstances. The sensitivity of saccadic eye movements to neuroleptics
was confirmed in the current review, as shown in Figure 1. More comparative
studies are necessary to determine the most useful tests for the other
neuropsychological domains.
Electroencephalography (eeg) has also been claimed to be sensitive to
antipsychotic medication. On average, the eeg showed a decrease in alpha,
and an increase in delta and theta frequencies, but the sensitivity was not as
large as for saccadic eye movements. The evaluation of evoked potentials as
potentially useful biomarkers was severely impaired by the small number of
studies using this technique.
Baseline levels of growth hormone and cortisol are relatively low, and
decreases therefore rarely reach significance in small groups. Significant
changes were only detected after pre-drug growth hormone and cortisol
ref. 21, 23
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levels were elevated by exercise or heat. Prolactin response showed a
pronounced consistent effect across studies, antipsychotics and dosages.
The relative dose equivalence to induce a prl-response was clearly related to
the affinity for D2-receptors and to the recommended therapeutic starting
dose. Theoretically, this information could be used to predict a likely
therapeutic (starting) dose for a new neuroleptic, by plotting its prl-inducing
dose equivalence on the curve of Figure 2. In practice, this application could
be limited by the logarithmic scaling, and by the lack of reference data for
(potential) neuroleptics that cause more prl-release than haloperidol. Also,
the data were derived from a large variation in studies and methods, and the
applicability could benefit from a systematic characterisation of dose-prl-
response curves for a range of antipsychotics. 
Despite these practical limitations, the findings clearly show that prl
response is the best validated biomarker for ‘clinical’ effects of antipsychotic
drugs, although it is unclear what these effects are. At first glance, Figure 2
suggests that prl-release directly reflects the antipsychotic potency,
because both may be related to D2-antagonism. Our review indicates that
D2-affinity is significantly (albeit weakly) related to clinical potency. Neither
relationship showed a difference between older/‘classic’ and
newer/‘atypical’ neuroleptics. This is in agreement with a postulated
common action of antipsychotics on cortical D2-receptors, irrespective of
class. There may also be another explanation for the close relationship
between the prl-inducing and therapeutic potencies. Both in drug
development and medical treatment it is common practice to look for a
maximum tolerated dose, to increase the chance of a therapeutic success.
Consequently, many recommended antipsychotic doses are too high. By
increasing the dose to maximum tolerated levels, any therapeutic selectivity
that may exist between ‘classic’ and ‘atypical’ neuroleptics (or amongst novel
antipsychotics) could disappear. In this case, the prl-inducing dose
equivalence is as much a measure of tolerability as of clinical efficacy. This
would explain why no differences were found between the two classes in any
of the more sensitive neuropsychological or subjective domains, including
motor skills reflecting extrapyramidal side effects. Ideally, this suggestion can
be examined by comparing the effects on a biomarker for efficacy to the
prolactin dose equivalence and/or therapeutic dose. However, no validated
biomarker for efficacy is currently available.
Obviously, the clear relationship between prl-inducing and therapeutic
potencies does not imply that all mentioned antipsychotics will necessarily





47 section 1: literature evaluation – chapter 2
typically develops during prolonged treatment, and is usually characterised
by higher levels of prolactin than measured in the single-dose experiments
reported here. Thus, chronic and acute prolactin elevation may differ, and we
cannot exclude that ‘classic’ and ‘atypical’ neuroleptics have different long-
term effects on prl-release. The maximum extent to which neuroleptics can
cause prolactin release (Emax) cannot be determined from the prl-inducing
dose equivalence relative to haloperidol, shown in Table 1 and Figure 2. This
can only be derived from fully characterised individual dose-response
relationships.
In conclusion, the number of different neuropsychological, subjective,
neurophysiological and neuroendocrine tests that are used to measure
effects of antipsychotic agents in healthy volunteers, far outweigh the
number of studies. This greatly impairs the usefulness of these tests in drug
development. Only a few neuropsychological domains appear to be sensitive
to neuroleptics in clinically relevant single doses, notably subjective and
objective measures of decreased alertness, and of reduced visual-
visuomotor-auditory and motor skills. Most studies used several methods,
which in part overlapped in these domains, and in part were aimed at
insensitive areas. Useful biomarkers should be particularly sought in the
most specific and sensitive tests within each of these susceptible domains.
All neuroleptics caused an increase in prolactin, which was closely related to
the therapeutic dose. This relationship could reflect the clinical practice of
aiming for maximum tolerated levels, or it could represent proximity of
pathways involved in prolactin release and antipsychotic activity. The number
of tests used in human psychopharmacology appears to be excessive and
reduction of the number of tests as well as further evaluation and validation
is long overdue.
ref. 42, 43
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Abstract
Studies of novel centrally acting drugs in healthy volunteers are traditionally
concerned with kinetics and tolerability, but useful information may also be
obtained from biomarkers of clinical endpoints. A useful biomarker should
meet the following requirements: a consistent response across studies and
drugs; a clear response of the biomarker to a therapeutic dose; a dose-
response relationship; a plausible relationship between biomarker, pharma-
cology and pathogenesis. In the current review, all individual tests found in
studies of benzodiazepine agonists registered for anxiety in healthy
volunteers since 1966 were progressively evaluated for compliance with
these requirements. A MedLine search yielded 56 different studies,
investigating the effects of 16 different benzodiazepines on 73 different
(variants of) neuropsychological tests, which could be clustered into seven
neuropsychological domains. Subjective and objective measures of alertness
were most sensitive to benzodiazepines. The most consistent effects were
observed on saccadic peak velocity (spv) and visual analogue scores (vas) of
alertness, where 100% and 79% of all studies resp. showed statistically
significant effects. A dose-response relationships could be constructed for
temazepam and spv, which was used to determine dose equivalencies
relative to temazepam, for seven different benzodiazepines. These dose
equivalencies correlated with the lowest recommended daily maintenance
dose (R2 = 0.737, p<0.05). This relationship between spv-reduction and
clinical efficacy could reflect the clinical practice of aiming for maximum
tolerated levels, or it could represent a common basis behind spv reduction
and anxiolytic activity for benzodiazepines (probably sedation). The number
of tests used in human psychopharmacology appears to be excessive and
their sensitivity and reproducibility low.
Introduction
Traditionally, phase 1 studies are mainly concerned with the pharmaco-
kinetics and tolerability of a new drug in healthy volunteers. However,
increasing efforts are made to include measures for efficacy as early as in
56 a question based approach to drug development
phase 1 studies. This is especially the case for neuropsychiatric disorders
where phase 2 studies in patients can be difficult to realise due to practical 
or ethical issues such as concomitant or previous treatment, adaptation 
of dose, and the wide variety of types and severity of psychopathology.
Studies in healthy volunteers evade most of the methodological and logistic
problems of patient studies, but other complications arise. Most early phase
1 studies are highly dependent on the used biomarker. However, useful
information on the potential therapeutic effects of the investigational drug 
at an early stage could enhance the drug development program of the new
compound.
Although no validated biomarker for anxiolysis exists, in general a useful
biomarker for activity of a drug class should meet the following criteria:
1 a clear, consistent response across studies (from different research 
groups) and drugs from the same class
2 a clear response of the biomarker to therapeutic doses
3 a dose (concentration)-response relationship
4 a plausible relationship between the biomarker, the pharmacology of 
the drug class and the pathogenesis of the therapeutic area.
Previously, these criteria were used to evaluate the usefulness of biomarkers
for the effects of antipsychotic drugs in healthy volunteers. In the current
review, the effects of benzodiazepines in healthy volunteers were evaluated
using the same methodology. Benzodiazepines are registered for different
indications (like anxiety disorders, epilepsy treatment, insomnia and pre-
medication in anesthesiology), often with various doses and formulations 
for each indication. To facilitate the review, it was limited to (doses of)




A broad MedLine search, (keywords: (anxiety or anxiolytic) and (model or
parameter or effect or *dynamic) and healthy and (subjects or volunteers))
revealed a large number of individual tests, with an apparent lack of stan-
dardisation between the studies even for the same tests. First, all studies
where an anxiolytic benzodiazepine was administered were filtered out. 
ref. 1
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The results of these studies for each individual test, drug and dosage were
put into a database (Microsoft® Access 97 sr-2, Microsoft Corporation,
Redmond, wa, usa). Most studies used different tests on different doses 
of a benzodiazepine, which were all regarded as independent measures of
drug effect. The tests could then be roughly divided into neuropsychological/
motor skills, subjective assessments, and neurophysiological measurements.
This approach allowed the preservation of individual study data in early
stages, followed by a progressive condensation of results in logical clusters. 
Grouping of individual test results 
A structured procedure described previously was adopted in order to obtain
an overview. This method includes progressive evaluation of all the reported
tests on the basis of the mentioned criteria. The purpose of this review was
to identify generally applicable biomarkers of benzodiazepine action. Results
from tests that were used only once or by one research group could not be
generalised, and were therefore not individually analysed. Such tests were
grouped with other comparable tests. The first step in this process included
grouping of tests that could be regarded as variants from a basic form (e.g. 
all tests determining the ability to discriminate flash- or flicker frequencies
grouped as the test cluster ‘flicker discrimination’). Subsequently, a catalo-
gue of psychological tests was used to group these test clusters further to 
the neuropsychological domain it actually measures. The results of the
effects on these domains were also reviewed.
In most cases, individual test results could not be recorded quantitatively,
considering the large diversity of methods, parameters and treatments.
Instead, the ability of a test to show a statistically significant difference from
placebo or baseline was scored as + (improvement/increase), = (no signi-
ficant effect) or - (impairment/decrease). Although statistical significance is
not only determined by the test variance but also by other factors like group
size, this approach at least allowed an evaluation of the applicability of a test
as a biomarker in typical early drug development studies. No efforts were
made to further quantify the level of statistical significance at this stage.
Dose normalisation
The chance that a test will detect a difference from placebo is expected to
increase with dose. To investigate this possibility, it was determined for each
ref. 1
ref. 2
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individual benzodiazepine and test whether the number of statistically
significant results increased with the dose. In this way, the most frequently
used tests and drug dosages could be compared for dose-dependency. 
In many cases however, the number of tests or doses was too small to
determine a relationship. To obtain an overview of dose-effects across
benzodiazepines, drug dosages were pooled into ‘lower’, ‘medium’ and
‘higher’ dosages. The ‘medium’ dose was determined as the lowest
recommended therapeutic dose. The ‘lower’ and ‘higher’ doses were all
dosages below or above this level. Benzodiazepines often have different
doses for different indications. In such cases, the recommended anxiolytic
starting dose was chosen.
This approach allowed the identification of tests showing a consistent
response across studies and benzodiazepines and those with a clear
response to a therapeutic dose of the anxiolytic (requirements 1 and 2 from
the introduction). All measurements fulfilling these criteria were further
tested for compliance with requirements 3 and 4: the existence of dose-
response relationship and the plausibility of a mechanistic relationship, 
by reference to the original publications and the neuropharmacological
literature. In this case, the original test-results were used if possible, rather
than statistical significance and effect direction.
Neuropsychological/motor skill tests
In the first phase of the literature review, tests from different studies were
only grouped if they were equal as judged from name and description or
literature reference (e.g. all Digit Symbol Substitution Tests (dsst)), but all
variants or related forms of the tests (dcct, sdst etc.) were treated
separately.
Next, all tests that could be regarded as variants from a basic form were
clustered as indicated in Table 1. Thus, all tests determining the ability to
discriminate flash- or flicker frequencies were grouped as ‘flicker discrimi-
nation’. These data were used to determine the consistency of results within
test clusters and to identify potential dose-effects.
Although many different methods are used to evaluate the functional effects
of benzodiazepines, most actually measure a limited number of core
features. Neuropsychological/ motor skills-tests can be categorised
according to a catalogue of neurocognitive tests (attention, executive etc.), ref. 2
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table 1 Neuropsychological tests reported and clustered with similar tests and the 
affected domain
Test Cluster Domain
arithmetic addition test Intelligence Achievement
differential reinforcement of low response rate

















mean rt signal identification
repeated acquisition
repeated acquisition (2nd order) Executive
sequence completion
signal identification
subjektieve Leistungseinschätzung Complex Information Processing
Prepulse inhibition
Stroop colour word test Inhibition Task
15 words test (delayed)
auditory recall (delayed)
cued recall test




word stem completion Delayed Recall
15 words test (immediate)
auditory recall (immediate)
immediate visual memory









Williams’ word memory test
word recall (immediate)
word recognition Immediate Recall
memory scanning Learning
finger tapping Manipulation
anterior tibialis activation latency
Motor
body sway












complex choice reaction time Visual, visuomotor and auditory
reaction time
simple choice reaction time
simple reaction time
Sternberg memory test
visual reaction time Reaction time
Bourdon cancellation
letter cancellation
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as presented in Table 1. This catalogue divides tests according to different
neuropsychological domains, assuming that the results of each test are
mainly (although not exclusively) determined by one of these domains. 
Subjective assessments
For the subjective assessments, most individual scales corresponded to
‘alertness’, ‘mood’ and ‘calmness’. These are similar to the scales proposed
by Norris and applied to cns-drug evaluation by Bond and Lader. Other
subjective scales could be grouped under ‘craving’, ‘dizziness’, ‘drug effect’,
‘psychomimetic’, ‘sleep’ and ‘symptoms’.
Neurophysiological assessments
electroencephalography (eeg)   eeg is sensitive to a wide
range of centrally active substances, although the exact mechanism is hardly
ever known. eeg-studies differ in numbers of leads, technical settings 
and eeg-quantification methods, but they usually report effects per eeg-
frequency band, which are divided into delta (0.5-3.5 Hz), theta (3.5-7.5 Hz),
alpha (7.5-11.5 Hz) and beta (above 11.5 Hz; subdivided into beta 1 (11.5-30Hz)
and beta 2 (above 30 Hz) if possible). Results describing the total eeg-
spectrum were scored under the cluster eeg.
eye movements   Smooth pursuit and saccadic eye movements have
been frequently used to assess cns-drug (side)-effects. Saccadic eye
movements provide information on the sedative properties of benzodiaze-
pines. Although there are different techniques to measure eye movements,
most studies report peak velocity for visually guided saccades or sometimes
anti-saccades (where subjects are instructed to look away from the target).
No- and antisaccadic movements involve more complex cognitive processing
than stimulus-evoked saccades and are considered as a separate cluster.
Smooth pursuit eye movements are also treated separately. They are often
reported as deviations from the time that the eyes closely followed the
target. Eye blink is the cluster containing tests concerning spontaneous eye
blinking. Dopaminergic pathways are thought to be involved in spontaneous
eye blinking. Startle eye blinks can be elicited by sudden noise bursts. They
are part of the polysynaptic startle reflex and occur involuntarily as fast as 20
– 150 ms after stimulus onset. The tests clustered under ‘startle reflex’ were
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Analysis of relationship with therapeutic
efficacy and in vitro pharmacology
Biomarkers that complied with the first three mentioned criteria were
subsequently evaluated for potential relationships between the biomarker
and the therapeutic effects of the drugs. Establishing such relationships
would require clear dose-response relationships for each drug, to determine
potency measures for the biomarker and therapeutic effects. For the
validation of the biomarker finding a close relationship between the potency
of the drug to show an effect on this biomarker and the therapeutic doses
would be extremely valuable. Establishing this relationship is only possible
with well-defined potencies to affect the biomarker determined from dose-
response relationships for each found benzodiazepine. For most benzodiaze-
pines this relationship was not provided by the literature. As an alternative
approach, a reference curve was constructed for each of the biomarkers,
using quantitative results from the most frequently used benzodiazepine.
Next, the potencies of other benzodiazepines were expressed relative to 
this reference agent, by plotting the observed effect of the benzodiazepine 
on the curve and determining the corresponding dose of the reference drug.
Benzodiazepine dosages that caused a larger response than observed with
the reference drug were not plotted on the reference curve; i.e. data were not
extrapolated beyond the extent of the curve. In this way, for each benzo-
diazepine dose an equipotent reference drug dose was determined, that
would theoretically cause a similar response. Subsequently, the mean of
these values was calculated per benzodiazepine. Comparing these mean
biomarker-affecting potencies to the lowest recommended daily therapeutic
maintenance dose was the next step in examining the value of a biomarker
for predicting the eventual therapeutic efficacy. Finally, the mean biomarker-
affecting potencies were plotted against in vitro Kd affinities for the benzo-
diazepine binding site to evaluate the relationship between the biomarker
and the in vitro pharmacology of the drugs. This investigation of a plausible
relationship between the biomarker, the pharmacology of the drug class and
the pathogenisis of the therapeutic area (the last defined requirement of a
useful biomarker) was performed using data from studies that include effects
of drugs from the benzodiazepine class irrespective of their registered
indication.
Dose-response reference curve could only be constructed, if for a particular
test (cluster) enough quantifiable data were available for a single benzo-
diazepine. Often, the number of studies with the potential reference drug
was too low, or the presentation of results too variable. In these cases, doses
ref. 9-10
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of different benzodiazepines were represented (‘normalised’) as fractions of
the medium therapeutic dose. Similarly quantified test results were plotted
against these ‘normalised’ doses, to identify relationships between the
biomarker and the therapeutic (anxiolytic) benzodiazepine doses.
Results
The literature search yielded 56 different studies using 16 different benzo-
diazepines, published since 1966. There were 173 different tests used, on
average 3.1 tests per study. On average 20 subjects participated in each 
study (range 4 to 145 subjects). On average 1.2 doses were given per study. 
All reported psychological tests and the relevant clusters and psychological
domains are represented in Table 1. The benzodiazepines reported in the
reviewed articles are listed in Table 2 with the therapeutic dose ranges for 
the various routes of administration. Fifty-eight tests that never showed any
significant effect are listed in Table 3.
Neuropsychological/motor skill tests
There were 73 different test (-variants) as shown in Table 1. Seventeen of
these were used only once and 55 tests were used less than five times in
combination with a benzodiazepine dose. Sixteen tests never showed any
significant effects at all. Tests that showed a consistent response across
different benzodiazepines include the digit symbol substitution task (dsst),
which was measured 33 times and showed significant impairment in 21 
of these cases. Tracking showed impairment in 8 out of 9 cases and visual
reaction times showed impairment in 3 out of 5 cases. Similarly, the choice
reaction time showed impairment in 53% of the 15 observations. The critical
flicker fusion was used 16 times and showed impairment in 6 cases but 
all these cases include high benzodiazepine dose. Both dsst and tracking
showed significant responses at therapeutic doses. The only observation 
of effects on visual reaction time at a therapeutic dose was not significant.
Choice reaction times results were similar at low, medium or high dose;
impairment was observed in half the cases. The responsiveness of both 
dsst and tracking improved after discarding the low dose results.
Subsequently, comparable tests were clustered. The clusters ‘complex
information processing’ (9 out of 21), ‘dsst-like’ (25 out of 38), ‘flicker
discrimination’ (6 out of 20), ‘hand-eye coordination’ (17 out of 34),
ref. 14-67
64 a question based approach to drug development
‘manipulation’ (4 out of 11), ‘other vigilance’ (8 out of 17), and ‘reaction time’
(19 out of 34) showed consistent responses across studies. However, at
therapeutic dose, only ‘dsst-like’ and ‘hand-eye coordination’ showed
responses in half the cases or more. ‘dsst-like’ tests showed the clearest
dose response-relationship (25% significant results for low dose, 67% for
medium and 94% for high dose).
table 2 Benzodiazepines reported in the reviewed articles, therapeutic dose ranges, 
dissociation constants at benzodiazepine binding site and spv dose equivalences
(see text for explanation). i.m, intramuscular; i.v, intravenous; p.o., per os
DrugName Route Lowest Highest Kd at spv dose 
therapeutic therapeutic benzodiazepine equivalences 
dose (mg) dose (mg) site (nM) (10 mg 
Temazepam)
Aldipem po 50 50
Diazepam po 6 10 9.8 (11.2) 4.3
iv 7.5 15
im 7.5 15
Camazepam po 10 10
Adinazolam po 20 20
Chlorazepate po 15 15
Clobazam po 20 20
Flutoprazepam po 2 2 (12.0)
Lorazepam po 1 1 3.8 (2.6) 1.7
iv 2 2
Medazepam po 15 15 (2322)
Oxazepam po 30 30 39 (37.4)
Premazepam po 25 25
Abecarnil po 10 10
Alprazolam po 0.75 0.75 10.6 (13.8) 0.6
iv 1 1
Midazolam po 10 15 4.86 2.5
iv 7.5 15
Quazepam po 15 15 66 10.2
Temazepam po 10 20 58 10.8
iv 10 20
Bretazanil po 0.5 0.5
Bromazepam po 4.5 4.5 (39.8) 5.5
iv 4.5 6
Flunitrazepam iv 0.5 1 6.2











Repeated acquisition (2nd order) 26
Restless-calm 29
Self-rated concentration ability 65
Sequence completion 30
Serum gastrin levels 37
Sternberg memory test 42
Stroop colour word test 21





Two flash fusion 55




Wiener Gerät 53, 44
Worst-best ever 29
table 3 Tests or parameters that never showed any significant effect after administration
of a benzodiazepine registered or investigated for anxiety
Test ref id Test ref id
Antisaccadic peak velocity 46
Antisaccadic velocity 63
Anxiety 25, 26, 27, 56
Attentive-dreamy 30
Basle mood scale 44
Blood pressure 25
Bodily symptom scale 33
Calm-anxious 60
Clearheaded-muzzy 30
Clyde mood scale 24
Compensatory effect 21
Contendedness 27, 33, 34, 60, 64
Cortical excitability 38
Differential reinforcement of low response rate 26




Gastric acid secretion 37
Happy-sad 29
High 26





Long term visual memory 16
Maddox wing 67
Max force 25
Attempts were made to construct a reference dose-response curve for 
the ‘dsst-like’ cluster. There were too many different parameters to allow
clear dose-response-relationships for any of the 11 benzodiazepines that
were studied with ‘dsst-like’ tests. Some studies measured “number of
correct substituted symbols over 90 seconds”. Others measured “time
needed to substitute 90 symbols” or “power of dsst (correct number 
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divided by time needed for correct substitutions)”. The most commonly
reported parameter (“score/90 seconds”) was plotted against the fraction 
of therapeutic dose for all benzodiazepines in Figure 1. No clear relationship
was observed between this ‘normalised’ therapeutic dose used and the result
on the dsst.
figure 1 The effects on dsst (R2=0.03) and subjective alertness (R2=0.29) of 
benzodiazepine doses normalised to fraction of therapeutic dose
In order to investigate the overall effects of benzodiazepines on the major
neurocognitive domains, the clusters were further condensed to domains.
The results are displayed in Figure 2. The results for low, medium and high
dose are represented in the same Figure. This differentiation showed that
most domains are affected by high dose benzodiazepines.
Subjective assessments
Fifty-eight different subject assessments were used. Thirty tests never
showed any significant effects. Most tests were used fewer than five times
(48 assessments) and 15 tests were only used once. The most consistently
responsive scale was ‘alertness’, which was significantly impaired in 11 out 
of 14 cases. Other responsive scales included ‘sedation’ both scored by the
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subjects and by the investigator (11 out of 14 and 3 out of 5 times significant
results respectively). However, the scale ‘sedation’ showed improvement in 
3 cases and impairment in 8 cases. Similarly, the investigator-rated ‘sedation’
scale showed improvement once and impairment thrice.
figure 2 The averaged significant effects of benzodiazepines on neuropsychological 
domains, subjective assessment and neurophysiological parameters (see text 
for explanation). Averaged overall scores (I) and effects after low dose 
(C), therapeutic (medium) dose (C) and above therapeutic (high) benzodiazepine 
dose (C)
impairment no effect improvement






































Clustering the results for subjective assessments showed that the scales
‘alertness’, ‘mood’ and ‘calmness’ as described by Norris and adapted by
Bond and Lader were frequently employed. The most consistently responding
scale was ‘alertness’, which showed 35 reductions and 4 improvements out
of the 94 times it was used.
Alertness also complied with the second and third requirement. All obser-
vations at medium doses were significant reductions. A quantitative analysis
was performed to assess the fourth requirement as shown in Figure 1. 
This analysis showed no relationship between a decrease in alertness and 
the different dosages (‘normalised’ for therapeutic dose) of benzodiazepines
assessed by alertness. There were too few results to perform a more
quantitative analysis of the test alertness.
Neurophysiological assessments
Sixty-two different neurophysiological parameters were identified. Twelve
parameters never showed any significant effect and 22 parameters were
used only once. Thirty-seven parameters were used less than five times. 
electroencephalogram (eeg)   Inconsistent responses were
observed for eeg Theta: 2 increases, 3 decreases and 1 non-significant result.
eeg Delta was increased in 2 cases whereas remained unaffected in 3 cases.
eeg alpha showed significant reductions in 5 out of 8 cases and eeg Beta
was increased in all 5 instances.
eye movements   Eye movement tests were the most consistently
responsive tests. Smooth pursuit eye movement recordings (measured 12
times) showed impairment in 50%. No-/antisaccadic eye movements were
used 13 times and showed impairment in 54%. Saccadic latency showed
impairment in 4 out of 9 observations. Saccadic eye movements showed
impairment in 80% of all cases and were measured most frequently (31
times). The most frequently used parameter was saccadic peak velocity 
(11 times) and it showed significant impairment compared to placebo in all
cases. 
Saccadic peak velocity (spv) also showed consistent effects at therapeutic
doses. A reference dose response curve could be constructed for temazepam,
since saccadic peak velocity was reported in all studies where saccadic eye
movements were used with this drug. An Emax model with E0 (placebo
ref. 68
ref. 69
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response) was used to construct a reference curve using 9 placebo responses
and 10 temazepam responses at various doses according to the following
equation:
(243.7 * Dose 2.9)
∆spv = 34.3 +
Dose 2.9 + 23.1 2.9
Subsequently, ∆spv responses of all benzodiazepines were used to calculate
the corresponding temazepam dose. These values were averaged for each
benzodiazepine and plotted against the lowest recommended therapeutic
maintenance dose as shown in Figure 3. A significant correlation was
observed for seven benzodiazepines according to the equation (R2 = 0.737,
p<0.05): Lowest maintenance dose = 0.94 + 1.08 * spv dose equivalence.
figure 3 spv-decreasing dose equivalencies compared to lowest daily therapeutic 
maintenance dose for various benzodiazepines (see text for explanation). 
The 95% confidence interval (95% ci) of the linear regression is shown in thin 
lines. Insert: reference curve for temazepam dose (x-axis) and spv-decrease 
relative to baseline (y-axis)
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Furthermore, the spv dose equivalences of these seven benzodiazepines
strongly correlated to the Kd at benzodiazepine binding sites (R2 = 0.894,
p<0.01) as shown in Figure 4: Kd at benzodiazepine binding sites = -4.06 + 
6.24 * spv dose equivalence.
figure 4 spv-decreasing dose equivalencies compared to dissociation constants at benzo-
diazepine binding site for various benzodiazepines (see text for explanation). The
95% confidence interval (95% ci) of the linear regression is shown in thin lines
evoked potentials   Evoked potential tests were used 3 times and
showed impairment in all. Evoked potentials were measured in two studies
using two benzodiazepines. Auditory evoked response potentials (aerp) P300
was used once, as was aerp slow wave positivity. These results came from
the same study. The auditory 40 Hz response amplitude was used also once
in another study. 
startle reflex  Startle reflex tests were used 4 times and in each case
showed benzodiazepine-induced reductions. ‘Startle blink’ was used three
times in one study with one benzodiazepine. ‘Acoustic startle’ was used once.
71 section 1: literature evaluation – chapter 3
0 2 104 126










































The aim of this review was to evaluate the usefulness of methods used in
healthy volunteer studies, to assess effects of anxiolytic benzodiazepines. 
A strikingly large number of different neurocognitive tests were identified
(173). About a third of all tests used in combination with benzodiazepines
(58) never showed any significant response to a benzodiazepine dose. Only
very few methods were used often enough to allow individual evaluation.
Consequently, tests had to be grouped, to observe trends for relationships
between comparable tests and benzodiazepine effects. Several different
meaningful ways to group tests were used in this review, although each
method inevitably led to a loss of information. Even grouping tests with the
same name and/or description could bypass differences among research
groups or test variants. Some methods only used once or twice or by a single
research groups may have had all the characteristics of ideal biomarkers, 
but this would have been missed in this review, simply because part of the
definition of ‘ideal’ was general widespread use of the biomarker. Evoked
potentials and startle responses for instance showed consistent results, 
but only in less than a handful of studies from even fewer research groups. 
At this stage, it is difficult to evaluate the usefulness of these techniques 
in drug development, and more studies are needed to allow definite
judgements. Also, useful methods were defined in this review as tests that
produced a statistically significant result in typical healthy volunteer studies,
i.e. with small subject numbers. Some tests may be very useful biomarkers 
in larger studies, but these would not be identified in this review.
As expected, increasing doses caused more significant results for many tests.
The sedative properties of benzodiazepines at high doses caused some
impairment in most of the neurocognitive domains, probably secondary 
to reduced alertness. However, a useful biomarker should show responses 
at therapeutic levels (preferably also at low dose to allow dose-response
relationships). This precludes ‘critical flicker’ discrimination tests, which
despite widespread use only seems to respond to high dose levels of benzo-
diazepines. The more useful biomarkers identified in this review (saccadic 
eye movements, ‘dsst-like’ tests and subjective scores of alertness) seem to
all be related to the sedative properties of benzodiazepines which apparently
correlate with the therapeutic effects of the selected benzodiazepines.
Effects of other sedating compounds have been demonstrated with saccadic
eye movements, suggesting that saccadic eye movements quantitatively
reflect alertness. ref. 70
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All benzodiazepines caused an impairment of saccadic peak velocity, which
was closely related to the therapeutic dose. There are several possible
explanations for this close relationship. Firstly, it could reflect the clinical
practice of aiming for maximum tolerated levels. Secondly, the anxiolytic
effects of benzodiazepines could be linked to sedation ‘in parallel’, if both 
are regulated by closely related neurobiological systems (e.g. different 
gaba-receptor subtypes or different components of the ascending reticular
activating system; the latter probably connects saccadic eye movements 
to alertness/sedation). Thirdly and perhaps less plausibly, the link could be
‘in series’, if reduced alertness would be the basis for reduced anxiety (e.g.
by reduced susceptibility to (disturbing) exogenous and endogenous stimuli).
Research on partial agonist benzodiazepines that potentially discriminate
between sedation and anxiolysis should include saccadic peak velocity as 
the most sensitive measure of sedation. Similarly, the effects of non-benzo-
diazepine anxiolytic agents could show a different effect profile. A review 
of the effects of such variable compounds (similar to the current benzodia-
zepine review) would be difficult, because the diverse effect profiles would
hamper any relationship between biomarkers and pharmacology of the
drugs. Also, most of these drugs are registered for multiple indications 
(e.g. depression).
cns drug development is likely to increase as the attention of the pharma-
ceutical industry shifts further in the direction of this area with the largest
unmet therapeutic need. Additionally the improvements in biological
knowledge through genomics will undoubtedly produce new targets that
require further validation. Early evaluation of these new drugs must be done
with the best possible methodology and it is highly surprising that the field
apparently uncritically uses untested and often insensitive methodology.
Healthy volunteers should not be exposed to procedures that can a priori be
assumed not to produce any useful data. In addition, the cost of these
studies is high especially when no or possibly confusing data arise from this.
A large number of the methods included in this review are actually used for
studies that eventually appear in dossiers for registration and the uncritical
approach to this methodology seems to extend to the registration authorities
in many countries. 
Similar to the conclusion of a review on the effects of antipsychotic drugs in
healthy volunteers, this review confirms that the number of tests used in
human psychopharmacology appears to be excessive and reduction of the
number of tests as well as further evaluation and validation is long overdue.
ref. 71
ref. 1
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This review investigated the potential use of Rapid Eye Movement (rem)
sleep effects as a biomarker for the therapeutic effects of antidepressants 
in healthy volunteers. A literature search was performed to select studies
investigating the effects of antidepressants on rem sleep. To assess the
specificity of rem sleep effects as a biomarker, the effects of other cns drugs
on rem sleep were also investigated. A significant rem sleep reduction was
shown for 16/21 investigated antidepressants after single dose (mean
reduction 34.1%) and for 11/13 drugs after multiple dose administration
(mean reduction 29.2%). The median increase in rem latency was about
60% after single- or multiple-dose administration. rem sleep effects were
linearly normalised to therapeutic doses, by dividing the rem sleep effect by
the investigated dose and multiplying by the therapeutic dose. Normalised
rem sleep effects were highly variable (range –27.0 to 81.8% for rem sleep
and range –17.0 to 266.3% for rem latency) and showed no relationship with
relevant pharmacological properties of the investigated drugs. No quanti-
fiable dose-response relationship could be constructed after single and
multiple dose administration. rem sleep effects were not specific for
antidepressants. Benzodiazepines for instance caused an average dose
normalised rem sleep reduction of 8.7% and a median 8.6% increase of 
rem latency. This review demonstrates that although rem sleep effects occur
with most of the antidepressants, it is by itself of limited value as a biomarker
for antidepressant action. Its specificity for antidepressants is limited, and it
does not show a quantitative dose-response relationship to antidepressant
agents. This is at least partly due to the complex relationships between drug
pharmacokinetics and the variable time course of rem and other sleep stages
throughout the night. Models that take these complex relationships into
account may provide more comprehensive and quantifiable results.
Introduction
Nearly 10% of the population suffers from a depressive disorder making it
one of the most common diseases of the world. Pharmacological treatments
of depressive disorders include three major classes of antidepressants:
selective serotonin reuptake inhibitors, tricyclic antidepressants and mono-
amine oxidase inhibitors. The exact therapeutic mechanism of action of
antidepressants is still not known, although the binding to specific receptors
has been elucidated and most antidepressants enhance monoaminergic
neurotransmission. Although antidepressant activity can be fairly reliablyref. 1-2
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predicted from these specific pharmacological characteristics and from
preclinical animal models, it remains difficult to establish efficacy in clinical
practice, mainly because of the heterogeneity of the patient population,
fluctuations in disease severity, and a delayed onset of antidepressant action.
Consequently, it is difficult to establish therapeutic doses, and compounds
can still fail in later phases of development. Therefore, efforts have been
made to identify biomarkers for the therapeutic effects of new antidepres-
sants as early as in phase i.
Some investigations have suggested that the therapeutic effects of anti-
depressants are caused by suppression of Rapid Eye Movement (rem) sleep.
In 1975, it was suggested that antidepressants do not have a consistent effect
on sleep in healthy volunteers. Since then, many more studies have been
published on the possible effects of new antidepressants on sleep in healthy
volunteers. The aim of this review is to investigate the relationship between
different antidepressants and the effect on rem sleep in healthy volunteers
and to examine the potential use of rem sleep effects as a biomarker for de-
pression in healthy volunteers. To identify the specificity of rem sleep effects
as typical biomarker for the effects of antidepressants, the effect of other
Central Nervous System (cns) drugs on rem sleep was also investigated.
Methods
A literature review was performed by a PubMed search (keywords: antidepres-
sive agents, rem and healthy human) for all antidepressants. From this search,
studies determining the effects on rem sleep of one or more antidepressant
dose (single or multiple dose) in healthy subjects were selected. The results of 
all selected studies were stored in a database. To allow a quantitative compa-
rison of study results, the reported average rem sleep effects were expressed
as a percentage of the difference between rem sleep effects during treatment
and rem sleep effects at baseline. Assuming linear dose-effect relationships, 
rem sleep effects were normalised to therapeutic dose by dividing the rem
sleep effects of each antidepressant by the used dose, and multiplying the
result with the therapeutic daily starting dose (for single dose results) and
lowest therapeutic maintenance dose (for the multiple dose results). To
determine whether relevant drug concentrations were reached during the
night, the time of drug administration was compared with the expected Tmax,
for all single-dose studies where this information was available. The effects
after single and multiple dose administration were compared to investigate
potential differences in rem sleep effects during prolonged treatment. 
ref. 3
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Single dose
For each individual antidepressant, the rem sleep effects after a single dose
normalised to hypothetical responses at therapeutic doses were averaged
(assuming linear dose-effect relationship), to investigate the average
response at therapeutic doses. Next, the relationships between rem sleep
effects and specific receptor affinities were investigated. Affinity was
expressed as the antidepressants’ equilibrium dissociation constant (Kd), and
was obtained from the same source for all antidepressants for serotonin,
noradrenaline, dopamine and muscarinic receptors. The normalised rem
effects were plotted against the affinity constants of the various receptors
and the specificity ratio of serotonin over noradrenaline. Finally, changes in
rem sleep effects of antidepressants that are typically referred to as selective
were compared to non-selective (‘classic’) agents.
Multiple dose
rem sleep effects and normalised rem sleep effects were plotted for each
antidepressant individually against the number of days of administration.
Normalised rem sleep effects of studies with constant repeated doses and
the same number of administration days were reviewed to predict response
to antidepressant therapy. Normalised rem sleep effects of different
antidepressants with the same amount of days of administration were
averaged and compared with each other. Finally, the same receptor affinity
relationships that were investigated for single dose administration were
examined.
Other cns drugs
To assess the specificity of rem sleep effects as a potential biomarker for
particularly the effects of antidepressants, a PubMed search was performed
(keywords: cns drug, rem, healthy human) to determine the effects of other
cns drugs on rem sleep. 
Results
The literature search yielded 41 articles published since 1977. Twenty-four
articles could be used, because some collected articles were reviews, inves-
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Sleep ElectroEncephaloGraphy (eeg) recordings to determine rem sleep were
sometimes performed ambulantly but most frequently in a sleep laboratory.
Standard sleep polygraphy was typically performed for 8 hours and daytime
napping was prohibited. Most of the studies had on average two adaptation
nights before the eeg recording night(s). The sleep eeg recordings were
typically visually scored according to the criteria of Rechtschaffen and Kales.
On average, antidepressants caused 34.1% rem sleep reduction after single
dose administration and 29.2% after multiple doses in healthy volunteers.
Other cns drugs caused on average 12.2% rem sleep reduction.
Single dose 
Twenty articles, investigating 21 different antidepressants and 45 different
doses of an antidepressant, were reviewed for the effects on rem sleep after
single dose administration. In the cases where this information was available
(17 of 32), times of drug administration seemed to be based on the predicted
Tmax-values. Paroxetine was always administered in the morning before the
sleep recording, which is in agreement with the long duration of action of
this compound. Only fluoxetine was given relatively late (‘at lights out’)
considering the Tmax of 4-8 hr and the accumulation of an active metabolite.
In one imipramine study, a low dose was given at 21:00 hr, leading to an early
peak concentration before midnight. In all other cases, the expected Tmax-
ranges lay between 23:00 and 03:00 hr, covering most of the normal rem
sleep period.
rem sleep effects of all reported antidepressant doses are presented in Table
1. Sixteen antidepressants showed significant, consistent responses on rem
sleep reduction. Inconsistent or non-significant results were reported for five
antidepressant agents. Nefazodone never showed a significant reduction but
rather an increase in one case and no effect in the other, consistent with
previous findings in patients. rem sleep reductions that were statistically
significant varied widely, from 1.8% for 100 mg trimipramine to 81.8% for 75
mg oxaprotiline. The antidepressant doses used ranged from 50% to 600%
of the therapeutic dose. Consistent significant increases in rem latency were
exhibited by fifteen of twenty antidepressants, although the magnitudes of
the responses varied widely. The median increase of dose-normalised rem-
latency for all agents was 60.1% (range –15.1% to 266%).
Twelve antidepressant therapeutic doses were administered. Eight dosages
showed reduction, three showed no significant change and one dose
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resulted in a significant increase of the rem sleep. This includes the
mentioned two doses nefazodone (increase in one case and no effect in the
other). Trimipramine 25 mg and fluoxetine 20 mg did not produce significant
effects on rem sleep at therapeutic doses either. After normalising to
hypothetical effects at therapeutic dose the normalised effects varied
between –27.0% for trimipramine and 81.8% for oxaprotiline.
table 1 Single dose antidepressants and observed rem sleep effects in healthy 
volunteers
Antidepressant Reference ∆ rem ∆ rem ∆ rem sleep ∆ rem latency
(dose) sleep sleep normalised normalised
(min)a (%)b (%)c (%)c
Amitriptyline (25mg) (Nakazawa et al., 1977) 37 32.3 64.6 -
Amitriptyline (75mg) (Riemann et al., 1990) 60.9 67.2 44.8 122.7
Clomipramine (50mg) (Maeda et al., 1990) 70.3 80.7 80.7 266.3
Dexnafenodone (20mg)(Jobert et al., 1999) 55.5 64.3 - -
Dothiepin (100mg) (Wilson et al., 2000) 16.0 n.s. 19.3 n.s. - n.s. -
Fluoxetine (20mg) (Nicholson et al., 1988) 9.3 n.s. 9.0 n.s. 9 n.s. -17.0n.s.
Fluoxetine (40mg) (Nicholson et al., 1988) 3.2 n.s. 3.1 n.s. 1.5 n.s. -1.8 n.s.
Fluoxetine (60mg) (Nicholson et al., 1988) 45.9 44.4 14.8 8.4 n.s.
Fluoxetine (60mg) (Nicholson et al., 1989) 36.4 31.4 10.5 -0.4 n.s
Fluvoxamine (100mg) (Wilson et al., 2000) 36 43.4 43.4 53.8
Imipramine (40mg) (Yamadera et al., 1998) 49.1 43.8 27.4 53.1
Imipramine (75mg) (Jobert et al., 1999) 54 62.6 20.9 115.3
Indalpine (25mg) (Nicholson et al., 1986a) 55.5 48 - -
Indalpine (50mg) (Nicholson et al., 1986a) 85.3 73.7 - -
Indeloxazine (40mg) (Kajimura et al., 1991) 43.2 35.5 - -
Lofepramine (140mg) (Hopes,  1989) 50.6 56.1 40.1 85.3
Lofepramine (140mg) (Herdman et al., 1993) 43.3 49.5 35.4 48.5
Maprotiline (75mg) (Nicholson et al., 1986a) 38.1 32 10.7 -0.7 n.s.
Maprotiline (150mg) (Nicholson et al., 1986a) 54.6 45.9 7.7 4.3 n.s.
Mianserin (20mg) (Maeda et al., 1990) 17.6 16.7 25 40.1
Mianserin (20mg) (Nicholson et al., 1986b) 33.4 29.9 44.9 54.1 n.s
Mianserin (40mg) (Nicholson et al., 1986b) 45.8 41 30.8 105.1
Mirtazapine (30mg) (Ruigt et al., 1990) -21 n.s. -13.7 n.s. -6.9 n.s. 18.2
Nefazodone (200mg) (Sharpley et al., 1996) 14.0 n.s. 13.5 n.s. 13.5 n.s. -13.3 n.s.
Nefazodone (200mg) (Ware et al., 1994) -24.4 -27 -27 -16.9 n.s.
Nomifensine (100mg) (Nicholson et al., 1986a) 55 49.3 24.7 34.2 n.s.
Nomifensine (100mg) (Nicholson et al., 1986a) 48.1 40.5 20.2 47.2
Nomifensine (100mg) (Nicholson et al., 1986a) 44.9 38.8 19.4 -11.3 n.s.
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Nomifensine (100mg) (Nicholson et al., 1988) 38.9 37.7 18.8 1.7 n.s.
Nomifensine (50mg) (Nicholson et al., 1986b) 25.3 22.6 22.6 34.8 n.s.
Nomifensine (100mg) (Nicholson et al., 1986b) 31.9 28.6 14.3 18.7 n.s.
Oxaprotiline (75mg) (Gnirss,  1986) 76.5 81.8 81.8 125.8
Paroxetine (20mg) (Sharpley et al., 1996) 39.0 37.5 37.5 140.0
Paroxetine (20mg) (Saletu et al., 1991) 26.6 34.1 34.1 102.8
Paroxetine (30mg) (Saletu et al., 1991) 34.6 44.3 29.5 105.5
Paroxetine (40mg) (Saletu et al., 1991) 42.9 54.9 27.5 93.2
Trazodone (100mg) (Ware et al., 1994) 12.33 13.6 20.5 86.7
Trazodone (100mg) (Yamadera et al., 1998) -10 -8.9 -13.4 14.6
Trimipramine (25mg) (Nicholson et al., 1989) 13.6 n.s. 11.7 n.s. 11.7 n.s. -0.4 n.s.
Trimipramine (50mg) (Nicholson et al., 1989) 28 24.1 12.1 13.9 n.s.
Trimipramine (75mg) (Nicholson et al., 1989) 25.1 21.6 7.2 11.3 n.s.
Trimipramine (100mg) (Feuillade et al., 1992) 1.6 1.8 0.5 15.1
Venlafaxine (75mg) (Salin-Pascual et al., 1997) 99.9 79.7 79.7 -
Zimelidine (100mg) (Nicholson et al., 1986a) 43.2 38.7 77.5 106.7 n.s.
Zimelidine (200mg) (Nicholson et al., 1986a) 83.2 74.6 74.6 118.5
a rem sleep (min) after drug dose - rem sleep (min) placebo or baseline
b (∆rem sleep (min) /rem sleep placebo or baseline (min)) x 100 %
c % ∆rem effects normalised to the therapeutic starting daily dose if possible
- unknown therapeutic starting daily dose
n.s. not significant
For ten antidepressants, two or more dose levels were investigated. As doses
increased, nine antidepressants showed greater reductions in rem sleep,
with the exception of trimipramine. Fluoxetine did not produce significant
results at doses of 20 mg (the therapeutic dose) and 40 mg but showed
significant reductions at 60 mg (300% of therapeutic dose). It was impossible
to quantitatively determine dose-response relationships because of the lack
of sufficient data. No clear linear dose-response relationship was observed
for most antidepressants.
Table 2 shows the relationships with receptor affinities for each anti-
depressant. The antidepressants are presented in order of decreasing acute
effect on rem sleep. The rem sleep effects plotted against the serotonin,
noradrenaline and dopamine transporter affinities and muscarinic receptor
affinities did not show any consistent relationship with the rem sleep effects
at therapeutic dose. 5-ht/na selectivity ratios were used to examine
relationships with serotonergic selectivity, rather than absolute affinity.
Zimelidine and clomipramine have higher 5-ht/na selectivity values than
many other drugs and cause the most significant rem sleep reductions. 
ref. 4-6, 8, 11, 
13-14, 18-21, 27
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table 2 Antidepressants (in descending order of normalised rem sleep reduction), equili-
brium dissociation constants (Kd’s) for human serotonin (5-ht), noradrenaline (na) 
and dopamine transporters and the 5-ht/na selectivity value (from Kd values)*
Antidepressants Serotonin Noradrenaline Dopamine Muscarinic 5-ht/na
Kd (nM) Kd (nM) Kd (nM) Kd (nM)
Oxaprotiline 3900 4.9 4340 2900 0.0012
Clomipramine 0.28 38 2190 37 130
Venlafaxine 8.9 1060 9300 - 120
Zimelidine 152 9400 11700 13000 62
Amitriptyline 4.3 35 3250 18 8.1
Fluvoxamine 2.2 1300 9200 24000 580
Lofepramine 70 5.4 18000 - 0.077
Mianserin 4000 71 9400 820 0.018
Paroxetine 0.13 40 490 - 300
Imipramine 1.4 37 8500 90 27
Nomifensine 1010 15.6 56 250000 0.015
Maprotiline 5800 11.1 1000 570 0.0019
Fluoxetine 0.81 240 3600 2000 300
Trimipramine 149 2450 3780 58 16
Trazodone 160 8500 7400 324000 53
Mirtazapine >100000 4600 >100000 - -
Nefazodone 200 360 360 - 1.8
- unknown value
* Tatsumi et al., 1997 and Richelson et al., 1984
However, fluoxetine, paroxetine and fluvoxamine also have high 5-ht/na
selectivity values, but did not cause as large rem sleep reductions as
zimelidine and clomipramine. The ‘selective’ antidepressants caused rem
sleep reductions ranging from 12-34%. The non-selective antidepressants
amitriptyline and dothiepin showed high affinities for all investigated
receptors, but they did not cause consistent rem sleep reductions, ranging
from no significant effects to nearly maximum rem sleep reduction. Thus, 
no associations could be found between the rem sleep effects caused by
antidepressants and any pattern of receptor binding affinity.
Multiple dose
Antidepressant effects typically develop over time, so studies using 
prolonged treatment were evaluated separately. Twelve articles were 
ref. 1-2
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included, investigating the rem sleep effects of 13 different antidepressants
and 28 evaluations after multiple dose administration. Sometimes, doses
were increased gradually. The final doses ranged from 50% to 210% of the
therapeutic dose, and duration of treatment ranged from 2 to 25 days. 
A consistent significant rem sleep reduction was observed for most drugs 
(11 of the 13 investigated antidepressants showed only significant results).
Nomifensin 3 de die 25 mg (3dd25 mg, 150% of the therapeutic dose) for 
5 days and nefazodone 2dd100 mg (67% of the therapeutic dose) for 4 days,
2dd200 mg (134% of the therapeutic dose) for 16 days and 1dd200mg for
eight days and 1dd400 mg for 16 days demonstrated non-significant rem
sleep effects. A significant rem sleep induction was observed after
nefazodone 1dd400 mg (134% of the therapeutic dose) on day two of
treatment. The significant rem sleep reductions per drug varied from
respectively 17.2% for indeloxazine 1dd40 mg (unknown therapeutic dose)
for 3 days and 20.9% for paroxetine 1dd30 mg (150% of the therapeutic dose)
for 25 days, to 100% for venlafaxine 1dd150 mg (200% of the therapeutic
dose) for 4 days. Similar results were found for rem-latency, although this
was not reported in all articles. After multiple dose treatment, consistent
significant increases in rem-latency were exhibited by eight of eleven
antidepressants. The median increase of dose-normalised rem-latency 
for all agents was 62.1% (range –10.1 to 236%).
Normalisation to the hypothetical effect at therapeutic dose did not reduce
the variability in significant response. The significant rem sleep reductions
normalised to therapeutic dose varied from 13.9% for paroxetine 1dd30 mg
(150% of the therapeutic dose) for 25 days to 91.1% for venlafaxine 1dd75 mg
(at the therapeutic dose) for 2 days after multiple dose administration. Four
antidepressant doses were at therapeutic dose and showed responses
varying from 39.6% for fluoxetine (1dd20 mg for 6 days) to 91.1 for
venlafaxine (1dd75 mg for 2 days).
For the relationship between antidepressants and rem sleep effects, each
study was investigated individually, due to the wide variability in the design of
the different studies. Most drugs (amitriptyline, clomipramine, imipramine,
indeloxazine, lofepramine, paroxetine and dexnafenodone) caused a rem
sleep reduction which diminished over time. rem-reductions did not
diminish with mianserin, trazodone or venlafaxine. For most antidepressants,
rem-latency-effects also diminished over time, except for trazodone and
dexnafenadone. The averaged rem sleep and the averaged normalised rem
sleep effects of the antidepressants with the same number of treatment days
demonstrated no consistent relationship with the number of treatment days.
ref. 5-7, 9-10, 
13-16, 23-25
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A dose-response relationship with a rem sleep response could not be
evaluated without the confounding factor of time.
Relationships with transporter affinities of each antidepressant were only
investigated for antidepressants with the same number of administration
days and a constant repeated dose. Only four studies produced comparable
results, which showed no relationship with any of the affinities.
Other cns drugs
To obtain an impression of the specificity of rem sleep effects for (mono-
aminergic) antidepressant, a literature search was also performed for other
cns-active drugs. Most of these articles were on benzodiazepines (15 studies
investigating 13 different benzodiazepines). The number of cns-active drugs
from other classes was too limited to get a comprehensive overview of 
class-effects on rem sleep. The results for 2 nonbenzodiazepine hypnotics, 
2 antipsychotics and 1 antihistamine are presented for reference. The 19
articles found, together with results of a review that investigated the effects
of drugs on sleep in healthy volunteers and patients published in 1996
provided the following results:
benzodiazepines   With the exception of 3 benzodiazepines (fosaze-
pam, nitrazepam and doxefazepam) sleep effects of all drugs were determi-
ned after single dose administration. Fosazepam and nitrazapam were
administered on two consecutive days and doxefazepam was administered
for 30 days. Six (brotizolam, flurazepam, fosazepam, lorazepam, midazolam
and nitrazepam) of the 13 investigated benzodiazepines caused consistent
rem sleep reductions. Brotizolam and midazolam were administered at the-
rapeutic dose and showed 24% and 26% rem sleep reduction, respectively.
Flunitrazepam (at 200, 400 and 800% of the therapeutic dose), oxazepam
(50 and 83% of the therapeutic dose) and triazolam (200 and 400% of the
therapeutic dose) showed both non-significant and significant rem sleep
reductions in different studies. Clorazepate (at a therapeutic dose), doxefa-
zepam (unknown therapeutic dose), nordiazepam (33 and 67% of the thera-
peutic dose) and temazepam (150% of the therapeutic dose), showed no
significant rem sleep effects. Together with the findings of the review
published earlier, it seems that about half the studies with benzodiazepines
caused a rem sleep reduction (normalised to the therapeutic dose) of 8.7%,
on average (range –4.5-35.0%). The median increase of dose-normalised




ref. 48, 48, 47
ref. 55, 51, 58, 60,
48, 50, 57, 48-56







88 a question based approach to drug development
other cns drugs   The antihistaminic agent promethazine at 
doses of 50mg, 100 mg and 200 mg (above the therapeutic dose of 25 mg)
showed rem sleep reductions of 21%, 35% and 45%, respectively. The 
non-benzodiazepine hypnotic zopiclone (at therapeutic dose) also showed 
a rem sleep reduction of 31%, but results for its congener zolpidem were
less clear: at therapeutic doses, rem sleep reductions were significant (10%)
in one study, but non-significant effects in another. The antipsychotic agent
olanzapine showed non-significant rem sleep effects below therapeutic
dose and a 39% rem sleep reduction at therapeutic dose. The antipsychotic
pimozide (at 400% of the therapeutic dose) demonstrated no significant
effects on rem sleep. 
Discussion
This review aimed to systematically evaluate the use of rem sleep effects 
as a potential biomarker for therapeutic effects of antidepressant agents in
healthy volunteers. A systematic stepwise approach to literature evaluation
was adopted. Firstly, the usefulness of rem sleep effects as a biomarker was
assessed by investigating the consistency of responses across various anti-
depressants. Secondly, the responses at therapeutic levels were determined.
The effects on rem sleep of other different cns drugs also were investigated,
to get an impression of the specificity of rem sleep effects for antidepres-
sants. Next, possible dose-response relationships were evaluated. Finally,
attempts were made to relate the responses to the pharmacology of the
drugs. This approach showed several links between the depression, rem
sleep and monoaminergic antidepressants.
Significant reductions of rem sleep were observed with most of the investi-
gated antidepressants, both after single (on average 34.1% normalised rem
sleep reduction) and multiple (on average 29.2% rem sleep reduction) dose
administration. The median increase in rem latency was about 60% after
single- or multiple-dose administration. Statistically significant effects of
single therapeutic doses were found in about three-quarters of all anti-
depressants for rem sleep and in two-thirds for rem latency. Responses
generally increased with rising doses, but rem effects were too variable to
identify a meaningful dose-response relationship. Statistically significant
rem sleep reductions were also found for other cns-active agents (at similar
rates for benzodiazepines), but the effects were generally less consistent and
smaller (on average 8.7% reduction of normalised rem sleep and median
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There are several clues for relationships between rem sleep and the
pathophysiology of depression. Sleep disturbances of various types are
among the most frequent symptoms of major depressive disorders. Aside
from sleep continuity disturbances, sleep in depressed patients is
characterised by a reduction of slow wave sleep (sws), a reduction of rem
latency, an increased amount of rem sleep, a prolongation of the first rem
period and an increased number of eye movements during rem periods.
Sleep deprivation causes short-term improvement of depressive symptoms.
rem sleep is regulated by a complex mechanism in the brain, which is still
not completely understood but seems to involve monoaminergic activity. It is
suggested that laterodorsal tegmental (ldt) and pedunculopontine (ppt)
neuron activity is high and both serotonergic and noradrenergic cells have
their lowest discharge rates during rem sleep. Serotonergic/noradrenergic
activity is believed to suppress ldt and ppt activity and thereby reduce rem
sleep. rem sleep is probably also generated, in part, by stimulation of the
muscarinic cholinergic receptors in the medial pontine reticular formation.
Serotonin and noradrenaline have been shown to inhibit brainstem
cholinergic neurons.
Despite these biochemical links between depression, rem sleep and
monoaminergic antidepressants, none of the investigated drugs evidenced
relationships between their pharmacological characteristics and their rem
sleep effects. Also, rem sleep effects showed a considerable overlap among
different cns-active drug classes, although the effects were generally more
consistent and larger with monoaminergic antidepressants. Finally, in spite
of a general increase of rem sleep reduction with rising doses, rem effects
were too variable to show a meaningful quantitative dose-response
relationship. These limitations thwart the practical applicability of rem sleep
reduction as a biomarker during development of monoaminergic
antidepressants. Nonetheless, the associations with rem sleep reduction
seem stronger for antidepressants than for other cns-active drugs. There
may be many reasons why even a strong relationship would not become
apparent in a literature review. One important factor is common to all the
explored levels of potential relationships: the method used to quantify rem
sleep reduction. Most of the reviewed articles determined rem sleep as
absolute periods of time, or the percentage rem sleep within the total sleep
eeg. The individual results were recalculated as percentage reduction, to
allow quantitative comparisons in the current review. The hypnographic
sleep recordings are typically scored by determining for each consecutive 30
second epoch, whether the subjects are awake, in rem sleep, or in non-rem
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pattern. After 80-90 minutes of non-rem sleep, the subject goes into rem
sleep, which is followed by alternating cycles of non-rem and rem sleep with
a period of about 100 minutes. In most hypnographic analyses, sleep stage
scores are aggregated over the night, resulting in the various parameters
including rem sleep duration. This makes it impossible to examine the time
course of the effects on sleep and the relationships with the
pharmacokinetics of the investigational drug. Most studies based their time
of administration on the expected Tmax of the antidepressant agent,
apparently aiming for pharmacologically active concentrations when rem
sleep is most abundant. However, the individual variabilities in Tmax-values
and rem sleep patterns, and the constant transitions of the various sleep
stages require more complex concentration-effect analyses, than are
possible with aggregated rem sleep effects. For temazepam, the overall sleep
effects did not show any significant pharmacokinetic/pharmacodynamic
(pk/pd) relationships. Useful concentration-effect relationships were only
found, after analyses with a first-order Markov mixed effect model, using 
the individual time-arrays of individual hypnographic 30-second epochs and
each subject’s pharmacokinetic estimates. This analysis yielded descriptions
of the probability of changes in sleep stages as a function of time, and
quantified the influence of drug concentrations on these probabilities.
Similar methods are probably needed, to show dose- (concentration)-rem
sleep effect relationship, and potential correlations with the pharmacological
characteristics of antidepressants. Without such complicated analyses, the
practical usefulness of rem sleep reduction as a predictive biomarker for
antidepressant action is limited.
ref. 69
ref. 70
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The value of research on biomarkers
Estimating the hypothetical additional value of reviews on biomarkers assumes 
that useful knowledge about biomarkers for the effects of cns drugs in healthy
volunteers allows better selection of the appropriate marker for answering a
relevant question. In the traditional drug development plan, this would lead to 
a higher probability of success to enter phase ii (or a lower probability the drug 
will be abandoned after phase i). To investigate the impact of the phase i to phase ii
transition probability, a general drug development plan is constructed using
historical data. This development plan has a limited amount of options during the
execution of the plan: drugs can ‘fail’ or ‘succeed’ in phase i, phase ii and phase iii.
Success in phase iii means payoff of the estimated market value.
The marketvalue is arbitrarily chosen as M¤ 400 making the overall project value
positive (otherwise, the drug will not be developed at all). Failure in any of the
phases obviously implies no payoff and a negative outcome (equal to the
cumulative costs made in the phases until failure). An historical probability is
assigned to each of the phase transitions. The defined costs throughout the three
clinical phases are also based on historical data [1-2]. The input parameters for this
general drug development program are listed in table 1.
table 1 Hypothetical input parameters of the classic development plan
Parameter Value
Success probability phase i 70%
Success probability phase ii 50%
Success probability phase iii 85%
Costs phase I M¤ 15 
Costs phase ii M¤ 60 
Costs phase iii M¤ 100 
Market value M¤ 400 
The project value at the start of the development of this hypothetical plan would
have to take all the probabilities into consideration. The drug can fail in phase I, ii
or iii or it can successfully be introduced on the market. Each of these options has 
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a value defined by the probability it will happen multiplied by the net cash flow 
at that point. The estimated project value is the sum of these probability-corrected
cash flows of all possible events. In the presented example, the estimated value of
the program equals M¤ 27. This is represented in table 2.
table 2 Value estimation of all possible outcomes of the classic development plan
Possible development Probability Costs Payoff Profit Profit*
outcomes (M¤) (M¤) (M¤) Probability (M¤)
Successful development 0.2975 (70%*50%*85%) 175 400 225 66.9375
Abandoned after phase iii 0.0525 (70%*50%*15%) 175 0 -175 -9.1875
Abandoned after phase ii 0.35 (70%*50%) 75 0 -75 -26.25
Abandoned after phase I 0.3 (30%) 15 0 -15 -4.5
Total: 1 (100%) 440 400 -40 27
Another way to represent this is by using a decision tree (generated by decision
tools®) showing that the positive project value makes the decision to go ahead 
with the development of the drug is ‘true’ (Figure 1).
The fact that drug development is a risky process [4-6] can be reflected in the risk
profile of a decision tree [7]. The risk profile of this example is presented in Figure 2.
The graph is a graphical display of table : all possible ‘profits’ are displayed on the 
x-axis and the probability this will occur is represented on the y-axis. From this
graph it can be concluded that it is most likely the development of the drug will 
be abandoned after phase ii losing M¤ 75 (35%).
Assuming that knowledge on biomarkers for the effects of cns active drugs
eventually has impact on the probability of success from phase i to phase ii,
sensitivity analysis on this input value quantitatively estimates the effect of each
change of 1% success probability. Varying the success probability phase i 10%
around the initial 70% and recalculating the project value yields a linear relationship
between the two parameters (Figure 3).
The corresponding linear trendline equation suggests that for every 1% improve-
ment of the probability that the compound will successfully enter phase ii, there 
is an estimated a priori project value increase of about M¤ 0.18).






















figure 1 Decision tree for a classical drug development program
figure 2 Risk profile of a classical drug development program


























































figure 3 Sensitivity analysis of the success in phase i probability on the project value
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Project value =  18.063 * Success phase I + 14.321
A similar decision tree can be constructed using the question-based approach. 
The same overall initial values are used (i.e. the probability the hypothetical
compound will reach market launch remains 30%, the overall costs remain 
M¤175 and the market value payoff remains M¤ 400; table 3). The combination 
of the probabilities and costs are chosen in a way that the project value estimate 
is M¤ 27 (similar to the ‘classic’ phase development project value). The estimated
probabilities that the drug will successfully answer the question is assumed to be
based on consensus between experts and are valid for a new cns active drug (e.g. 
a new antipsychotic or anxiolytic or antidepressant) [8]. The purpose of replacing 
all the phases by questions is to try and clarify the real issues that need to be solved
throughout the development (see introduction).
table 3 Hypothetical input parameters question based development plan
Parameter Value
Success action site 75%
Success pharmacological effect 65%
Success clinical efficacy 80%
Success therapeutic window 85%
Success population 90%
Costs action site M¤ 25
Costs Pharmacological effect M¤ 25
Costs Clinical effect M¤ 60
Costs Clinical window M¤ 30
Costs Population M¤ 35
Estimated marketvalue M¤ 400
By creating this question-based decision tree (qbd tree), a new factor is introduced
in drug development optimisation: sequence. In contrast to the phase oriented
development plan, the sequence in which the questions will be addressed is
variable. The five questions can be arranged in 5! (=5*4*3*2*1) ways. The decision
tree therefore consists of 120 different sequence options of successful drug
development. The fact that the sequence is introduced as an extra variable is
reflected in the risk profile of the qbd tree. Analysis shows that the first question
addressed determines the risk profile of the development program. The risk profile
of all first options is represented in Figure 4.
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figure 4 Risk profile for the question based development tree for the first choices only
This graph shows the first decision has a substantial effect on the risk profile of the
development plan. All first choices have different negative outcome values if the
drug is abandoned at some later stage. If all questions are successfully answered,
there is always a 30% probability the profit will be M¤ 225 independent of the
sequence. However (similar to the example shown in table 2), the expected project
value also incorporates the probabilities and costs if the drug development is
eventually abandoned. Obviously, this reckoning varies for each sequence. For
instance, table 4 compares the possible outcomes for the (optimal) sequences
starting with ‘pharmacology’ and ‘clinical’.
table 4 Comparison of the possible outcomes (M¤) in the question based development 
for the first questions ‘pharmacology’ and ‘clinical’
1st question: Pharmacology 1st question: Clinical
Outcome Probability Outcome Outcome Probability Outcome*
*Probability Probability
-175 3% -6 -175 3% -6
-140 8% -12 -140 6% -8
-80 7% -6 -110 13% -14
-50 16% -8 -85 28% -24
-25 35% -9 -60 20% -12
225 30% 67 225 30% 67
Total: 27 Total: 3































This table shows that if the first question is ‘pharmacology’, the estimated optimal
project value is much higher than the estimated optimal project value if the first
question is ‘clinical’. Similarly, the optimal choice of the remaining questions can 
be analysed. From the risk profiles and decision analysis on all sequence options 
the unique optimal sequence of events can be determined which is given in table 5.
This table represents the optimal path among the 120 different successful options
of the all-sequence-decision tree and the only sequence with an estimated project
value of M¤ 27. All other sequences have lower estimated project values.







Subsequent sensitivity analyses of the success probabilities on the estimated
project value highlight the impact of changed success probabilities on the project
value of the question based development tree (Figure 5). Furthermore, sensitivity
analyses can serve as a check of the initial model estimations by showing their
relevant contributions to the project value.
The reviews presented in this section affect both the ‘clinical’ and ‘pharmacology’
question by increasing the knowledge on available biomarkers to answer these
questions in the development of new drugs. Therefore, two-way sensitivity analyses
were performed to show how the project value changes with combined changes in
the success probabilities for these questions (Figure 6). The data used to construct
Figure 6 is represented in the break-even table 6. This table shows the estimated
project value for different sets of success probability estimations.
This break-even table and the 2-way sensitivity graph show that, for each 1%
increase in the probability of success on ‘pharmacology’, the project value increases
by M¤ 0.8. In other words, introduction of additional costs up to M¤ 0.8 on research
that increases the probability of successfully answering the ‘pharmacology’ 
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table 6 Break-even table for changes in the estimated success probability for ‘clinical’ 
and ‘pharmacology’ on the project value (M¤)
Success clinical
Success 72% 74% 75% 77% 78% 80% 82% 83% 85% 86% 88%
pharmacology
59% 12 14 16 18 20 22 24 26 28 30 32
60% 13 15 17 19 21 23 25 27 29 31 33
61% 14 16 18 20 22 24 26 28 30 32 35
62% 15 17 19 21 23 25 27 29 31 34 36
64% 15 18 20 22 24 26 28 30 33 35 37
65% 16 18 21 23 25 27 29 31 34 36 39
66% 17 19 21 24 26 28 30 32 35 37 40
68% 18 20 22 25 27 29 31 34 36 39 41
69% 19 21 23 26 28 30 32 35 37 40 42
70% 20 22 24 27 29 31 33 36 38 41 44
72% 20 23 25 27 30 32 35 37 40 42 45
question by 1% does not negatively affect the overall project value. Similarly, 
for each 1% increase in the estimated success on the ‘clinical’ question, M¤ 1.4 
is gained in project value for each review.
Assuming that the knowledge obtained on the available methods for evaluating
three cns drugs presented in the three reviews each increase the probability of
success on both ‘pharmacology’ and ‘clinical’ with only 1%, the increase in project
value in each case is M¤ 0.8 + M¤ 1.4 = M¤ 2.2. If an antipsychotic drug, a
benzodiazepine and an antidepressant are developed using the question-based
approach, the estimation of success probabilities and required costs for answering
the questions yields one unique question priority list with an optimal project value
of M¤ 27. If the three reviews each increase the probability of success on both
‘pharmacology’ and ‘clinical’ by 1%, the combined increase in project value for the
three drugs amounts to M¤ 6.7. Furthermore, the probability will be reduced that 
a method will be selected which will not show an effect at a therapeutically relevant
dose of an efficacious drug. This approach can prevent studies that may produce
conflicting or misleading results.
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figure 5 Spider graph after sensitivity analysis on the success probabilities in the 
question based drug development program
figure 6 Two-way sensitivity analysis of the success of  ‘pharmacology’‚ probability and 
success of  ‘clinical’‚ on the project value
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rationale   Rilmenidine is a centrally acting antihypertensive. At the
present time, the dosage for rilmenidine is 1 mg once a day, which in some
patients needs to be increased to 1 mg twice a day. In order to increase the
duration of the effect without increasing the occurrence of peak-dose related
side effects, a sustained release (sr) formulation has been developed at a
dose of 2 mg. This study aimed to investigate the relationship between in
vitro and in vivo characteristics of dissolution of the slow release formulation.
Secondly, the clinical effects and pharmacokinetics of this formulation of
rilmenidine compared to a solution in healthy volunteers were investigated. 
methods   This was a double-dummy, double blind, randomised, two-
way cross-over study in four healthy male and four healthy female volunteers
with a six days washout between administrations. Rilmenidine was
administered either as a 1 mg solution or a 2 mg sr tablet. Blood samples
were taken prior to dosing and at various times up to 36 hours after
administration and plasma analysed for unchanged rilmenidine.
Deconvolution was used to determine the in vivo dissolution of the tablet,
which was compared to the in vitro dissolution using linear regression. In
order to estimate the prediction error of this correlation, the observed in vivo
results were compared with the predicted in vivo kinetics according to the
appropriate Food and Drug Administration (fda) guideline. The clinical
effects were evaluated by blood pressure, heart rate and visual analogue
scales (vas) of alertness, mood and calmness.
results   The slope of the mean in vitro-in vivo dissolution correlation
was 1.1 with a range from 0.71 to 1.7. The average predicted area under the
curve (auc) and maximum observed concentrations (Cmax) deviated 6.7%
and 12% from the observed values. The mean absolute average internal pre-
diction errors of the in vitro-in vivo correlation (ivivc) were 32% for auc and
14% for Cmax. Cmax values were 3.7 ± 0.77 ng.ml-1 with the solution, and 2.6
± 0.32 ng.ml-1 after the tablet, normalised to a 1 mg dose. These concentra-
tions were reached later for the sr formulation than for the solution (5.4 ±
0.52 h compared with 2.1 ± 0.79 h). The time during which the concentration
was greater than 75% of Cmax (t75) was 3.4 h longer for the tablet than for the
solution (95% confidence interval: 0.5, 6.3 h). The relative bioavailability of
the tablet compared to the solution was 126 ± 54% (coefficient of variation
43%). Both preparations showed similar treatment effects on blood pressure
and alertness vas, with a significantly earlier maximum for the solution
(around 3A hrs) than for the slow release tablet (about 5-6 hours).
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conclusion   Although the internal prediction errors of the in vitro-
in vivo correlation exceeded fda guideline values, the in vitro dissolution
kinetics are predictive of the in vivo dissolution kinetics. However, the
pharmacokinetic properties of rilmenidine appear to be highly variable as
illustrated by the high variability in relative bioavailability. The clinical effects
of the rilmenidine 2 mg tablet and the 1 mg solution were not statistically
significantly different. 
Introduction
Rilmenidine (2-(dicyclopropylmethyl)-amino-2-oxazoline) is registered as 
an anti-hypertensive drug in several European countries. Rilmenidine is 
a centrally acting drug with binding selectivity to I1 imidazoline receptors
over 12-adrenoceptors. Early clinical studies have indicated that after
single administration the drug has a dose-dependent blood pressure
lowering effect at doses of 0.5 mg or higher. The maximal effect occurs
between 2-3 hrs after drug administration and lasts a minimum 
of 12 hours. Comparative studies in hypertensive patients have shown 
that the drug effectively lowers blood pressure compared to congeners
like clonidine at equipotent doses. In the same dose range, mild sedation
and reduced salivary flow have been reported, although these side effects
are considerably less than for the nonspecific 12 agonists. The drug is
commonly prescribed in a dose of 1 mg orally once daily, but some
patients require twice daily dosing. In order to increase the duration of 
the effect without increasing the occurrence of peak-dose related side
effects, a 2 mg tablet has been developed which has sustained release (sr)
properties in vitro. This formulation is intended to provide around-the-
clock therapeutic drug concentrations after a once daily administration. 
To aid in the optimisation of the sustained release profile of novel formu-
lations, the dissolution characteristics were compared in vitro and in vivo
for a 2 mg tablet. Deconvolution techniques were used to determine the
in vivo sustained release dissolution profile, and a 1 mg solution was used
as an ‘immediate release’ form to correct for the absorption of rilmeni-
dine. The sr dissolution profile was subsequently compared to the in vitro
characteristics of the new tablet. This study aimed to investigate the
relationship between in vitro and in vivo characteristics of dissolution 
of the slow release formulation. Secondly, the clinical acceptability and
pharmacokinetics of this formulation of rilmenidine compared to a
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Methods
Study design
This was a double-dummy, double blind, randomised, two-way cross-over
study in eight healthy volunteers with a washout between administration of
at least six days.
Subjects
Subjects were male or female subjects, healthy as determined during
screening, who gave signed informed consent. The study was approved by
the Medical Ethics Review Board of Leiden University Medical Center, and
performed according to the principles of the Helsinki Declaration. Eight (4
males, 4 females) subjects completed the study. 
Drug administration 
All subjects received a sustained release formulation of rilmenidine, 2 mg
(active treatment) with the solution vehicle as placebo or a rilmenidine
solution, 1 mg (active treatment) with sustained release placebo tablet.
The sustained release formulation and placebo tablets were produced by
Servier, Gidy France. Servier also produced a rilmenidine 1 mg/ml solution,
according to gmp procedures. One ml of this solution was further diluted by
adding 150 ml water. This final dilution was prepared the afternoon before
dispensing and placed in a refrigerator (4°C) overnight.
Sampling
Subjects were studied after an overnight fast (with the exception of
occasional water). Alcohol and xanthine containing food and beverages were
not allowed from 12 hours before until 36 hours after dosing. A cannula was
inserted in a forearm vein to facilitate repeated blood sampling. Samples
were collected pre-dose and A, 1, 1A, 2, 2A, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24,
and 36 hours after drug administration in heparin-containing polypropylene
tubes (Sarstedt ®) for rilmenidine assay. The tubes were immediately
centrifuged for 10 minutes at 4°C and 1500 g and plasma was subsequently
divided into two aliquots, frozen and stored at -20°C until analysis. Four
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hours after drug administration a standardised lunch was provided and a
dinner was given after ten hours. Subjects went home after 24 hours and
returned to the research unit 36 hours after drug administration for final
measurements. The same procedure was repeated in the second study
period.
Drug concentration analysis
Rilmenidine concentrations were determined using gas chromatography-
mass spectrometry (gc-ms) following liquid-liquid extraction according to
the method described by Ung et al.
In vitro dissolution
sr tablets containing 2 mg rilmenidine were placed into a 37 °C medium 
of 0.05 M phosphate buffer at pH 6.8 (according to the fda guideline) using
USP apparatus ii (paddles). Samples (10 ml) were taken at 0, 1, 2, 4, 8, 12 and
16 hours. After filtration of the samples through a 10 µm polypropylene filter,
an aliquot (5 µl) was injected onto the hplc column (Nucleosil 100-3 C 18
(Macherey Nagel), 150 x 4.6 mm). The concentration of rilmenidine was
determined spectrophotometrically at 205 nm by reference to a calibration
curve.
Pharmacokinetic analysis
A non-compartmental pharmacokinetic analysis was performed for each
subject and each treatment. The estimated parameters were the maximum
observed concentration (Cmax; normalised to a 1 mg dose assuming linear
kinetics, Cmax,norm) and corresponding tmax as well as the last measurable
concentration (Clast). The area under the concentration versus time curve
from 0 to Clast was calculated using the linear trapezoidal rule for rising or
static concentrations and the logarithmic trapezoidal rule for declining levels
(auct; normalised to a 1 mg dose assuming linear kinetics, auct,norm). 
The terminal half life (tA) was estimated using the slope of the elimination
phase. The concentration 24 hours after dosing was also determined (C24).
Additionally, the time interval between administration and first measurable
concentrations (tlag) and the time during which the concentration was 
equal to or greater than 75% of the Cmax (t75) were estimated. The relative
ref. 9
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bioavailability of the sr tablet compared to the solution was estimated
according to the following equation:
frel = 100 •
dsol • auctab
dtab • aucsol
were Dsol and Dtab are the doses for the solution and tablet, and aucsol
and auctab are the auct values for the solution and the tablet respectively.
Compartmental modelling was carried out for the solution data of each
subject using WinNonlin software version 3.1 (Pharsight Corp, Mountain
View, ca) in order to provide parameters for the numerical deconvolution. 
A mono- or bi-exponential model, with or without lag time was fitted to 
the data and the best model fit assessed by comparison of the value of the 
Akaike Information Criterion (aic). Coefficients and exponentials from the
model fit with the lowest value for aic were used for the subsequent
deconvolution analysis.
Deconvolution analysis
Numerical deconvolution was performed using pcdcon software version 
3.0 (William R. Gillespie, Ph.D., The University of Texas at Austin) according
to the method described by Gillespie et al. The model-fitted coefficients and
exponentials for the solution were used to describe the unit impulse
response. The input of rilmenidine was deconvolved from these two profiles
to provide a percentage cumulative amount dissolved (equivalent to the in
vivo dissolution). The in vivo dissolution profile for each individual subject was
related to the mean in vitro dissolution profile for the sr tablet using linear
regression. In addition, an average in vivo dissolution profile from all subjects
was related to the in vitro dissolution profile, yielding a predicted in vivo
dissolution profile. 
In order to estimate the predictive value of this in vivo-in vitro correlation,
internal prediction errors were assessed according to the appropriate fda
guideline. The predicted in vivo dissolution of the tablet was convolved with
the individual solution concentration profiles. This resulted in predicted 
auc and Cmax values for the tablet that were compared to actually observed
values, and absolute percent prediction errors were calculated for both
individual and mean group values.
ref. 10
ref. 11
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Pharmacodynamic determinations
Blood pressure and heart rate were measured immediately before drug
sampling (except at 18 hours), and at b and c hours after the drug
administration. These vital signs were measured after the subject had been
sitting in a semi-recumbent position for at least 5 minutes. An automated
blood pressure monitor (mpv1072, Nihon Kohden, Japan) was used, which
displays an average value for two duplicate measurements at each time
point. Visual analogue lines as originally described by Norris were also used
in this study. The subjects were asked to indicate with vertical marks on 16
horizontal 100-mm lines how he/she felt at that moment. The 16 categories
were (Dutch translations of): Alert/Drowsy, Calm/Excited, Strong/Feeble,
Confused/Clear-headed, Well-coordinated/Clumsy, Lethargic/Energetic,
Contented/Discontented, Troubled/Tranquil, Mentally slow/Quick-witted,
Tense/Relaxed, Attentive/Dreamy, Incompetent/Proficient, Happy/Sad,
Antagonistic/Amicable, Interested/Bored and Withdrawn/Gregarious. From
this set of lines three factors were derived as identified by Bond and Lader,
corresponding to alertness, mood and calmness. These factors were used 
to quantify subjective central nervous system effects. Visual analogue scores
were recorded at A, 1, 2, 4, 6, 8, 10, 12, 14, 24 and 36 hours. Reports of
adverse events were elicited by the question “How do you feel” and by
recording spontaneous reports.
Statistical analysis
Pharmacodynamic measurements were characterised by calculating the
time of maximum effect (tmax) and the corresponding measurement (Emax),
and the area under the curve (auec) over the 0-12 hours time period. These
auecs were subsequently divided by the corresponding time span resulting
in a weighted average value. Measures were compared between treatments
using paired t-tests. Calculations were performed using spss for Windows
V10.0.7 (spss, Inc., Chicago, il).
Results
Subject demographics
All subjects completed both study occasions. No serious adverse events
occurred during the study. Subjects were 23 years of age (range 18-27 years),
ref. 12
ref. 13
115 section 2: developing a new formulation – chapter 5
with an average weight of 69.8 kg (range 49.1-87.7 kg) and height of 177 cm
(range 161-191 cm). Average pre-dose blood pressures were
(systolic/diastolic) 114/62 mmHg (range 97-139/52-72 mmHg) and a heart
rate of 65 bpm (range 48-85 bpm).
Pharmacokinetic parameters
The main pharmacokinetic parameters are represented in Table 1. The mean
plasma concentrations after both solution and sr tablet are represented in
Figure 1.
Tmax was reached on average 3.3h later for the sr formulation than for the
solution (95% ci: 2.5, 4.0 h). Cmax,norm for the sr tablet was on average 1.1
ng/ml lower for the tablet than for the solution (95% ci: 0.6, 1.6 ng/ml). 
The time during which the concentration was greater than 75% of Cmax
(t75) was 3.4 h longer for the tablet than for the solution (95% ci: 0.5, 6.3 h).
Average normalised auc was similar for both treatments but more variable
for the solution than for the tablet (cv of 37% and 17% respectively). 
The relative bioavailability of the sr tablet compared to the solution (Frel) 
was 126 ± 54 % (Mean ± standard deviation). TA was similar for both
treatments but more variable for the solution than for the tablet (cv of 
68% and 43% respectively).
table 1 Average pharmacokinetic parameters after oral administration of a 1 mg 
rilmenidine solution and a 2 mg sustained release tablet including P-values
for the difference
Parameter Solution sr Tablet
Mean sd cv (%) Mean sd cv (%) P-value
Cmax (ng/ml) 3.7 0.77 21 5.2 0.64 12 0.000
Cmax, norm (ng/ml) 3.7 0.77 21 2.6 0.32 12 0.001
tmax (h) 2.1 0.79 37 5.4 0.52 10 0.000
t75 (h) 2.8 1.9 67 6.2 3.258 53 0.028
tlag (h) 0.56 0.18 31 0.75 0.27 36 0.197
auct (ng.h/ml) 33 12 37 73 12 17 0.000
auct, norm (ng.h/ml) 33 12 37 37 6 17 0.470
C24 (ng/ml) 0.59 0.22 37 1.12 0.62 56 0.126
tAz (h) 10.1 6.9 68 8.0 3.5 43 0.288
Frel (%) - - - 126 54 43
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figure 1 Average rilmenidine plasma concentration after oral administration of a 1 mg 
solution (C; solid line) and a 2 mg sustained release tablet (G; dashed line)
figure 2 Relationship between in vitro and in vivo dissolution of the 2 mg sustained 
release tablet (C; solid line). y=1.126x + 0.692, R2=0.99, cv=44%. Dashed line  
is the line of identity
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In vitro – in vivo correlation of the 
dissolution
The relationship between the in vitro and mean in vivo dissolution is given 
in Figure 2. The slope of the mean in vitro – in vivo correlation was 1.12. 
The variability in the in vivo dissolution was considerable with a range of 
the individual slopes of 0.71 to 1.67. 
The overall difference between the average predicted values and observed
values was 6.8% for the auc and 11.9% for the Cmax. However, the means 
of the individual absolute percent prediction errors (the internal prediction
errors) were 32.4% for the auc and 13.6% for the Cmax.
Pharmacodynamic parameters
blood pressure and heart rate   The main results on the
average pharmacodynamic parameters are listed in Table 2. The mean time-
effect curve for diastolic blood pressure is represented in Figure 3. Blood
pressures dropped during treatment: the maximum decrease (systolic /
diastolic) was 15.6/10.6 mmHg with the rilmenidine solution (from 111/60 
at baseline), and 22.1/14.2 mmHg with the tablet (from 117/63 at baseline).
The difference between the two preparations was not statistically significant
(95% confidence interval (95% ci) -1.5, 14.4 mmHg systolic, and –0.6, 7.7
mmHg diastolic). The differences in average response (auec over 12 hours)
were also not significant (Table 2).
The maximum effect of the tablet (Table 2) occurred on average 2.9 h (95%
ci 0.5, 5.3 h) later for systolic, and 2.5 h (95% ci 1.0, 4.0 h) later for diastolic
blood pressure, compared to the solution.
A significantly higher increase in Emax of heart rate of 4.6 bpm was observed
for the solution (95% ci: 1.2, 7.9 bpm). The time of maximal effect for heart
rate was similar for the two preparations.
visual analogue scores   Clear differences in times of maximal
effect were noted for vas alertness as represented in Table 2. Tmax occurred
on average at 3.5 h after the administration of the solution, and 5.4 h 
after the ingestion of the sustained release tablet resulting in an average
difference of 1.9 h (95% ci 0.1, 3.7 h) between the two treatments. 
There were no differences in the other vas factors (mood/calmness).
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table 2 Average pharmacodynamic parameters after oral administration of a 1 mg 
rilmenidine solution and a 2 mg sustained release tablet including P-values 
for the difference
Parameter Solution sr Tablet
Mean sd Mean sd P-value
Systolic blood pressure
tmax (h) 3.3 1.9 6.2 2.9 0.026
Emax (mmHg) 15.6 6.2 22.1 9.4 0.097
auec0-12h (mmHg) 105.0 8.7 104.8 9.3 0.908
Diastolic blood pressure
tmax(h) 3.4 1.9 5.9 2.1 0.005
Emax (mmHg) 10.6 3.6 14.2 5.2 0.083
auec0-12h (mmHg) 55.7 4.9 56.1 5.2 0.521
Heart rate
tmax (h) 5.0 3.1 5.3 1.1 0.846
Emax (bpm) 12.3 5.4 7.8 2.6 0.014
auec0-12h (bpm) 65.6 6.3 66.2 5.3 0.574
vas Alertness
tmax (h) 3.5 1.8 5.4 0.9 0.044
Emax (mm) 16.4 14.4 25.4 10.1 0.163
auec0-12h (mm) 63.6 17.1 63.0 14.8 0.815
Discussion
This study shows that sustained release has been achieved for the tablet:
maximum levels were lower, levels above 75% of the Cmax were maintained
for longer periods, and concentrations were two-fold higher at 24 hours after
ingestion. The dose-normalised Cmax for the sr tablet was lower than for the
solution, while the corresponding tmax and t75 were much longer for the sr
tablet. The relative bioavailability of the tablet was 126%, indicating that a
slow release formulation could have a favourable absorption profile
compared to the solution. 
Deconvolution assumes that the only difference between the two modes of
drug administration for a subject lies in the in vivo dissolution of the tablet.
All other pharmacokinetic parameters and processes are assumed identical.
Therefore the (between subject) variability in the plasma auc after tablet
administration must be equal to or higher than the auc after the solution.
Dissolution of the tablet can be the only source of additional variability. 
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figure 3 Average diastolic blood pressure after oral administration of a 1 mg solution 
(C; solid line) and a 2 mg sustained release tablet (G; dashed line)
However, we found that the auc is more variable after the solution (cv=37%) 
than after the sr tablet (cv=17%). This can only be attributed to other
sources of variability, for instance due to differences in the absorption
process. Additional evidence is provided by the fact that average relative
bioavailability is larger than 100% which must be due to either differences 
in the relative absorption process or high variability in pharmacokinetic
parameters within a subject. These arguments imply that the basic
pharmacokinetic behaviour (absorption, distribution, elimination) is not
identical for the two occasions resulting in high variability in the in vitro – 
in vivo correlation. As a result, the internal prediction errors were higher 
than 10% for auc and Cmax, thus exceeding the stringent criteria mentioned
in the guideline for evaluating the predictability of a level A in vitro - in vivo
correlation (deconvolution followed by comparison of the fraction of drug
absorbed to the fraction of drug dissolved). Nevertheless, the percent
difference between the mean observed and predicted auc and Cmax were
relatively low, indicating that the average in vitro dissolution kinetics of the 
sr tablet is predictive of its in vivo characteristics.
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Despite a two-fold difference in exposure, no significant difference was
observed for the auec0-12h between the rilmenidine slow release formulation
and solution on blood pressure, heart rate and visual analogue scores.
However, the maximum effects occurred significantly later after ingestion 
of the tablet compared to the solution. Although diurnal influences cannot
be excluded without use of a placebo, it seems very likely that these different
time effects are due to the ‘slow release’ profile of the tablet, compared 
to the ‘immediate release’ profile of the solution. The data from this study
can be used to optimise the dissolution characteristics of a sustained release
preparation. Such a preparation could prolong the antihypertensive activity,
while reducing peak-concentration related side effects of rilmenidine.
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objectives   The aim of this study was to compare the effect profiles of
iv administered rilmenidine aimed at the same target plasma concentration,
but attained with different rates.
methods   The study was placebo controlled, randomised, double-
blind, double-dummy, three-way, cross-over in nine healthy volunteers. 
All subjects randomly received either a fast infusion, a slow infusion or a
placebo infusion. The target concentration was set at 8 ng/ml with a five-fold
difference in the time to reach the maximum concentration. Saccadic eye
movements, electroencephalography (eeg), blood pressure and heart rate
were measured every half hour. Drug plasma concentrations, adverse events,
salivary flow and visual analogue scales were obtained every hour.
results   Changes in systolic/diastolic blood pressure at the end of the
infusion were (mean ± sd) 13.3 ± 16.4/ 7.9 ± 7.5 mmHg with the fast
infusion and 16.3 ± 12.7/10.2 ± 7.9 mmHg during the slow infusion,
compared to 0.0 ± 13.2/1.3 ± 8.3 mmHg for the placebo occasion. Decrease
of saccadic peak velocity (spv) at the end of the infusion was 18.0 ± 5.2%
during the fast infusion, 23.0 ± 7.0% with the slow infusion, and 6.1 ± 5.2%
with placebo. pk/pd analysis showed similar concentration-dependent linear
reduction in spv and blood pressure up to the maximum observed
rilmenidine plasma level for both the fast and the slow infusion.
conclusions   The rate of infusion of rilmenidine in healthy volunteers
does not influence the pk/pd relationship of saccadic eye movements and
blood pressure up to the maximum observed rilmenidine plasma concen-
trations. Rilmenidine causes clear concentration-dependent blood pressure
reductions in healthy volunteers.
Introduction
Rilmenidine (2-(dicyclopropylmethyl)-amino-2-oxazoline) is a centrally
acting anti-hypertensive drug with binding selectivity to newly described 
I1 imidazoline receptors (identified in the lateral reticular nucleus in the
brainstem and proximal tubular cells in the kidney) over 12-adrenoceptors. 
It has dose-dependent blood pressure lowering effects above 0.5 mg in 
both healthy and hypertensive subjects. Rilmenidine is registered in several
European countries as 1 mg tablets, and the most frequently used dose is 
ref. 1-5
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1 tablet once daily. Its concentration-related side-effects (sedation, xerosto-
mia) are less important in comparison to congeners (e.g. clonidine), and are
probably mediated by 12-adrenoceptor stimulation. Recently, the central
nervous system effects of rilmenidine 1 and 2 mg po were studied using
saccadic eye movements, electroencephalography (eeg) and auditory evoked
responses (aer). Rilmenidine caused a dose-dependent reduction of
saccadic peak velocity (spv), but little change in the other parameters. These
effects were clearly smaller than with lorazepam 2.5 mg. Characterisation 
of concentration-effect relationships for dry mouth and sedation (which 
were not determined in the previous study) may be helpful in optimising 
the clinical dose. 
In addition to the plasma concentrations, the rate of increase of concen-
tration may also influence the effect. The classic example is provided by
Kleinbloesem et al who demonstrated that a high rate of increase of
nifedipine concentrations did not lead to a blood pressure reduction in
healthy volunteers, contrary to a low rate of increase of nifedipine concen-
trations. The current study was therefore designed to compare the effect
profiles of iv administered rilmenidine aimed at the same target plasma
concentration, but attained with different rates. The target concentration
was set at high concentrations of 8 ng.ml-1, i.e. above the therapeutic range.
The iv infusions were programmed to yield a five-fold difference in the time
to reach the maximum concentration.
Methods
Design
This was a placebo controlled, randomised, double-blind, double-dummy,
three-way, cross-over, monocentric study in nine healthy volunteers, with 
a one-week wash-out period.
Subjects
Subjects were male or female, healthy as determined during screening, who
gave signed informed consent. The study was approved by the Medical Ethics
Review Board of Leiden University Medical Center, and performed according
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Treatments and measurement times
Infusions were performed with a volumetric infusion pump (Sigma 6000+,
Stöpler Instrumenten & Apparaten b.v., Utrecht, The Netherlands) with a
constant infusion rate of 0.25 ml/min over the first 4 hours followed by a
constant infusion rate of 1.0 ml/min over 1 hour. The total volume infused
was 120 ml. Infusion rates were determined after simulation using pk data
from previous studies. 
All subjects randomly received the following treatments:
Fast infusion: NaCl 0.9% over 4 hours followed by rilmenidine infusion 
(1.8 mg/hr) over 1 hour resulting in a total administered dose of 1.8 mg.
Slow infusion: rilmenidine (0.52 mg/hr) over 5 hours resulting in a total
administered dose of 2.6 mg.
Placebo infusion: NaCl 0.9% over 5 hours.
Blood samples were obtained hourly for the first six hours, with more
frequent measurements around the end of the infusion (seven samples in
the 4-6 hour period), and at increasing time intervals for 24 hours. Pharma-
codynamic measurements were performed at half-hour intervals for six
hours and at decreasing frequency after the end of the infusion.
Blood Pressure
Blood pressure and heart rate were measured with an automated blood
pressure monitor (mpv1072, Nihon Kohden, Japan), which displays an
average value for two sequential (duplicate) measurements at each time
point. All measurements were made after the subject had been sitting in 
a semi-recumbent position for at least 5 minutes.
Saccadic Eye Movements
Saccadic eye movements are a sensitive measure for central nervous 
system effects of rilmenidine and clonidine. Saccadic eye movements 
were recorded as described previously using a micro-computer-based 
system for data recording (Cambridge Electronics Design, Cambridge, uk),
Nihon Kohden equipment for stimulus display, signal collection and
amplification (Nihon Kohden Corporation, Tokyo, Japan), and disposable
surface electrodes (Medicotest N-oo-s, Olstykke, Denmark). Average 
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(difference between stimulus angle and corresponding saccade in %) were
calculated for all artifact-free saccades.
ElectroEncephaloGraphy (eeg)
eeg-registrations have been used previously to quantify drug effects of
rilmenidine and clonidine. eeg registrations of total power for Delta- (<4Hz),
Theta- (4-7.5 Hz), Alpha- (7.5-12.5 Hz) and Beta- (12.5-30 Hz) activity were
obtained at leads Fz-Cz and Pz-Oz., as described previously.
Visual Analogue Scales
Visual analogue scales as originally described by Norris were previously used
to quantify subjective effects of benzodiazepines. From the set of sixteen
lines three factors were derived as described by Bond and Lader, correspon-
ding to alertness, mood and calmness. These factors were used to quantify
subjective drug effects.
Salivary Flow
Salivary production was estimated by measuring the weight increase 
of three dental rolls put into the oral cavity over a period of 3 minutes. 
Salivary production was assessed regularly up to eleven hours after start of
the infusion with an additional 24-hour measurement. The dental rolls and
accompanying collection tubes used for this measurement were Sarstedt
neutral Salivettes7 (Sarstedt, Etten Leur, The Netherlands).
Analyses
pharmacokinetics   Rilmenidine plasma levels were measured
using gas chromatography/mass spectrometry. The limit of detection was
0.3 ng/ml and the linearity of the assay has been checked over a range of 
0.3 - 2 ng/ml. The pharmacokinetics were described using nonmem version
V (nonmem Project group, ucsf, San Francisco, ca), applying the first order
conditional estimation (foce) method with the interaction option. Intra-
individual error was modelled using a combination a constant (small)
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pharmacokinetic/pharmacodynamic relationships
The observed pharmacodynamic effects were plotted against the predicted
rilmenidine concentrations for each individual. pk/pd modelling was
performed using nonlinear mixed effect modelling as implemented in
nonmem. Rilmenidine pharmacokinetics was described using empirical
Bayes estimates for the pharmacokinetic parameters. First order conditional
estimation was used with an additive residual error. Models with and without
a hypothetical effect compartment were used. Concentration-effect
parameters for the fast infusion were determined along with parameters
estimating the difference between slow and fast infusion. Additive inter-
individual variability was used on paired (within-subject) data. Only pd data
obtained during and after the actual infusion of rilmenidine were used.
Nested models were compared on the basis of the change in the minimum
value of the objective function. A change of 3.8 (associated with 1 degree of
freedom) was considered significant at p=0.05. Contrast parameters between
the slow and fast infusion are reported with approximate 95% confidence
intervals calculated using two times the reported standard error.
statistics   Changes from baseline at the end of the infusion were
calculated for the pharmacodynamic parameters and compared between
treatments using paired Student t-tests. Differences are reported with 95%
confidence intervals (95% ci). Data are shown as average with standard
deviation (M ± sd) unless indicated otherwise. Calculations were performed
using spss for Windows V9.0.1 (spss, Inc., Chicago, il).
Results
Demographics
All nine (5 males, 4 females) subjects completed the study. Subjects were on
average 22.2 years of age (range: 19-26 years). No serious adverse events
occurred during the study.
Pharmacokinetics
The time-concentration profiles for the two infusion regimens are shown in
Figure 1. The maximal concentrations were 9.6 ± 1.0 ng/ml with the fast rate
infusion, and 8.1 ± 2.4 ng/ml after the slow rate infusion. Prior experience
with rilmenidine and visual inspection of the individual data clearly indicatedref. 17
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the need for a two-compartment model. The average pharmacokinetic
parameters with inter-individual variation coefficients (cv) were: clearance 
of 0.53 L/min (cv 31%), initial half-life of 15.7 min (cv 21%), terminal half-life
of 361 min (cv 23%), and central volume of distribution of 129 L (cv 33%).
These results correspond to the pharmacokinetics found in previous healthy
volunteer studies after single dose administration.
figure 1 Time-concentration profiles (Mean + sd) for slow- (C) and fast- (D) rilmenidine 
infusions
Pharmacodynamics
Table 1 presents differences between the three treatments in changes from
baseline at the end of the infusion for pharmacodynamic parameters.
blood pressure and heart rate   The average time effect
curves for diastolic blood pressure are shown in Figure 2, and similar profiles
were seen for systolic blood pressure. At baseline, blood pressure was similar
for all three treatments. Changes in systolic/diastolic blood pressure at the
end of the infusion were 13.3±16.4/ 7.9±7.5 mmHg with the fast infusion
and 16.3±12.7/10.2±7.9 mmHg during the slow infusion, compared to
0.0±13.2/1.3±8.3 mmHg for the placebo occasion. Blood pressure decreased
significantly compared to placebo, but no significant differences were
observed between the slow and fast infusions (Table 1). Heart rate decreased
slightly during slow but not fast rilmenidine infusion. At the end of the
rilmenidine infusions, blood pressures slowly returned to normal, without
apparent differences between the fast and slow rate infusions. 
ref. 17
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table 1 Placebo corrected changes from baseline (95% confidence intervals) in 
pharmacodynamic parameters at the end of the infusion
Fast Infusion Slow Infusion Fast minus Slow 
Infusion
Systolic bp (mmHg) -13.3 (-23.3/-3.3) -16.3 (-24.3/-8.4) 3.0 (-9.6/15.6)
Diastolic bp (mmHg) -6.6 (-11.8/-1.3) -8.9 (-15.0/-2.8) 2.3 (-5.8/10.5)
Heart rate (bpm) -4.0 (-13.1/5.1) -7.2 (-13.0/-1.5) 3.2 (-3.9/10.4)
Saccadic Peak Velocity (% change) -11.9 (-17.5/-6.2) -16.9 (-22.6/-11.1) 5.0 (-2.2/12.2)
eeg Delta Pz-Oz (% change) 28.8 (11.4/46.1) 28.7 (16.0/41.3) -3.3 (-21.9/15.4)
eeg Beta Fz-Cz (% change) 21.5 (-1.5/44.4) 15.6 (-1.0/32.1) 0.8 (-26.0/27.7)
vas alertness (% change) -11.9 (-29.0/5.1) -13.9 (-29.4/1.6) 2.0 (-13.5/17.4)
Salivary flow (% change) -78.8 (-120.5/-37.1) -82.3 (-122.4/-42.2) 3.5 (-16.0/23.1)
figure 2 Time-effect profiles (Mean + sd) for diastolic blood pressure for placebo-
(A), slow- (C) and fast- (D) rilmenidine infusions
saccadic eye movement   The average time profiles for the
saccadic peak velocity (spv) is shown in Figure 3. Decrease at the end of the
infusion was 18.0±5.2% during the fast infusion, 23.0±7.0% with the slow
infusion, and 6.1±5.2% with placebo (Table 1). No significant differences were
found in saccadic inaccuracy (as defined in the method section) and saccadic
latency between the two active treatments.
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figure 3 Time-effect profiles (Mean + sd) for saccadic peak velocity for placebo- (A), 
slow- (C) and fast- (D) rilmenidine infusions
electroencephalography (eeg)   Delta Pz-Oz activity
increased significantly during both slow and fast rilmenidine infusion
compared to placebo, with a similar trend for eeg Beta Fz-Cz power (Table 1).
There were no significant differences between the two active treatments. No
significant differences were observed for any of the other eeg parameters.
visual analogue scales (vas)   Decrease in vas scores of
alertness at the end of the infusion was 13.6±21.5% during the fast infusion
and 15.6±12.6% with the slow rate infusion, compared to 1.7±11.9% with
placebo (Table 1). After both infusion regimens, vas-alertness returned to
baseline within about 6 hours. There were no significant effects for vas
scores of calmness and mood between the three treatments.
salivary flow   Saliva production decreased significantly to similar
levels during both rilmenidine infusions (Table 1, Figure 4). At the end of the
infusion, salivary flow had decreased 60.7±13.2% during the fast infusion
and 64.2±19.9% during the slow infusion, compared to an increase of
18.1±49.0% with placebo. The production of saliva slowly returned to normal
baseline values after the infusions were stopped. No differences between
slow and fast infusions were observed.

























figure 4 Time-effect profiles (Mean + sd) for saliva production for placebo- (A), slow- (C) 
and fast- (D) rilmenidine infusions
Pharmacokinetic/pharmacodynamic 
relationships (pk/pd)
Concentration effect relationships between rilmenidine, saccadic peak
velocity and diastolic blood pressure were examined. nonmem parameters 
of the final models are presented in Table 2. For saccadic peak velocity, a
linear concentration-effect model was used with a hypothetical effect
compartment. Inclusion of this effect compartment resulted in a significant
improvement in fit. Visual inspection of the individual concentration-effect
graphs did not suggest the need for a more complex concentration-effect
model. For diastolic blood pressure, a linear concentration-effect model 
was used without a hypothetical effect compartment. Inclusion of this effect
compartment did not result in a significant improvement in fit, indicating
that no hysteresis loop was observed. Visual inspection of the individual
concentration-effect graphs did not suggest the need for a more complex
concentration-effect model.
Both slopes and intercepts for saccadic peak velocity and diastolic blood
pressure did not differ between the slow and fast infusion (Table 2). However,
the slope of the concentration-effect curves for diastolic blood pressure after
the slow infusion seems to be larger than after the fast infusion. This is
supported by the slightly lower concentrations and higher maximum effect
on diastolic blood pressure after the slow infusion. The lack of significance
could be due to the small population size.
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table 2 Mean pk/pd parameters for saccadic peak velocity and diastolic blood pressure 
for fast infusion and difference slow-fast infusion
Mean 95% ci inter-individual variability (sd)
Saccadic peak velocity1
t1/2 Ke0 (min) 5.6 1.5/9.7 0.0 (fixed)
Intercept fast infusion 445 418/472 32
Difference in intercept (slow-fast) 11.8 -6.9/30.5 16
Slope fast infusion -11.3 -14.0/-8.6 1.3
Difference in slope (slow-fast) -1.1 -3.1/0.8 0.0
Residual error (sd) 31.2
Diastolic blood pressure2
Intercept fast infusion 61.4 58.2/64.6 3.1
Difference in intercept (slow-fast) 2.2 -0.9/5.3 0.9
Slope fast infusion -1.20 -1.68/-0.72 0.13
Difference in slope (slow-fast) -0.48 -1.12/0.16 0.29
Residual error (sd) 4.29
1. units for intercepts in deg/sec; units for slopes in (deg/sec)/(ng/ml)
2. units for intercepts in mmHg; units for slopes in (mmHg)/(ng/ml)
Discussion
The current study showed clear relationships between the rilmendine
concentration and reduction of blood pressure, saccadic peak velocity and
salivary flow in normotensive subjects. Concentration-effect relationships
were not affected by the rate of infusion per se, contrary to the effects of the
calcium channel blocker nifedipine, where blood pressure reduction is larger
with slow rate than with fast rate infusion. This difference could be due to
the different modes of action of the two antihypertensive agents. Nifedipine
acts peripherally, and fast blood pressure reductions are probably rapidly
counteracted by the baroreceptor reflex (with tachycardia), whereas slow
increases in plasma concentrations allow the baroreceptor reflex to reset
downward. Rilmenidine on the other hand acts centrally, possibly by
reducing the level around which blood pressures fluctuate (without changes
in heart rate), and may therefore evade counter-regulatory mechanisms. 
The central nervous system (cns) effects of rilmenidine on saccadic peak
velocity (spv) and eeg-Delta- and -Beta-power were also not affected by the
infusion rate. Another study where infusion rate-effects were evaluated on
the same pharmacodynamic endpoints, was performed with temazepam.
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after fast- than after slow-rate infusion, but this rate-effect was marginal 
and not observed for spv or any other cns-parameter. Thus, cns-effects 
of temazepam and rilmenidine were unaffected by infusion rates.
In the current study, rilmenidine reduced spv, similar to previous reports.
The average spv-reductions at the end of the rilmenidine infusions were
18.0-23.0%. However, it is difficult to interpret these changes clinically. 
The concomitant occurrence of (statistically non-significant) reductions in
visual analogue scales of alertness suggests that the spv-reduction reflects
sedation. However, the clinical relevance of these changes is difficult to
determine, since saccadic eye movements have not been quantitatively
related to clinical effects of centrally acting antihypertensive agents. For
benzodiazepines, the clinical correlates of such spv-changes are well
validated. Isolated spv-effects at low benzodiazepine levels reflect a larger
sensitivity of this biomarker to cns-depression, than other
pharmacodynamic or subjective measures. Other cns-effects only occur 
at higher benzodiazepine doses. The clinical relevance of spv-reductions 
is not only determined by the size but also by the duration of the effect. 
The impact of short-lasting effects on daily life is subject to a wide inter-
subject variability, and strongly influenced by external factors like activities
(e.g. demanding circumstances), day time, coffee-intake, etc. Also, the
duration of treatment is relevant, since patients may develop tolerance to 
or become imperceptive of the sedative properties of drugs during prolonged
treatment. The current study showed clear concentration-dependent effects
of rilmenidine on blood pressure and on the central nervous system. 
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objectives   The current study was designed to assess the concentra-
tion-effect relationships for the anti-hypertensive effects of rilmenidine in
patients to aid in the design of an optimised concentration profile of a
sustained release formulation.
methods   This was a placebo controlled, randomised, double-blind, 
two-way partial cross-over, study in subjects with hypertension. Twenty-six
patients were randomised to receive two of three possible 12-hour infusion
regimens, each consisting of a loading phase (2 h) and a maintenance phase
(10 h): Low Profile infusion (total dose of rilmenidine 1.45 mg), high profile
(total dose 3.3 mg) or placebo. Drug plasma concentrations, adverse events,
blood pressure and heart rate, and visual analogue scales were measured
frequently up to 24 hours after dosing. Salivary flow was determined up to 
15 hours.
results   The high concentration profile was well tolerated and still
produced a significant blood pressure reduction of 10.4/5.8 mmHg after 
24-hours. After 24 hours, the low concentration profile showed no significant
effects on blood pressure compared to placebo. Decreases in salivary flow
were -36% for the high infusion and -20% for the low profile compared to
placebo. Pharmacokinetic-pharmacodynamic analyses show infusion rate
independent linear concentration-dependent reductions in dbp and salivary
flow up to the maximum observed rilmenidine concentration for both
infusions.
conclusions   The high concentration profile was well tolerated and still
produced a significant blood pressure reduction after 24-hours. Pharmaco-
kinetic-pharmacodynamic relationships were linear and unaffected by the
rate of infusion. These results should aid in the design of an optimal slow
release profile.
Introduction
Rilmenidine (2-(dicyclopropylmethyl)-amino-2-oxazoline) is a centrally
acting anti-hypertensive with binding selectivity to the I1 imidazoline
receptors over 12-adreno-ceptors. It has dose (concentration)-dependent
blood pressure lowering effects above 0.5 mg in both healthy and hyper-
tensive subjects. Rilmenidine is registered in several European countries 
ref. 1-4
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at a recommended dose of 1 tablet of 1 milligram once or twice daily. Clinical
experience indicates that with 1 mg dosing blood pressure control might not
be maintained for 24 hours per day in all patients. Twenty-four hour moni-
toring of the effects of 1 mg rilmenidine in 80 hypertensive patients after 4
weeks treatment with this dosage suggested a significant duration of action
of 14 hours. In a study of 146 patients with hypertension (95 < diastolic blood
pressure [dbp] < 115mmHg), trough level blood pressure control was consi-
dered inadequate in 56% of subjects after 4 weeks of treatment. An unspeci-
fied number of these patients became adequately controlled after increasing
the dosing frequency to 1 mg twice daily. This dosage regimen is less accep-
table during chronic treatment, while on the other hand elevating the dose of
once-daily administration may increase the incidence of peak concentration-
related side-effects, such as sedation and dry mouth (xerostomia).
A sustained release formulation of the drug could maintain plasma levels 
in between a minimum effective (anti-hypertensive) concentration and a
maximum non-sedative peak level. In addition to the plasma concentrations,
the rate of increase of concentration may also influence the effect. The
classic example is provided by Kleinbloesem et al who demonstrated that a
high rate of increase of nifedipine concentrations did not lead to a blood
pressure reduction in healthy volunteers, contrary to a low rate of increase 
of nifedipine concentrations. However, a previously performed study showed
no influence of the rate of infusion of rilmenidine on both blood pressure and
development of side-effects. The current study was part of several investi-
gations aimed at the design of an optimal slow release profile. The present
study aimed to establish minimum anti-hypertensive 24 hour trough
concentrations in hypertension, and to identify pharmacokinetic / pharma-
codynamics relationships that could aid in the design of an optimal
controlled release concentration profile. The low profile had a plateau phase
with estimated minimum effective concentrations. The high profile was
designed to reach a plateau phase with estimated maximum tolerated
concentrations, and a minimum effective trough level.
Methods
Design
This was a placebo controlled, randomised, double-blind, double-dummy,
single-dose, two-way partial cross-over, monocentric study in subjects with
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Subjects
Hypertensive subjects, treated with a maximum of two different anti-
hypertensive drugs, gave signed informed consent to participate in this 
non-therapeutic study. Patients were included after their treating physicians
were informed. After a general health screen (during which relevant
additional conditions were excluded, including causes for secondary
hypertension or hypertensive complications) all anti-hypertensive agents
were withdrawn (gradually in the case of ß blockers), while blood pressure
was monitored regularly. After return of diastolic blood pressure (dbp) to
values between 95-115 mmHg, patients were scheduled for their first study
occasion within five days following the detection of hypertension. Subjects
who remained normotensive or whose blood pressure were higher than 
115 mmHg on two consecutive occasions or once above 120 mmHg, were
referred to their treating physicians, and excluded from further participation.
The study was approved by the Medical Ethics Review Board of Leiden
University Medical Center, and performed according to the principles of the
Helsinki Declaration.
Treatments
Hypertensive patients were randomised to receive two of three possible 
12-hour infusion regimens, each consisting of a loading phase (2 h) and a
maintenance phase (10 h):
Low Profile infusion: (estimated minimum effective plateau phase of 2-3
µg/L): a constant rate infusion (14 mL/h) of a 25.3 mg/L rilmenidine solution,
0.35 mg/h over 2 hours followed by a ten hour constant rate infusion (3.0
mL/h) of the 25.3 mg/L rilmenidine solution, 0.075 mg/h. The total dose of
rilmenidine infused was 1.45 mg. The infusion regimen was modelled, based
on the maintenance of an estimated minimum effective peak level of ap-
proximately 2.9 µg/L for ten hours, leading to a trough concentration of
approximately 1.0 µg/L after 24 h.
High Profile infusion: (estimated maximum tolerated plateau phase of 6-7
µg/L): a constant rate infusion (14 mL/h) of a 56.6 mg/L rilmenidine solution,
0.8 mg/h over 2 hours followed by a ten hour constant rate infusion (3.0
mL/h) of the 56.6 mg/L rilmenidine solution, 0.17 mg/h. The total dose of
rilmenidine infused was 3.3 mg. The infusion regimen was modelled, based
on the maintenance of an estimated maximum tolerated peak level of
approximately 6.5 µg/L for ten hours, and an estimated minimum effective
trough concentration of approximately 2.3 µg/L after 24 h.
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Placebo infusion: a constant rate infusion (14 mL/h) of sodium chloride,
0.9% over 2 hours followed by a ten hour constant rate infusion (3.0 mL/h) 
of NaCl 0.9%. The total volume of NaCl 0.9% infused per subject was 
58 ml.
A syringe infusion pump (Harvard, model 22 Harvard Electronics, South-
natick, Mass, usa) was used to infuse one syringe of 40 ml during the loading
phase. During this time, a one-lead telemetric ecg-recording was obtained.
Subsequently, a volumetric infusion pump (Sigma 6000+, Stöpler
Instrumenten & Apparaten b.v., Utrecht, The Netherlands) was used to
administer during the maintenance phase from 2 to 12 hours. The infusion
syringes and bottles were connected to the iv cannula via a line that was
primed with the rilmenidine solution prior to the start of the infusion.
Hæmodynamics
Blood pressure and heart rate were measured with an automated blood
pressure monitor (mpv1072, Nihon Kohden, Japan), which displays an
average value for two sequential (duplicate) measurements at each time
point. All measurements were made after the subject had been in a semi-
recumbent position for at least 5 minutes.
Visual Analogue Scales
Visual analogue scales (vas) as originally described by Norris were previously
used to quantify subjective effects of benzodiazepines. From the set of
sixteen lines three factors were derived as described by Bond and Lader,
corresponding to alertness, mood and calmness. These factors were used to
quantify subjective drug effects.
Salivary Flow
Saliva flow was estimated by measuring the weight increase of three dental
rolls put into the oral cavity over a period of 3 minutes. The dental rolls and
accompanying collection tubes used for this measurement were Sarstedt
neutral Salivettes® (Sarstedt, Etten Leur, The Netherlands). For each
measurement three dental rolls and a collection tube were weighed together.
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positioned between each lower gum and cheek. After 3 minutes, the dental
rolls were immediately put in their collection tubes and weighed later on the
same day.
Telemetric electrocardiography
During the first hour of the infusion, a one-lead telemetric ecg-monitoring
was performed using the Nihon Kohden Lifescope ii telemetric recording
system (Nihon Kohden Europe, Amsterdam, The Netherlands).
Measurement times
For the first fifteen hours after the start of the infusion and 23 and 24 hours,
drug plasma concentrations, adverse events, blood pressure and heart rate,
and visual analogue scales were measured every hour. An additional blood
sample was obtained after 33 h. Salivary flow was determined at 0, 1, 2, 4, 8,
12 and 15 hours.
Analyses
pharmacodynamics   Pharmacodynamic parameters were
compared between treatments by calculating the area under the effect curve
over 0-15hrs (using the linear trapezoidal rule on protocol times) and dividing
this area by the corresponding time interval. The result is a weighted average
response. 
These areas-under-the-effect-curves (auecs) were compared between
treatments using an analysis of variance for cross-over design taking into
account treatment, period and subject effects. Carryover was assumed
absent because of the sufficiently long washout period. Treatment response
was quantified using Least Square Means with associated standard errors.
Contrasts between the treatments were calculated within the anova model
and are reported with 95% confidence intervals. Calculations were performed
using sas for Windows V6.10 (sas Institute, Inc., Cary, nc, usa) and spss for
Windows V10.0.7 (spss, Inc., Chicago, il, usa).
pharmacokinetics   Rilmenidine plasma levels were measured by
using a gas chromatographic/mass spectrometric method. The limit of
detection was 0.3 ng/ml and the linearity of the assay has been checked over
ref. 14
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a range of 0.3 - 2 ng/ml. The average assay precision (coefficient of variation)
is approximately 7% while the average assay accuracy (percentage of error) 
is 4%. The rilmenidine pharmacokinetics were described using a two-com-
partment model with constant coefficient of variation intra-individual error,
using nonmem version V (GloboMax llc, Hanover, Md), applying the first
order conditional estimation (foce) method with the ‘interaction’ option.
pharmacokinetics/pharmacodynamics (pk/pd)   
pk/pd modelling with sbp, dbp and salivary flow as effect measures was
performed. The average placebo profiles for these measures indicated a 
clear placebo response. Placebo correction was therefore implemented 
by subtracting the average placebo profile from the active treatment profiles
at corresponding timepoints. The empirical Bayes estimates from the pk
analysis were used to generate predicted rilmenidine concentrations. For
each timepoint the estimated rilmenidine concentration was plotted against
the placebo corrected pharmacodynamic response. A linear concentration-
effect model was estimated because individual and average graphs did not
suggest any other model. Hysteresis was not apparent and therefore a direct
concentration-effect relationship was assumed. Estimates were obtained for
slopes and intercepts for the low treatment with difference estimates for the
high treatment. A common additive between subject variability was assumed
for both treatments. Residual variability was also assumed additive. First-
order conditional estimation (foce) was used and 95% confidence intervals
(95% ci) for the difference estimates between low and high treatment were
calculated using population mean ± 2 times the approximate standard error
as obtained from the analysis. Data management was performed using spss
for Windows V10.0.7 (spss, Inc., Chicago, il, usa).
Results
Subjects
Forty-five subjects gave written informed consent for participation in the
study. Six subjects did not comply with the screening criteria: five for obesity
and one for use of more than two anti-hypertensives. After antihypertensive
withdrawal, eleven subjects did not comply with the inclusion criteria: seven
kept dbp below 95 mmHg, one withdrew for personal reasons, and three
developed dbp above 120 mmHg. Twenty-eight Caucasian subjects were
included in the study (18 males, 10 females) after withdrawal of co-medi-
cation for 1-6 weeks. These subjects were 53.7 years of age (range 38-65
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years), with an average weight of 83.4 kg (range 59-104.5 kg) and an average
height of 173.9 cm (range 161-190.4 cm). The average blood pressure at
inclusion was 175/102 mmHg (ranges sbp 155-192, dbp 96-114 mmHg).
From the 28 included patients, two subjects dropped out. One subject took
disallowed concomitant medication throughout the study and the other
subject withdrew for personal reasons. The study population therefore
comprised twenty-six (26) completed and analysed subjects.
Pharmacokinetics
The time-concentration profiles for the two infusions are shown in Figure 1.
Average clearance was 23.7 L/hr with a standard error of the mean (sem) 
of 1.25 L/hr and an inter-individual variability as coefficient of variation (iicv)
of 33%. Central volume was estimated as 213 L (sem 33.3 L, iicv 27%) and
the peripheral volume was 104 (sem 39.4 L, iicv 49%). The residual error was
11.6%.
figure 1 Time-concentration profiles (Mean + sd) for low- (C) and high profile (G) 
rilmenidine infusions
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The overall responses of the hæmodynamic parameters represented by time-
corrected auecs for the 0-15h period and contrasts between the three
treatments are shown in table 1. Average time effect curves are shown in
figure 2. No significant effects were observed for heart rate.
table 1 Time-corrected auecs (0-15 h) for all pharmacodynamic parameters: 
Least mean square means (lsm), standard errors (se) and contrasts (Delta)  
with 95% confidence intervals (95% ci) between treatments (* p<0.05)
Parameter Low infusion High infusion Placebo High vs Low vs High vs 
(n=19) (n=20) (n=13) Placebo Placebo Low
lsm se lsm se lsm se Delta Delta Delta 
(95% ci) (95% ci) (95% ci)
Systolic bp 155.1 1.63 138.6 1.57 161.3 2.14 -22.7 * -6.2 * -16.6 * 
(mmHg) (-28.5, -16.9) (-12.1, -0.3) (-21.3, -11.8)
Diastolic bp 89.5 0.94 79.7 0.91 92.8 1.23 -13.1 * -3.3 -9.8 *
(mmHg) (-16.5, -9.8) (-6.7, 0.1) (-12.6, -7.1)
HR 66.7 0.86 64.2 0.83 65.4 1.12 -1.2 1.3 -2.4 
(bpm) (-4.2, 1.9) (-1.9, 4.4) (-5.0, 0.1)
vas alertness 69.8 1.54 70.1 1.48 72.1 2.01 -2.0 -2.2 0.2 
(mm) (-7.4, 3.4) (-7.8, 3.3) (-4.3, 4.7)
vas mood 76.8 1.24 79.1 1.20 78.8 1.62 0.3 -2.0 2.2 
(mm) (-4.1, 4.7) (-6.5, 2.5) (-1.4, 5.9)
vas calmness 78.1 1.16 79.9 1.12 78.7 1.52 1.1 -0.6 1.7 
(mm) (-3.0, 5.2) (-4.8, 3.6) (-1.7, 5.1)
Salivary flow 1.89 0.11 1.50 0.11 2.37 0.15 -0.87 * -0.48 * -0.39 * 
(mL.3min-1) (-1.27, -0.48) (-0.89, -0.07) (-0.72,-0.07)
The average baseline blood pressures were hypertensive and quite similar
among the three treatment groups. At baseline, the average sbp/dbp varied
between 161.5/92.6 and 168.3/98.3 mmHg. Overall blood pressures (time-
corrected auecs 0-15h) diminished slightly during placebo, to average values
of 161.3 ± 2.1 mmHg systolic, and 92.8 ± 1.2 mmHg diastolic (least square
means and standard errors). Slightly stronger overall blood pressure reduc-
tions occurred with the low profile infusion, to 155.1 ± 1.6 mmHg for systolic
and 89.5 ± 0.9 mmHg for diastolic blood pressure. The effects of the high
profile infusion regimen were much stronger: the average systolic values over
the 0-15h period dropped to 138.6 ± 1.6 mmHg, and the diastolic pressure to
79.7 ± 0.9 mmHg. The contrasts between the different treatments showed
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statistically significant differences between placebo on the one hand and the
low and the high profile rilmenidine treatments on the other; and between
the two active treatments. No differences in heart rate response were found
between the three treatments.
figure 2 Time-effect profiles (Mean + sd) for diastolic blood pressure for placebo- (D), 
low- (C) and high profile (G) rilmenidine infusions
The high profile infusion regimen resulted in good blood pressure control
over the 0-15h period, but blood pressure slowly increased while the subjects
remained in the research unit over the next nine hours. As shown in figure 2,
the average blood pressures were still reduced twenty-four hours after the
start of the placebo infusion, compared to the baseline values: systolic values
were 162.8 ± 3.2 mmHg and diastolic pressure was 92.6 ± 2.0 mmHg (least
square mean and standard error). The effect of the high profile infusion
regimen after 24 hours differed significantly from placebo: blood pressure
was 152.4 ± 2.5 mmHg systolic and 86.8 ± 1.5 mmHg diastolic, and the
contrast with placebo was 10.4 (1.4, 19.4) mmHg and 5.8 (0.3, 11.3) mmHg,
respectively (difference and 95% confidence interval). The average blood
pressure at 24 hours after the start of the low profile infusion was 157.2 ± 
2.4 mmHg systolic and 89.8 ± 1.5 diastolic, which did not differ significantly
from the two other treatments. The difference from placebo was 5.7 (-3.3,
14.6) mmHg systolic and 2.8 (-2.7,  8.3) mmHg diastolic.
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pk/pd parameter estimations for sbp, dbp and salivary flow are represented
in table 2. The average placebo-corrected pk/pd relationships are presented
in figure 3 for dbp and figure 4 for salivary flow. All three parameters (sbp,
dbp and salivary flow) showed linear concentration-effect relationships. No
significant differences were observed between the low and the high infusion
for both slopes and intercepts for all effect parameters.
table 2 pk/pd parameters using empirical Bayes estimates vs placebo corrected 
diastolic blood pressure and salivary flow. Population average (Mean), standard 
error of the population average (sem), 95% confidence intervals (95% ci) and 
inter-individual variability as standard deviation (iisd)
Parameter Mean sem 95% ci p iisd
Systolic blood pressure
Intercept (mmHg) Low 3.85 11.9
High 0.23 11.9
Difference -3.62 4.71 -13.1, 5.8 ns
Slope (mmHg)/(ng/mL) Low -3.01 2.17
High -4.27 2.17
Difference -1.26 1.28 -3.8, 1.3 ns
Residual error (sd; mmHg) 11.3
Diastolic blood pressure
Intercept (mmHg) Low 0.243
High -2.38 1.15
Difference -2.62 2.77 -8.2, 2.9 ns 1.15
Slope (mmHg)/(ng/mL) Low -1.39
High -2.23 0.00
Difference -0.837 0.736 -2.3, 0.6 ns 0.00
Residual error (sd; mmHg) 6.69
Salivary flow
Intercept (mL/3min) Low -0.011
High -0.173
Difference -0.162 0.559 -1.3, 1.0 ns
Slope (mL/3min)/(ng/mL) Low -0.247
High -0.152
Difference 0.0948 0.105 -0.12, 0.30 ns
Residual error (sd; mL/3min) 0.682
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figure 3 Concentration rilmenidine-diastolic blood pressure profiles (Mean + sd) for 
low- (C) and high profile (G) rilmenidine infusions
figure 4 Concentration rilmenidine-saliva production profiles (Mean + sd), low- (C) 
and high profile (G) rilmenidine infusions
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Safety
No serious adverse events occurred during the study. 
sedation, alertness, mood or calmness   The contrasts
between the different treatments on visual analogue scales are shown in
table 1. There were no significant differences between the placebo-, the low
profile- or the high profile infusions for the three different scores derived
from the visual analogue scales. The visual analogue scale scores during the
placebo-infusion were quite variable, which precluded the demonstration 
of any effects of rilmenidine. Sedation was reported by 21 of the 26 subjects
during any stage of the study since selection. Mild sedation was reported by
4/13 subjects during the placebo occasion (31%), and by 13/19 and 13/20
subjects during the low and high profile rilmenidine treatments (65-68%).
Seven subjects reported sedation on both rilmenidine occasions. Three
subjects reported sedation during one of the rilmenidine infusions and
placebo infusion (one during the low profile infusion and placebo infusion,
one during the high profile infusion and the placebo infusion and one during
the high profile infusion, the placebo infusion and the pre-dosage period).
Nine subjects reported sedation on one of the two rilmenidine occasions 
(five subjects during the low profile infusion and four subjects during the
high profile infusion). 
dry mouth   The overall responses on the salivary flow represented 
by time-corrected areas-under-the-effect-curves (auecs) for the 0-15h
period and contrasts between the three treatments are shown in table 1. 
The contrast between the different treatments indicated that the average
saliva production differed significantly between the placebo infusion, the 
low profile infusion and the high profile. The average saliva production over
the 0-15h period was 1.50 ± 0.11 ml.3min-1 with the high profile (-36%), and
1.89 ± 0.11 ml.3min-1 with the low profile infusion (-20%), compared to 2.37
± 0.15 ml.3min-1 with placebo (mean ± standard error). Spontaneous reports
of dry mouth (xerostomia) were only slightly more prevalent with rilmenidine
(on 4/19 low and 5/20 high profile occasions, 21 and 25%, respectively) than
with placebo (on 2/13 occasions, 15%).
headaches   Headaches occurred frequently during all stages of the
study. Three subjects had headaches during the placebo occasion, but two 
of these also had headaches during the pre-treatment and washout periods.
During the low profile infusion, 13 subjects developed headache, three of
whom had similar complaints before and after treatment, and one only
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during the washout period. Five patients had headaches with the high profile
treatment, two of whom also complained of headache during either the pre-
treatment or the washout period.
telemetric electrocardiography   No clinically significant
ecg-changes or heart rate changes were noted by telemetric ecg monitoring
in any patient, during the first hour of the rilmenidine- or placebo-infusions.
Discussion
Both rilmenidine treatments produced demonstrable anti-hypertensive
effects. The low infusion profile was aimed to maintain a 10-hour plateau 
at estimated minimum effective concentrations for around 10 hours. Even 
so, a mean hypotensive effect of 5.7/2.8 mmHg still existed twelve hours
after the low dose infusion was stopped (24 hours after the start of the
infusion), although the differences form placebo were not statistically
significant. These results are difficult to compare to the clinical effects of
anti-hypertensive agents, because clinical trials usually deal with prolonged
treatment, and blood pressure reduction may gradually develop over time.
The Veteran Affairs Cooperative Study Group on Anti-hypertensive Agents 
for instance reported systolic/diastolic changes from baseline in the order 
or 11-16/10-12 mmHg after six weeks of treatment with a variety of anti-
hypertensive drugs. Compared to a blood pressure reduction of 5/3 mmHg
with placebo in the same study, this would indicate a net chronic anti-
hypertensive effect in the order of 6-11/7-9 mmHg, compared to an acute
reduction of 6.2/3.3 mmHg (on average over 24 hours), found in the present
study after short-term infusion of a low dose of rilmenidine.
The effects of the high profile rilmenidine infusion were more pronounced.
Average blood pressures of 138.6/79.7 over the fifteen-hour period after 
start of the infusion are virtually normotensive. Compared with the effects 
of placebo, an average anti-hypertensive effect of 10.4/5.8 mmHg still
existed 12 hours after infusion was stopped (24 hours after the start of the
infusion) and continued to be statistically significant. The average blood
pressure of 152.4/86.8 mmHg at this time was borderline hypertensive on
systolic blood pressure, and 5/19 patients were still normotensive (defined 
as a blood pressure below 140/90), compared to 1/13 with placebo and 2/19
after the low rilmenidine profile infusion. Assuming that blood pressure
would improve further with prolonged treatment, as seen with most anti-
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may be efficacious in most patients. This dose is higher than the currently
recommended dose of 1-2 mg/day. Obviously, this would need to be
confirmed in clinical studies, because the effects may still increase during
prolonged treatment.
The occurrence of side effects could pose limitations on the administration 
of higher doses of rilmenidine treatment. Nevertheless, salivary flow display-
ed a dose-related reduction, and the time-effect profiles corresponded
linearly to the average predicted time-concentration profiles as shown in
figure 4. The clinical relevance of these findings is uncertain, since spon-
taneous reports of dry mouth were only slightly more prevalent. Mild
sedation was more often reported during the low and high profile rilmenidine
treatments compared to placebo but this difference between placebo and
rilmenidine did not recur in the vas scores measuring alertness, mood or
calmness. This was largely attributable to a larger than expected variability 
of vas-scores, as shown by the wide variety in responses during placebo
treatment. All subjects received standardised instructions about the visual
analogue scales, but there may have been a partial lack of understanding of
the purpose of the scales. This instrument has been developed for drug
studies in young healthy volunteers, who form a generally well-educated, 
co-operative and homogeneous group. Patients not only differ widely in
social and educational background, but also in their perception of the study.
The patients’ preoccupation with the therapeutic effects of the drug during
the study is likely to have influenced their capability and motivation to adopt
the self-reflective attitude needed to fill in the visual analogue lines. The
influence of circumstances on the sensitivity of visual analogue scales is
well-known: healthy subjects readily reported the sedative effects of diphen-
hydramine 25 mg on visual analogue scales in the laboratory, whereas the
same subjects did not indicate any sedation on the scales with doses below
100 mg during a driving test. At least for 12-adrenoceptor agonists like cloni-
dine, this apparent methodological discrepancy may be due to the fact that
the attenuation of attention under resting condition caused by clonidine is
overcome by arousal. Methods other than subjective assessments, such as
saccadic eye movements where circumstances are kept more constant, are
more sensitive to sedation than visual analogue lines, and showed linear
concentration-effect relationship up to concentrations of 8.43 ng/ml in
healthy volunteers. However, the influence of arousal on attention could also
indicate that reduction of saccadic peak velocity under laboratory conditions
would overestimate the level of sedation during clinical treatment, i.e. under
every-day circumstances. Also, tolerance to sedation may develop during 
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The results of this study combined with additional investigations of the
effects of different infusion rates on blood pressure, salivary flow and
saccadic peak velocity in healthy volunteers and the evaluation of a sustained
release profile in vivo are very helpful in assessing the benefits of a controlled
release formulation in an early stage of drug development. The data from 
the current study suggest that a sustained mean plasma concentration 
of rilmenidine circa 4-6 ng/mL will be needed to permit once daily mono-
therapy with rilmenidine and to achieve modern therapeutic goals of
sbp<140 and dbp<80 mmHg. Further multiple dose studies of oral sus-
tained release tablets in patients should be performed to confirm adequate
sustained blood pressure control. Furthermore, potential tolerance to side
effects over an extended treatment period should be investigated to define
the optimal therapeutic window of a new sustained release formulation.
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aims   Previous single dose studies showed clear blood pressure lowering
effects of a potential sustained release profile rilmenidine, with concen-
tration dependent effects on the central nervous system. The aim of this
study was to evaluate potential changes in concentration-effect-relation-
ships for these central nervous system effects during a 4-week treatment
period with an experimental sustained release (sr) formulation of rilmenidine
3 mg once daily in mild to moderate hypertensive patients.
methods   Fifteen mild to moderate hypertensive patients were with-
drawn from their own anti-hypertensive treatment (gradually in the case 
of beta-blockers) and switched immediately to a 4 week rilmenidine sr
treatment. The central nervous system effects of the treatment were
evaluated using saccadic eye movements for sedative effects and visual
analogue scales for subjective effects on alertness, mood and calmness.
Measurements for pharmacokinetic (pk) and pharmacodynamic (pd)
evaluations were performed on the first day of the treatment period and
repeated after one week and four weeks of treatment.
results   No serious or severe adverse events were reported. Blood
pressure control remained adequate. Drug concentrations increased during
the study, whereas treatment related reductions in saccadic peak velocity
(spv) remained similar on all three study days. The slopes of the concen-
tration-effect-curves for spv remained unchanged throughout the study,
while the intercepts tended to increase as a result of increased pre-dose
values. Similar effects were observed for visual analogue scales for alertness:
pre-dose values increased significantly during the study, while the size of the
treatment responses (slopes) remained unaltered.
conclusions   Four-week treatment with rilmenidine sr 3 mg od
produced slight adaptations to drug-induced cns-effects. The reasons for
these adaptations cannot be determined but may include drug tolerance 
and habituations to study procedures. Blood pressure control remained
stable and adequate throughout the study.
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Introduction
Rilmenidine (2-(dicyclopropylmethyl)-amino-2-oxazoline) is a centrally
acting anti-hypertensive with binding selectivity to the I1 imidazoline
receptors over 12-adrenoceptors. It has dose (concentration)-dependent
blood pressure lowering effects above 0.5 mg in both healthy and
hypertensive subjects. Rilmenidine is registered in several European
countries at a recommended dose of 1 tablet of 1 milligram once or twice
daily. Clinical experience indicates that with 1 mg dosing blood pressure
control might not be maintained for 24 hours per day in all patients. In a
study of 146 patients with hypertension (95<dbp<115mmHg), trough level
blood pressure control was considered inadequate in 56% of subjects after 
4 weeks of treatment. An unspecified number of these patients became
adequately controlled after increasing the dosing frequency to 1 mg twice
daily. This dosage regimen is less acceptable during chronic treatment, 
while on the other hand elevating the dose of once-daily administration 
may increase the incidence of peak concentration-related side-effects, 
such as sedation and dry mouth (xerostomia). 
A sustained release formulation of the drug could maintain plasma levels 
in between a minimum effective (anti-hypertensive) concentration and a
maximum non-sedative peak level. In addition to the plasma concentrations,
the rate of increase of concentration may also influence the effect. The
classic example is provided by Kleinbloesem et al who demonstrated that 
a high rate of increase of nifedipine concentrations did not lead to a blood
pressure reduction in healthy volunteers, contrary to a low rate of increase 
of nifedipine concentrations. However, a previously performed study showed
no influence of the rate of infusion of rilmenidine on both blood pressure and
central nervous system effects (visual analogue scales and saccadic eye
movements). The current study was performed after several investigations
aimed at the design of an optimal slow release profile. From these studies, 
it was concluded that a 3 mg sustained release formulation would have the
optimal profile for adequate blood pressure control with an improved side-
effect profile. Since many centrally active drugs show some tolerance
development to side effects during prolonged treatment, the current study
aimed to investigate the effects of four-week treatment with a 3 mg
sustained release formulation on the pk/pd relationships between
rilmenidine plasma concentrations and central nervous system effects
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Methods
Design
This was a phase ii single centre open non-controlled study without direct
individual benefit for patients. Screening assessment took place within 17
days prior to the rilmenidine treatment. Patients were acquainted with the
experimental methods and conditions in a short training session taking place
within one week prior to rilmenidine treatment. Eligible patients were then
withdrawn from their own anti-hypertensive treatment and switched directly
into a 4-week 3 mg o.d. rilmenidine sr treatment. The withdrawal was
gradual for beta-blockers, and immediate for other anti-hypertensive agents,
but in all cases as short as possible in order to prevent loss of blood pressure
control. Measurements for pk/pd evaluation were performed on the first day
(D1-D2) of the rilmenidine treatment period and repeated after one week
(D8) and four weeks (D29) of treatment. At the end of the 4-week rilmenidine
treatment period, patients were re-allocated to their own anti-hypertensive
treatment.
Subjects
Mild to moderately hypertensive subjects (males and females), treated with a
maximum of two different anti-hypertensive drugs, gave signed informed
consent to participate in this study. After a general health screen (during
which relevant additional conditions were excluded, including causes for
secondary hypertension) eligible patients were enrolled in the study.
Treatments
Rilmenidine Sustained Release (sr) was presented as white round-shaped
film coated tablets containing 3 mg of active medication. Patients were
requested to take one tablet of rilmenidine every morning under fasting
conditions, with approximately 150 ml of water, 30 minutes before breakfast
time. Patients were instructed to take their study medication regularly
(between 07:00 and 09:00 h in the morning). Patients were instructed to
maintain a diary, where intake of study medication was to be recorded.
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Hæmodynamics
Blood pressures were measured after the patient had been sitting quietly for
at least 10 minutes, pre-dose and repeatedly post-dose on each of the three
study days. All measurements were carried out with an automated sphygmo-
manometer Nihon Kohden mpv 1072.
Visual Analogue Scales
Visual analogue scales as originally described by Norris have been used
previously to quantify subjective effects of benzodiazepines. From these
scales, three factors can be derived as described by Bond and Lader
corresponding to alertness, mood and calmness. These visual analogue
scales were practiced at a training session (three times), and measured 
pre-dose and every hour for twelve hours after dosing, on each of the three
study days.
Saccadic eye movements
Saccadic eye movements have been used previously to quantify drug effects
of rilmenidine and clonidine. Saccadic eye movements were practiced at a
training session (three times), and measured pre-dose and every hour for
twelve hours after dosing, on each of the three study days, with an additional
measurement after 24 hours for the first dosing. Recording of eye move-
ments was performed in a quiet room with ambient illumination. There 
was only one patient per session in the same room. Recording and analysis 
of saccadic eye movements was conducted with a microcomputer-based
system for sampling and analysis of eye movements. The equipment used 
for stimulus display, signal collection and amplification was from Nihon
Kohden (Nihon Kohden Corporation, Tokyo, Japan). Disposable silver-silver
chloride electrodes (Medicotest N-oo-s, Olstykke, Denmark) were applied 
on the forehead and beside the lateral canthi of both eyes of the patient for
registration of the electro-oculographic signals. Skin resistance was reduced
to less than 5 kOhm before application of the electrodes. Head movements
were restrained using a fixed head support. The target consisted of an array
of light emitting diodes on a bar, fixed at 50 cm in front of the head support.
Saccadic eye movements were recorded for stimulus amplitudes of ± 15
degrees to either side. Fifteen saccades were recorded for each stimulus
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seconds. Average values of latency (i.e. reaction time), saccadic peak velocity
and inaccuracy of all artifact-free saccades were used as parameters.
Saccadic inaccuracy was calculated as the absolute value of the difference
between the stimulus angle and the corresponding saccade, expressed as a
percentage of the stimulus angle.
Blood sampling
Patients were randomly allocated to one of the following investigation
schedules for pk/pd evaluation:
Days 1-2:
• Schedule 1: pre-dose and 1, 4, 7, 10 and 24 h after dosing or
• Schedule 2: pre-dose and 2, 5, 8, 11 and 24 h after dosing or
• Schedule 3: pre-dose and 3, 6, 9, 12 and 24 h after dosing.
Day 8 and Day 29
• Schedule 1: pre-dose and 1, 4, 7 and 10 h after dosing or
• Schedule 2: pre-dose and 2, 5, 8 and 11 h after dosing or
• Schedule 3: pre-dose and 3, 6, 9 and 12 h after dosing.
Blood samples for rilmenidine assay (9 ml) were obtained in lithium heparin-
containing polypropylene tubes. Blood samples were drawn from an iv
cannula (inserted into the arm opposite to the one where blood pressure 
was measured) which was kept patent using a heparin-NaCl solution. Blood
samples will be taken after discarding the contents of the cannula. At the 
24 hour time point on day 2, blood was collected using a vacuette with a
venapuncture.
Analyses
pharmacokinetics   Rilmenidine plasma levels were measured by
using a gas chromatographic/mass spectrometric method. Q Rilmenidine pk
was modelled using a one-compartment model with first order absorption
and a lag-time using nonmem Version V software (nonmem Project Group,
ucsf, San Francisco, ca, usa) using the first order conditional estimation
method with interaction. Residual error was modelled as a combination of
a constant coefficient of variation component and an additive component.
Individual empirical Bayes estimates for absorption half-life, elimination half-
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life, clearance and lag-time were determined for all occasions separately, and
predicted individual rilmenidine concentration profiles were obtained using
these estimates.
pharmacodynamics   Areas under the curve were calculated for
saccadic eye movement data and visual analogue scale scores using the
linear trapezoidal rule on (expected) protocol times. These auecs were
subsequently divided by the corresponding time span resulting in a weighted
average response. Additionally, the minimum measurement was determined
with the associated actual time point for parameters with a clear response. In
the case of multiple minima, the first occurrence was taken. No corrections
for baseline response were implemented for either auecs or Emin.
Response measurements (auec, Emin, Tmin) were compared between the 
3 days using paired Student’s t-tests without correction for multiple com-
parisons because of the limited number (3) of contrasts and because all
contrasts are sensible and clearly address the main objectives of the study.
pharmacokinetics/pharmacodynamics (pk/pd)   
Using the predicted rilmenidine concentrations, a linear concentration-effect
model with additive residual error was applied to saccadic peak velocity and
vas Alertness scores without use of an effect compartment, because indivi-
dual graphs did not indicate the need for a more complex model (eg delay or
non-linearity in the concentration-effect relationship). Parameter estimates
for slopes and intercepts were obtained using nonmem with the first order
conditional estimation method. Estimates were obtained for the parameters
on day 1 and changes were estimated from the day 1 value to the day 8 value
and from the day 1 value to the day 29 value. Significance of changes was
assessed by calculating 95% confidence intervals for the difference estimates
using 2 times the reported standard error of the estimates.
Data management and additional calculations were performed using sas for
Windows V8.2 (sas Institute, Inc., Cary, nc, usa).
Results
Subjects
Fifteen (7 male, 8 female) hypertensive patients were randomised to one of
the blood sampling schedules. The age ranged from 41 to 65 years with a
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mean of 51.3 (sd 7.2) years. All patients had mild to moderate essential
hypertension, and received one or two anti-hypertensive agents (ace
inhibitors 33.3%, beta-blockers 26.7%, diuretics 26.7 %, angotensin ii
inhibitors 26.7 %, calcium antagonists 6.7 %, combined form (beta-blocker
and diuretic) 6.7 % of the study population). Two patients suffered from
arthrosis and these patients used allowed concomitant medication
(ibuprofen 400 mg prn).
Safety assessments
No serious or severe adverse events were reported. The most frequently
reported adverse events were sleepiness, dry mouth and headache, which
occurred in 93%, 60% and 46.7% of the patients, respectively. Most adverse
events were of a mild intensity. No clinically significant abnormalities were
found for any of the safety laboratory measurements.
Pharmacokinetics
The concentration-time profile on days 1, 8 and 29 are represented in figure
1. The following population mean (approximate standard error of population
mean (SEM)) pharmacokinetic parameters were estimated: elimination half
life 567 min (72.0 min, inter-individual coefficient of variation (iicv) 65%),
absorption half life 270 min (44.7 min, iicv 81%), clearance 0.457 L/min
(0.0292, iicv 40%) and a lag time of 165 min (4.61, iicv 0%). 
Hæmodynamics
After patients switched rapidly from their own antihypertensive treatment(s)
to rilmenidine. The mean (sd) pre-dose blood pressures on day 1 were
131.7/76.6 (sd 12.1/7.9) mmHg. On day 29, the average (sd) pre-dose
systolic/diastolic blood pressure was 140.5/80.6 (sd 21.0/10.3) mmHg.
Saccadic eye movements
The effects of prolonged treatment on the auecs of saccadic peak velocity
(spv), reaction time (RT) and inaccuracy are presented in Table 1. The average
curves for saccadic peak velocity (spv) on days 1, 8 and 29 are presented in
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Figure 2. The primary endpoint of saccadic peak velocity (spv auec) showed
no significant changes during four weeks of treatment with rilmenidine sr
3.0 mg od. The minimum spv values during days 1, 8 and 29 of treatment
were comparable, with average (sd) values of 413.2 (48.2), 415.4 (53.7) and
401.5 (63.0) deg/sec, respectively. Hence, these data provide no indications
for tolerance development. There are clear indications for a treatment effect
that is comparable among the three treatment days. The average minimum
values (Emin) on the three treatment days all represent decreases in excess 
of 15%, which is well over the level of clinical significance of 10% below
baseline, associated with a decrease in spv observed after the loss of one
night of sleep. The other two parameters (reaction time and inaccuracy) did
not show any significant effects except for a decrease in auec inaccuracy 
for day 8 compared to day 1.
figure 1 Average rilmenidine concentration-time profiles at day 1, 8 and 29 (mean + sd)
Visual analogue scales
The auecs of vas alertness, mood and calmness are represented in Table 1.
The average curves for visual analogue scale alertness on days 1, 8 and 29 
are presented in Figure 3. All subjective scales showed significant increases
from day 1 to day 8 and from day 1 to day 29. No significant changes were
observed from day 8 to day 29. The vas baseline values all increased from 
day 1 to day 8 and from day 1 to day 29.
ref 15
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table 1 Time-corrected auecs (0-12 h) for all pharmacodynamic parameters: 
Mean, standard deviations (sd) and contrasts with 95% confidence intervals 
(95% ci) between treatment days (* p<0.05)
Day 1 Day 8 Day 29 Day 1 - 8 Day 1 - 29 Day 8 - 29
Mean Mean Mean Mean Mean Mean 
(sd) (sd) (sd) (95% ci) (95% ci) (95% ci)
Saccadic peak 
velocity (deg/sec) 458.9 (41.7) 458.9 (44.4) 456.5 (48.1) 0.0 (-12.1, 12.1) 2.4 (-17.1, 21.9) 2.4 (-13.6, 18.4)
Saccadic reaction 
time (msec) 236 (21) 229 (21) 231 (22) 7.1 (-0.5, 14.7) 4.7 (-3.7, 13.1) -2.4 (-9.0, 4.2)
Saccadic 
inaccuracy (%) 9.46 (3.19) 8.39 (2.62) 8.56 (2.86) 1.06 (0.38, 1.75) * 0.89 (0.10, 1.69) * -0.17 (-0.65, 0.31)
vas alertness (mm) 72.1 (13.5) 77.4 (12.6) 78.1 (12.7) -5.36 (-8.16, -2.56) * -6.04 (-9.18,-2.89)* -0.68 (-3.43, 2.08)
vas mood (mm) 78.9 (12.0) 81.4 (10.9) 82.4 (11.7) -2.45 (-4.23, -0.66) * -3.52 (-5.60,-1.44)* -1.07 (-2.82, 0.68)
vas calmness (mm) 79.9 (7.6) 83.9 (7.4) 84.5 (6.9) -3.95 (-5.92, -1.99) * -4.61 (-7.25,-1.96)* -0.65 (-2.69, 1.39)
Pharmacokinetics/pharmacodynamics
(pk/pd)
pk/pd parameter estimations for vas alertness and spv are represented in
table 2. The average pk/pd relationships are presented in figure 4 for spv
and figure 5 for vas alertness. Both parameters (vas and spv) showed linear
concentration-effect relationships. No significant changes in slopes between
days were observed for vas or spv, indicating that the cns-effect of
rilmenidine per unit concentration remained unaltered. The intercept for the
spv pk/pd relationships did not change significantly from day 1 to either day
8 or day 29. The intercept of the vas alertness scale increased significantly
after day 1: the difference between day 8 and day 1 was 12.5 (4.5, 20.5) mm
and the difference between day 29 and day 1 was 13.0 (2.9, 23.1) mm.
Discussion
This study was part of a series of investigations, designed for the
development of an optimal controlled release formulation of the centrally
active antihypertensive agent rilmenidine. Previous studies showed clear
concentration dependent effects on blood pressure and the central nervous
system of a potential sustained release profile of rilmenidine. Furthermore,
these studies suggested that the optimal therapeutic window would be
ref 8-10
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figure 2 Average saccadic peak velocity-time profiles at day 1, 8 and 29
figure 3 Average visual analogue scale alertness-time profiles at day 1, 8 and 29
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table 2 pk/pd parameters using empirical Bayes estimates for saccadic peak velocity 
and vas alertness. Population average, standard error of the population average 
(Mean), 95% confidence intervals (95% ci) and inter-individual variability as 
standard deviation (iisd)
Mean sem 95% ci iisd
Saccadic peak velocity
Slope day 1 (deg.sec-1.ng-1.mL) -6.66 1.63 -9.9 / -3.4 4.77
Change to day 8 -0.0870 2.35 -4.9 / 4.6
Change to day 29 -0.286 2.96 -6.2 / 5.6
Intercept day 1 (deg.sec-1) 476 9.69 457 / 495 37.5
Change to day 8 16.2 12.6 -9.0 / 41.4
Change to day 29 9.34 18.4 -27.5 / 46.1
Residual variability (sd) 26.1
vas alertness
Slope day 1 (mm.ng-1.mL) -0.828 0.519 -1.9 / 0.2 2.06
Change to day 8 -1.37 1.00 -3.4 / 0.6
Change to day 29 -1.32 1.08 -3.5 / 0.8
Intercept day 1 (mm) 75.5 3.47 68.6 / 82.4 9.42
Change to day 8 12.5 4.02 4.5 / 20.5
Change to day 29 13.0 5.06 2.9 / 23.1
Residual variability (sd) 7.17
would be 4-6 ng/ml. Although effective, these concentrations have shown 
to produce some changes in saccadic eye movements and visual analogue
scales effects, which could be consistent with the clinical phenomenon of
sedation. These effects could become less pronounced during prolonged
treatment, due to tolerance development. The aim of this study was to
evaluate potential changes in pharmacokinetic/pharmacodynamic (pk/pd)-
relationships for these central nervous system effects during a 4-week
treatment period with rilmenidine sr 3 mg od. 
The design of the study was based on two assumptions. First, a rapid switch
from prestudy antihypertensives to rilmenidine was considered unlikely to
affect the central nervous system effects. A rapid switch could affect the
blood pressure control, which soon after the switch would still be partly
affected by the interrupted prestudy treatment and would not be individually
optimised. However, adequate long-term blood pressure control has already
been established with rilmenidine, and this was not the aim of the study. 
The second assumption was that pk/pd-analyses reduce the need for a
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figure 4 Average pk/pd relationship between predicted rilmenidine concentrations 
and saccadic peak velocity
figure 5 Average pk/pd relationship between predicted rilmenidine concentrations 
and vas alertness
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between the drug concentration and the pharmacodynamic parameter.
Hence, a clear concentration-effect-relationship was considered a strong
argument for drug-dependency of the parameter.
pk/pd-analyses were essential for the aims of the study, because they can 
be used to quantify changes in sensitivity to the drug and the development 
of tolerance. For linear concentration-effect-relationships, changes can 
occur in the slope and/or the intercept of the concentration-effect-curve. 
A decreased slope signifies that the same concentration range produces 
a less pronounced response. In this case, the effect at the highest observed
concentration is decreased, for instance, due to desensitisation or dynamic
counter-regulation. An increase in the intercept signifies that the entire
concentration-effect-curve is right-shifted. Elevated pre-dose values will
usually lead to an increased intercept of the concentration-effect curve.
The accumulation of rilmenidine during the four week period did not lead 
to an increase in cns-effects. This was due to shifts in the concentration-
effect-relationships for spv and vas Alertness scores. There were no changes
in the slopes of the pk/pd-relationships from day 1 to day 8 or 29, whereas
the intercept tended to increase. This net effect of these changes was that
subjects became less sensitive to rilmenidine’s spv-effects. This finding was
corroborated by the subjective measures of sedation. The auec of the visual
analogue scales (vas) for alertness increased on days 8 and 29 compared 
to day 1. These elevated auecs could be largely attributed to an increase 
in predose alertness. The treatment responses remained unchanged, with
rising rilmenidine concentrations. As a result, the pk/pd-relationship 
with vas alertness showed a similar pattern as the pk/pd-relationship with
spv: slopes remained unaffected during multiple dosing, while intercepts in-
creased. Compared to day 1, vas alertness increased statistically significantly
on both day 8 and 29.
The mechanisms behind these changes are unclear. The main pk/pd-
changes for vas and spv are increases in the intercepts of the concentration-
effect relations. Thus, a higher concentration range produces a similar
treatment effect. Adaptation phenomena can cause an increased pre-dose
effect (eg rebound after drug withdrawal), but this has not been reported 
for rilmenidine, and is particularly unlikely considering the accumulation 
of the drug with this sustained release profile. Pharmacological tolerance
to the central nervous system effects of rilmenidine would primarily (or 
at least additionally) be expected to cause reductions in slopes of the
concentration-effect relations, which were not observed in this study.
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Therefore, explanations for the observed alterations do not seem to be purely
pharmacological. In addition, methodological causes can be considered,
related to learning effects or habituation to the study procedures. If causes
for the adaptations would be methodological, this would also be expected 
in a placebo group. However, a recent four-week placebo-controlled trial with
the imidazoline antihypertensive moxonidine did not reveal any changes in
the placebo-treated group. The concentration-effect-relationships in the
moxonidine-group displayed clear changes in intercepts but not in slopes -
quite comparable to the findings of the current study. Although the reasons
for these habituation processes cannot be determined exactly, it is clear that
the subjective predose assessment of alertness (and mood and calmness)
improved slightly during the study, while adequate blood pressure control
was observed throughout the four-week treatment period.
ref 19
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The value of timing additional studies
In this section, four studies were presented that investigated what the improved
profile of a new sustained release formulation would be and what its effects are in
patients with hypertension. Using blood pressure and the most sensitive marker 
for the side-effect sedation (saccadic peak velocity), the therapeutic window of the
new formulation was improved. Furthermore, it was possible to correlate the in vivo
with the in vitro dissolution of a new formulation. Combined, these studies helped
in designing an improved sustained release formulation for an existing drug with
adequate clinical effects at tolerated levels. Because the drug has been on the
market for quite some time, the development of the original formulation apparently
did not optimally answer these questions. Now additional studies had to be
performed at a post-registration stage. In this chapter it is investigated what the
value of these additional studies have if they are performed at an early stage versus
later on in the development.
table 1 Input parameters of the retrospective question-based approach for the 
development of rilmenidine
Parameter Input
Success action site 85.00%
Success pharmacological effect 85.00%
Success clinical efficacy 75.00%
Success therapeutic window 70.00%
Success population 80.00%
Estimated market value 400
Costs action site 30
Costs pharmacological effect 35
Costs clinical effect 40
Costs clinical window 35
Costs population 35
The first step in the analysis consists of estimation of the success probabilities 
and the accompanying costs. Obviously, this is done retrospectively since both the
original and the new formulations have already been developed. The set of input
parameters used in the qbd tree is shown in table 1. The overall probability of
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success, the cumulative costs and the final payoff equal the values in the previous
section and are based on historical data. It can be argued that for this compound
the window question will have the relatively lowest probability of success with this
compound. The clinical question would also be relatively difficult to answer and
would introduce substantial costs since this would involve large patient studies. 
The penetration to the site of action, and the pharmacological effects the drug
would exert, could have higher probabilities of success.
The optimal priority list of this question-based approach for the development of
rilmenidine yields the optimal sequence of questions represented in table 2.







However, the actual development of rilmenidine apparently did not fully answer 
the “window” and “clinical” question. This deficiency is reflected in the fact that 
in the actual development of rilmenidine, a sustained release formulation was
developed after registration of the original rilmenidine formulation. Rilmenidine 
is currently available in several European countries, but was not registered in, for
instance, the usa and the Netherlands. The development of a formulation with
sustained release properties could allow introduction of the drug in these countries.
In this section, a comparison of the optimal development plan with the actual
development sequence was made. The studies presented here all address the
“window” and “clinical” question and were performed late in the development
(assuming that worldwide registration is the endpoint). This approach yields the
sequence represented in table 3.
The project value of the question-based development of rilmenidine is (as demon-
strated in the previous sction) the sum of all possible outcomes weighted for the
probability that a particular outcome will happen. Calculation of the project value 
of the optimal sequence with the input parameters presented in table 2 yields an
estimated value of M¤ 14.9. However, the project value of the actual development
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program (with the same overall success probability and costs) is only M¤ 2.2. 
In order to investigate how this substantial drop in value is created, risk analyses
were performed that show all possible outcomes and the probability this will
happen. The results of these analyses are represented in figure 1.







This analysis shows substantial differences in the two different priority sequences.
Obviously, if all questions are answered successfully, no difference exists between
the two options; both have a payoff of M¤ 225 and a probability of 30% this will
happen. However, if the product is abandoned somewhere in the process, the
probabilities of the subsequent negative outcomes differ. In the optimal path, 
the higher the negative outcome is, the lower the corresponding probability is. 
The actual situation shows relatively high probabilities the outcome will be M¤ 
-137.5 (17,3% vs. 6,3%) or even M¤ -175 (10,1% vs. 5.4%). M¤ -137.5 will be the
outcome if the product is abandoned after answering “window” in the sequence
presented in table 3 and M¤ -175 if the product is abandoned after the last question
(“clinical”). By moving these questions to early in the development, the risk of late
abandonment is reduced in the optimal sequence.
The analysis shows that without reducing the probability of failure, the project value
can be increased simply by rearranging the sequence of studies. The increased value
allows additional studies to be performed that, in the npv approach, would only
introduce additional costs and development time. The studies presented in this
section are an example of additional studies that combined solves the “window”
and “clinical” question. While the npv would decrease, the question-based
approach adequately describes the impact of these studies.
The impact could have been even more valuable if the studies were performed 
at an early stage in the original development of rilmenidine. The inclusion of these
studies at an early stage in the original development of rilmenidine would have
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allowed the introduction of the improved formulation for this compound and
thereby reducing the additional costs of having to introduce a new formulation.
Remarkably, the npv of this hypothetical development plan would be lower than
the one actually used due to additional costs and development time. However, the
result would be a formulation that would potentially meet a larger market demand
(e.g. registration in the usa and other countries where rilmenidine is currently not
registered) and the revenues could therefore have been even higher.
figure 1 Risk profiles of the qbd programs of rilmenidine
From a business perspective, there is quite another view, which basically says
‘introduce the product into the market, if it is basically satisfactory, as soon as
possible. Additional useful information will be obtained from market experience 
and then consider what might be accomplished with an improved formulation’. 
This approach has been adopted in the nifedipine case, where after introduction 
of the original product, an improved formulation was successfully developed based
on the discovery of a novel pharmacodynamic property of the drug. The improved
product after the launch of the original product is sometimes referred to as a 
2nd-cycle product. Clearly, critical evaluation of emerging new post-launch data is
always necessary and additional investigations sometimes lead to highly successful
new products, as proven by the nifedipine case. However, the starting point for the
first cycle of development should be to develop the best possible treatment.
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tics of a single oral
dose of nitrazepam








background   Potential interethnic differences in drug disposition 
and effects between Japanese and Caucasians hamper the registration in
Japan of medications already used in Western countries. A systematic
comparison of potential mechanisms of differences in drug response
between racial groups can facilitate the transition of drugs between ethnic
groups.
objectives   To compare the pharmacodynamics and pharmacokinetics
of a single oral dose of nitrazepam (5 mg) in 8 Japanese and 8 Caucasian
matched healthy males and females, in a double-blind, placebo-controlled,
cross-over study.
methods   The study was performed in a Japanese and a Dutch centre,
using the same methods and study design. Japanese and Caucasian subjects
were individually matched for gender, age and body stature. Drug effects
were measured with saccadic and smooth pursuit eye movements and visual
analogue lines obtained from the scales of Bond and Lader.
results   There were no pharmacokinetic differences between the
Japanese and Caucasian subjects. Clearance was 0.91±0.165 and 1.17
±0.492 ml/min/kg, and tA was 22.1±4.96 and 21.5±7.51 hr, respectively.
Pharmacokinetic parameters showed no significant correlation with age,
height or weight. The average time-effect-curves for the different parameters
were comparable between the groups. Compared to placebo, both groups
showed similar significant reductions in average peak velocity (-75±40 vs -
85±24 °/sec; M ± sd), and increases in saccadic inaccuracy (2.3±2.1 vs
2.1±0.9%) and reaction time (17.1±13.3 vs 18.2±14.4 msec). Visual analogue
scores showed clear sedation in the Caucasians, but non-significant effects
in the Japanese subjects. Smooth pursuit did not change significantly in
either group. Slopes and intercepts of concentration-effect relationships 
for saccadic peak velocity showed considerable intersubject variability, but 
no clear differences between the two groups.
conclusions   The pharmacokinetics and pharmacodynamics of
nitrazepam are similar in healthy Japanese and matched Caucasian 
subjects. Interethnic comparative studies are feasible and provide
meaningful information about potential racial differences in disposition and
action of drugs. Such studies can form a rational basis for comparative
clinical trials.
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Introduction
Drug responsiveness may differ among racial and ethnic groups. For some
compounds and drugs, like alcohol, propanolol and debrisoquin, these
differences are caused by genetic diversity in factors such as drug
metabolism or pharmacodynamic sensitivity. In other cases, interethnic
differences may not be predictable. This may obstruct the transition of drug
information from the ethnic group in which they have been developed to
another. The possibility of interracial differences in drug disposition and
effect has contributed to the policy of the Japanese Ministry of Health and
Welfare, Koseisho, to require the repetition of a major part of the drug
development programme in Japanese subjects, before an agent used abroad
can also be registered in Japan. Considering the difficulties in organising
clinical trials in Japan, it would in many instances be more rational to identify
the factors that systematically determine interindividual and interethnic
differences in drug responsiveness, and to adapt subsequent clinical trials 
or treatment regimens accordingly.
Several systematic differences in determinants of drug responsiveness can 
be distinguished. Average body stature differs between Japanese and
Caucasians, and this is an important determinant of the disposition of many
drugs. Genetic diversity in drug metabolism or action are other potential
sources of variability in drug response between the Caucasian and Japanese
populations. The identification of potential interethnic differences in the
disposition or action of a drug that has already been widely studied in the
Western market, and is considered for registration in Japan, could therefore
start with a comparative study of Caucasian and Japanese subjects.
Systematic comparative ‘bridging’ studies are in line with the increasing
globalisation of drug development, that is brought about by the implemen-
tation of the International Conference on Harmonisation Guidelines on 
Good Clinical Practice (ich-gcp), in numerous countries including Japan.
‘Bridging’ studies are advocated in the draft ich guidelines on ethic factors 
in the acceptability of foreign clinical data. In such comparative studies,
research methods would have to be identical and subjects would have to be
carefully matched for demographic factors that are known to influence drug
disposition. The present study is aimed to test the feasibility of such an
approach, by studying the pharmacokinetics and pharmacodynamics of the
benzodiazepine nitrazepam in Caucasian subjects, carefully matched to the
participants of a study in Japan, using the same methods and study design.
The Japanese trial was performed prior to the Caucasian part of the study,






183 section 3: bridging the gap to japan – chapter 9
studies. The eye movement methods used in this study were carefully
matched during a mutual exchange programme among investigators of 




Caucasian subjects were individually matched with Japanese volunteers of a
previous study, for gender (four males, four females), age (intended allowed
difference up to 5 yrs), height (up to 5 cm) and weight (up to 5%). The study
was performed according to the Declaration of Helsinki and approved by the
Medical Ethics Review Board of Leiden University Medical Center and the
Institutional Review Board of Showa University.
Study design and group size estimation
The study was designed as a double-blind, randomised, placebo-controlled
cross-over trial with a two-week washout period. The study was indepen-
dently performed in two research institutes in The Netherlands and in Japan.
The sample size of four male and four female healthy volunteers was based
upon the size of the Japanese study group. Based on the extensive previous
experience with cns-effects of benzodiazepines, this sample size was
expected to allow the detection of nitrazepam effects using saccadic peak
velocity. The sample size would allow the detection of a 24% difference in
Clearance/kg between the two groups, with a power of 80% using an A of
5%. The power was less for the pharmacodynamic parameters.
Drugs
Nitrazepam was administered as 5 mg capsules, at which it is registered 
as a hypnotic in the Netherlands and in Japan. The nitrazepam capsules 
and identical appearing placebo capsules were from the same batch for 
the Japanese and the Caucasian study (Shionogi Co, Tokyo, Japan), and the
same randomisation order was used. The drugs were given orally, with a
glass of water (with the subject in a comfortable sitting position), under
fasted conditions, followed by a lunch after 4 hours. On all occasions, the
ref. 6
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time of ingestion of the trial medication was between 09:00 and 10:00 am
local time. Other medications, illicit drugs, alcohol, tobacco, or xanthine-
containing foods and beverages were not allowed during the study, except
oral contraceptives and occasional paracetamol.
Pharmacodynamic Determination
The primary pharmacodynamic parameters were determined from saccadic
eye movements, which have been shown to be highly sensitive to benzodia-
zepines. In addition, smooth pursuit eye movements and visual analogue sca-
les of sedation and unsteadiness were assessed. The conditions and methods
for these analyses were the same for the Japanese and the Caucasian part of
the study. Subjects were instructed not to use alcoholic or xanthine-contai-
ning products within 24 hours before drug administration, and to limit the
consumption of these products and maintain a regular diurnal rhythm for 
one week before each study day. Subjects were acquainted with the proce-
dures during a training session, prior to the first study occasion.
eye movements   Saccadic eye movements and smooth pursuit eye
movements were recorded 10 min before drug intake and at 30- 45- 60- 
75- 90- 105- 120- 135- 150- 165- 180- 240- 360- and 480 min after admi-
nistration. Recordings of eye movements were performed in a quiet room
with ambient illumination. Recordings and analyses of saccadic eye
movements and smooth pursuit eye movements were conducted with a
microcomputer-based system for sampling and analysis of eye movements,
and were performed as described previously with adaptions as described
below. In both centres, the same equipment was used for stimulus display,
signal collection and amplification (Nihon Kohden Corporation, Tokyo, Japan).
Sampling, analogue-to-digital conversion and analysis of eye movement
signals were also performed with the same equipment and software
(Cambridge Electronics Design, Cambridge, uk). Disposable silver-silver
chloride electrodes were applied on the forehead and beside the lateral
canthi of both eyes of the subject for registration of the electro-oculographic
signals. Skin resistance was reduced to less than 5 kOhm before application
of the electrodes. Head movements were restrained using a fixed head sup-
port. The target consisted of an array of light emitting diodes on a bar, fixed
at 50 cm in front of the head support. Saccadic eye movements were recor-
ded for stimulus amplitudes of: 10, 15 and 20 degrees to either side. Eleven
saccades were recorded for each stimulus amplitude with interstimulus
intervals varying randomly between 3 and 6 seconds. Average peak saccadic
ref. 6
ref. 6-7
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velocity of all artifact-free saccades were used as the primary parameter. 
For smooth pursuit eye movements the target moved sinusoidally at fre-
quencies ranging from 0.3 to 1.1 Hz in steps of 0.1 Hz. The amplitude of target
displacement corresponded to 20 degrees eyeball rotation to both sides. Four
cycles are recorded for each stimulus frequency. The time in which the eyes
were in smooth pursuit of the target were calculated for each frequency and
expressed as a percentage of stimulus duration. The average percentage of
smooth pursuit for all stimulus frequencies was used as efficacy parameter.
visual analogue scales   Subjective drug effects are often
quantified with a set of 10 cm visual analogue scales as described by Norris,
and Bond and Lader. These visual analogue scales have not been validate 
for Japanese subjects. Therefore, the six indicators most relative to sedation
were translated into Japanese, to assess three domains of sedation with two
indicators each: mental sedation (Alert-Drowsy and Muzzy-Clear headed),
tranquillisation (Calm-Excited and Tense-Relaxed) and physical sedation
(Well coordinated-Clumsy and Lethargic-Energetic). These indicators
corresponded to numbers 1,2,4,5,6,12 in the scales of Norris, and numbers
1,2,4,5,6,10 in the Bond and Lader scales. Visual analogue scales were
completed at the times of blood sampling: before administration and at 30-
60- 90- 120- 150- 180- 240- 360- 480- and 1440 min (24 hours) after drug
administration.
Blood sampling
Before drug intake, a cannula was inserted into a forearm vein, kept patent
with saline after each blood sample. Blood samples (9 ml) were collected in Li
heparin tubes. Plasma concentrations of nitrazepam were measured in blood
samples taken at the following times: two just before drug administration
(one extra for hplc calibration) and at 30- 60- 90- 120- 150- 180- 240- 360-
480- and 1440 min (24 hours) after administration.
Analyses
drug concentration analysis Plasma concentrations of
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pharmacokinetic, pharmacodynamic and statisti-
cal analyses   The pharmacokinetic and statistical analyses were
performed in a single centre, using the original Japanese and Caucasian 
raw data. Eye movement parameters were analysed as areas under the 
effect curve calculated using the linear trapezoidal rule over 0-240 min 
divided by 240 min to obtain a weighted average response. For each group
(Japanese/ Caucasian) separately, placebo results were compared to nitra-
zepam using paired Student t-tests. Groups were compared by analysing 
the difference compared to placebo using unpaired Student t-tests.
Differences between groups are presented with 95% confidence intervals
(95% ci). Model independent nitrazepam pharmacokinetic parameters
(Cmax, tmax, auc(0-24h), auc(0-∞), Clsys, Clsys/kg and tA) were calculated using
WinNonlin (V1.1; Scientific Consulting, Inc., Apex, nc, usa) using automatic
detection of the terminal part of the curve to be used for log-linear regres-
sion. Parameters were compared between groups using unpaired t-tests.
auc(0-∞) and Cmax were analysed after log-transformation, and the resulting
difference was back-transformed, yielding an estimate of percentage
increase with the associated 95% confidence interval (95% ci). 
Correlations between anthropometric measures (age, height, weight) and 
pk parameters were performed using Pearson’s and Spearman’s correlation
coefficients. Statistical analysis and calculations were performed using spss
for Windows V6.1.2 (spss, Inc., Chicago, il). Areas under the effect curve




The eight Caucasian subjects had and average age of 23.3 (range 19-27)
years, a weight of 58.3 (48.0- 82.0) kg and a height of 167.0 (157.0-179.5) cm.
The Japanese demographic characteristics were 22.8 (range 18-26) years,
56.4 (45.0- 78.0) kg and 164.1 (155-178) cm. Differences between some
matched subjects slightly exceeded the intended maximal values: age
differed by 6 yrs in two cases, weight by 10% in one and 6.5% in two cases
(but less than 5 kg in each), and height by 6 cm in one case.
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Pharmacodynamic Determinations
saccadic eye movement   The average time-corrected area-under-
the-effect-curves (auecs) for saccadic and smooth pursuit eye movements
after placebo- and nitrazepam-treatment in the two groups are presented 
in Table 1. In both groups, saccadic peak eye movements showed clear treat-
ment effects, as shown in Table 2. The average placebo-corrected time curves
of saccadic peak velocity for the Japanese and Caucasian subjects were com-
parable between the two groups (Figure 1). Comparison of the two groups
showed no significant differences in any of these parameters (Table 2).
table 1 Eye movement auecs (0-240min) for Japanese and Caucasian subjects
japanese caucasian
Parameter Mean sd N Mean sd N
Nitrazepam
Inaccuracy (%) 10.3 2.1 8 8.2 3.0 8
Peak velocity (°/sec) 301.5 33.2 8 315.8 33.4 8
Reaction time (ms) 221.2 18.7 8 219.3 10.0 8
Smooth pursuit (%) 59.0 12.2 7 48.9 14.9 8
Placebo
Inaccuracy (%) 8.5 2.2 7 6.1 2.2 8
Peak velocity (°/sec) 375.3 48.4 7 400.7 49.8 8
Reaction time (ms) 204.9 17.2 7 201.1 15.5 8
Smooth pursuit (%) 60.5 14.0 8 50.4 16.7 8
table 2 Treatment effects on eye movements for Japanese and Caucasian subjects
japanese caucasian difference
Parameter Mean 95 % ci Mean 95 % ci Mean 95 % ci
Nitrazepam-Placebo
Inaccuracy (%) 2.3 (0.3, 4.2) 2.1 (1.3, 2.8) 0.2 (-1.8, 2.2)
Peak velocity (°/sec) -74.5 (-111.4, -37.6) -85.0 (-105.2, -64.8) 10.5 (-28.3, 49.3)
Reaction time (ms) 17.1 (4.8, 29.4) 18.2 (6.1, 30.2) -1.1 (-16.5, 14.4)
Smooth pursuit (%) -2.4 (-8.6, 3.8) -1.5 (-7.7, 4.7) -0.9 (-8.8, 7.1)
smooth pursuit   The smooth eye movement auec data for the Japa-
nese and Caucasian subjects are represented in Table 1. Both groups failed to
show significant nitrazepam effects, as shown in Table 2. Also, no differences
in treatment effects were detected between the two ethnic groups.
188 a question based approach to drug development
visual analogue scales   The individual time-effect curves for
visual analogue scores showed clear sedative effects in the Caucasians. 
In contrast, the effects were non-significant in the Japanese subjects, and
often the reverse of the Caucasian effect. It was concluded that the two
ethnic groups had interpreted the visual analogue scales differently, and 
no comparative analysis was made.
figure 1 Average (+ sd) saccadic peak velocity-time curves for Japanese (C) and Caucasian 
(D) subjects, shown as difference from placebo
Pharmacokinetic determinations
The mean nitrazepam concentration-time profiles for both Japanese 
and Caucasian subjects are presented in Figure 2. The pharmacokinetic
parameters are shown in Table 3. Clearance (M±sd) was 0.91±0.165 and
1.17±0.492 ml/min/kg and tA was 22.1±4.96 and 21.5±7.51 hr, in the
Japanese and Caucasian groups, respectively.
The analysis of auc(0-24h), auc(0-∞) and Cmax after log-transformation and
back-transformation of the resulting difference showed that Japanese 
auc(0-24h) was 33.6 % higher (95% ci -1.1, 80.7 %), Japanese auc(0-∞) was
26.3 % higher (95% ci -5.8, 69.4 %) and Japanese Cmax was 15.9 % higher
(95% ci -18.0, 63.7 %). Similar interracial comparisons of clearance and
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clearance/kg showed that Caucasian clearance was 26 % higher (95% ci -6,
99 %) and Caucasian clearance/kg was 22 % higher (95% ci -10, 67 %).
None of these pharmacokinetic differences reached statistical significance
between the two racial groups after paired -or unpaired comparison. The
correlations between anthropometric measures (age, weight, height) and
pharmacokinetic parameters were not statistically significant.
figure 2 Average (+ sd) nitrazepam concentration-time curves for Japanese (C) and 
Caucasian (D) subjects
table 3 Pharmacokinetic parameters for Japanese and Caucasian subjects, obtained 
by model independent analysis
japanese caucasian difference
Parameter Mean sd N Mean sd N Mean 95% ci
tA (min) 1329 298 8 1292 450 8 36.5 (-378.9, 451.9)
tmax (min) 93.8 74.2 8 101.5 71.4 8 -7.75 (-85.89, 70.39)
Cmax (ng/ml) 75.8 28.9 8 62.1 11.7 8 13.7 (-11.1, 38.5)
Clearance (ml/min) 50.8 11.4 8 65.6 22.6 8 -14.8 (-34.6, 5.1)
Clearance/kg 0.91 0.17 8 1.17 0.49 8 -0.26 (-0.68, 0.16)
(ml/min/kg)































The individual nitrazepam concentration-time profiles could not be
adequately described using standard pharmacokinetic models. Individual
plots of saccadic peak velocity against concomitant (linearly interpolated)
nitrazepam concentration revealed possible hysteresis in some subjects,
possible proteresis in others and no sign of either in the rest. No indications
were present to consider a concentration-effect model that was more
complex than a simple linear association. Figure 3 shows the plots using
standard linear regression for both Japanese and Caucasian subjects. 
The mean slopes of the plots of the Japanese subjects were 0.26 (95% ci -
0.32, 0.84)° sec-1ml.ng-1 less steep than the corresponding slopes for the
Caucasian subjects (-1.66±0.69 vs -1.91±0.48° sec-1ml.ng-1). The intercepts
for the Japanese subjects were 2.0 (95% ci -43.2, 39.2)°/sec lower than for
Caucasian subjects (392.5±45.6 vs 394.5±51.9°/sec). The Caucasian slopes
were 24.2 (95% ci -20.2, 93.2) % steeper than the Japanese. Both the slopes
and the intercepts were not statistically different by paired and unpaired
comparison.
figure 3 Slopes of linear relationships between nitrazepam concentrations and saccadic 
peak velocities for Japanese and Caucasian subjects
191 section 3: bridging the gap to japan – chapter 9




























0 25 50 75 100 125
Discussion
The objectives of the study were to compare the pharmacokinetics and cns-
pharmacodynamics of a single oral dose of nitrazepam 5 mg between
Caucasian and Japanese male and female volunteers, matched for gender,
age and body stature. Nitrazepam was chosen because it is a widely used
benzodiazepine in both regions, but the pharmacokinetics in the Japanese
population have not been reported. In addition, nitrazepam is partly
metabolised in the liver by enzymes that exhibit polymorphism subject to
interracial differences. The study did not represent a formal ‘bridging’ study
for registration purposes, but was intended to assess the feasibility of such
studies as international enterprises.
Nitrazepam is metabolised by reduction of the nitro group to the
corresponding amine, followed by acetylation to the acetamido-compound.
The first step is catalysed by cytochrome P450 isoenzymes, which show
considerable interethnic variation, e.g. of the cyp2e1 and cyp2c sub-
families, such as cyp2c19. Polymorphism of these isoenzymes could
theoretically lead to differences in nitrazepam effects. The second metabolic
step is catalysed by N-acetyltransferase, which is also polymorphic and
potentially subject to interracial differences. Based on the activity of N-
acetyltransferase (nat2), individuals can be distinguished as fast or slow
acetylators. Ninety percent of the Japanese people are fast acetylators,
compared to less than 50% of the Europeans. More rapid metabolism in
Japanese subjects could theoretically reduce the duration of action of the
parent compound relative to Caucasians; both nat2 metabolites are inactive.
Demographic factors may also contribute to interethnic pharmacokinetic
differences. Body stature may influence the disposition of drugs like nitra-
zepam, while gender and age can cause differences in drug metabolising
enzymes. 
Most of these pharmacokinetic factors, which can contribute to interracial
variability in drug action, can be determined in the ethnic group where the
drug was initially developed. The identification and quantification of such
‘ethnically sensitive’ factors can thus provide a rational basis for subsequent
designs of clinical trials or treatment regimens in other populations, if the
factors affecting drug disposition are also known in the new population.
However, pharmacodynamic differences remain difficult to predict, and
comparative studies such as the current one may elucidate unexpected
interethnic differences in drug action. The design and size of such studies
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sensitive’ compounds should ideally be performed during the early phases 
of drug development. The current study was a phase I-type investigation,
intended to test the feasibility and informativeness of interregional
interethnic pharmacokinetic/ pharmacodynamic studies. The draft ich
guidelines on ethnic factors indicate that comparative studies can be
performed within the original region, in a population representative of the
new region, e.g. immigrants. However, this may eliminate only part of the
ethnic variability between the two regions, since many habits of culture,
feeding etc. which may influence drug effects, will have been adopted by 
the immigrants. Therefore, comparative studies are best performed in the
original populations, which however necessitates careful matching of
subjects, study designs and methodology. 
In the current study, subjects were matched for gender, age and body
stature, but the study was not designed to characterise the heterogeneity of
acetylator status or cytochrome P450 activity in the Japanese and Caucasian
populations. This would have required the determination of genetic poly-
morphism and careful identification of nitrazepam metabolites in much
larger samples. In the current study however, relevant differences in drug
metabolism would have become evident from differences in pharmacokine-
tics between the two groups. The results showed no significant pharmaco-
kinetic differences between the two groups, although the 95% confidence
intervals were too wide to confirm bioequivalence. Therefore, subtle inter-
ethnic differences in drug metabolism cannot be excluded, but these are
certainly not as important as the interindividual variability within each ethnic
group. Theoretically, sampling errors in this small study could have obscured
the detection of ethnic differences in drug disposition. In the Japanese group
however this is unlikely, since the most relevant ‘ethnically sensitive’ meta-
bolic factor in this study, nat2-activity, is present in 90% of the Japanese
population. The Caucasian study group also seems to be representative of
the European population, because their pharmacokinetic results agree well
with textbook data on nitrazepam (tA 20-28h, tmax 45-240 min, clearance
0.86 ± 0.12 ml.min-1.kg-1; cf. Table 3).
Apart from the mentioned drug-dependent differences, there are also ethnic
differences in methodology. An example is the difference in visual analogue
scales between the two study groups. Visual analogue scores showed clear
sedative effects in the Caucasians, but the majority of Japanese subjects
scored a value of approximately zero throughout the study day. It is likely that
young Japanese immigrants would have responded more like Caucasians,




193 section 3: bridging the gap to japan – chapter 9
in the original populations. This requires a thorough validation in particular of
subjective methods, such as descriptions of adverse events, visual analogue
scales, questionnaires etc., before they can be applied from one population to
another. The literal translation of relevant visual analogue scales performed
in this study did not take sufficient account of differences in instructions and
in sociocultural factors such as subject-investigator-relationships. Validation
requirements are more easily met for objective methods, which are therefore
more suitable to perform interethnic comparative studies. The eye move-
ment methodology used in this study was carefully adjusted during an
intensive mutual exchange programme between the Japanese and Dutch
research centres.
Although concentration-effect-relationships could be established only
crudely, no significant interethnic variations in pharmacokinetic / pharmaco-
dynamic relationships of nitrazepam were found. Intersubject variability was
much larger than interracial variation. However, the results did not meet
formal criteria for equivalence. Therefore, they would need confirmation,
repetition in special populations (elderly) and extension to some specific
situations (drug interactions). If similarity in drug disposition and effects
among the ethnic groups is confirmed, data from previous studies of
nitrazepam in Caucasian subjects can be translated to the Japanese situation,
leading to rational dose adaptations for treatment regimens. This could
reduce the need for repetition of large scale studies and would rationalise 
the dose selection for the ones that are still necessary. Thus, systematic
comparative studies could ease the burden for clinical reseach in Japan,
where resources that are fully up to the requirements of ich-gcp are
currently limited. The present study shows that interethnic comparative
pharmacokinetic/ pharmacodynamic investigations with rigorous similarity
in design, subjects and methodology are feasible across different regions.
Such studies can make a useful addition to in vitro assessment of ‘ethnically
sensitive’ pharmacokinetic differences, not only for global drug development
but also in multiethnic societies.
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Abstract
objectives   To compare the pharmacokinetic parameters and safety of
the progestagen Org 30659 ((171)-17-hydroxy-11-methylene-19-norpregna-
4,15-dien-20-yn-3-one) and ethinyl estradiol (ee) in Caucasian and Japanese
women after single and multiple doses.
methods   This was an open-label parallel design of a single dose
followed by a multiple dose period in healthy young Japanese and Caucasian
subjects.
results   The auc of Org 30659 after single dosing was increased by a
factor 1.75 (90% ci: 1.48-2.08) in Japanese women compared to Caucasian
women. At steady-state this difference increased to a factor 1.90 (90%
confidence interval [ci]: 1.60-2.25). The auc of ee after single dosing was
similar in Caucasian and Japanese women but at steady-state it was
increased by a factor 1.38 (90% ci: 1.15-1.64) in the Japanese. Weight
normalisation reduced but did not remove all the observed differences. 
Sex Hormone Binding Globulin (shbg) played no significant role in the
differences between Caucasian and Japanese subjects. Both the single and
multiple dose treatment with Org 30659/ee were generally well tolerated by
all subjects. The Japanese population reported more and different treatment
related adverse events than the Caucasian population.
conclusions   The peak concentration and extent of exposure of 
Org 30659 and to a lesser extent of ee in Japanese women are higher than 
in Caucasian women. Furthermore, the peak concentration and extent of
exposure at steady-state of Org 30659 and to a lesser extent of ee are higher
than would be predicted assuming linear pharmacokinetics over time. 
No major safety issues were observed.
Introduction
The main goal of combined oral contraceptives is prevention of pregnancy by
inhibiting ovulation without jeopardising safety. Because the early combined
oral contraceptives (cocs) had a relatively high steroid content, the prepa-
rations showed good contraceptive efficacy but also produced a great variety
of adverse effects, including some serious ones. In the late 1960s, various
reports raised concern about venous thromboembolic events occurring in 
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coc users, which were attributed to the estrogen administered with the pill.
Therefore, the estrogen content of newly developed cocs has been reduced.
Howeve, concern continued when in the late 1970s also the progestagenic
component became suspected in causing arterial thromboembolic accidents
(particularly, myocardial infarction). Thus, development of new oral
contraceptives has been directed towards designing regimens with aminimal
effective dose of both the estrogen and the progestagen. However, this
carries a number of drawbacks. Firstly, reducing the steroid dosage may
jeopardise contraceptive efficacy in certain subgroups of women, for
example, women with a low steroid bioavailability. Secondly, low steroid
doses may lead to an increase in the incidence of irregular bleeding. Thirdly,
as the dose is reduced in an effort to eliminate the negative effects, several of
the positive properties associated with oral contraceptives (ocs), like reduced
risk of fibrocystic tumors of the breasts and endometrial and ovarian cancer,
could also be eliminated.
In addition to the desired progestagenic activity, currently available progesta-
gens have a varying degree of intrinsic androgenicity. When these progesta-
gens are used at a high a dose, typical androgen-associated side effects such
as acne and hirsutism may become more frequent. Furthermore, androgenic
progestagens are associated with more pronounced metabolic disturbances
(e.g. in lipid metabolism and carbohydrate metabolism) than non-androgenic
progestagens. Research has been directed towards the development of
progestagens showing a strong dissociation between progestagenic and
androgenic activity like desogestrel and etonogestrel, in order to minimise
metabolic side effects. The new progestagen Org 30659 ((171)-17-hydroxy-
11-methylene-19-norpregna-4,15-dien-20-yn-3-one) is a novel selective
progestagenic steroid with low intrinsic androgenic activity. 
Modern low-dose ocs were launched in Japan in 1999, following the lifting 
of a ban on their licensing and sale. Ethnic differences could occur in the
pharmacological or pharmacokinetic properties of investigational new drugs.
Therefore, before a new drug is introduced in Japan sufficient data should be
presented on the effects of the drug in a Japanese population. In some cases
a comparison between the ‘western’ population and the Japanese population
can be used to extrapolate the data from ‘western’ studies to the Japanese
(especially when no differences are observed). In the current study, the
pharmacokinetics and safety of Org 30659 and ethinyl estradiol (ee) in
Caucasian and Japanese women were compared after single and multiple
dose administration of tablets containing a combination of 200 µg Org 30659
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Methods
Design
This was a two-centre, open-label, parallel design of a single dose (sd)
followed by a multiple dose (md) period in 18 Japanese and 18 Caucasian
healthy females. Japanese subjects were studied in Tokyo, Japan and
Caucasian subjects concurrently in Leiden, The Netherlands using the same
study protocol. Subjects not using oral contraception were to start treatment
(administration of sd) between 3 and 8 days after the first day of their last
menstrual cycle. Subjects using oral contraception were to start treatment
(administration of sd) between 28 and 30 days after they had stopped taking
their last oral contraceptive pill. All subjects enrolled in this study were
instructed to use adequate non-hormonal contraceptive measures
throughout the study period.
Subjects
Japanese (both parents Japanese) and Caucasian (both parents Caucasian)
female subjects were healthy as determined during screening. The study was
approved by the Medical Ethics Review Board of Leiden University Medical
Center and approved by the Institutional Review Board of Obara hospital, and
performed according to the principles of ich-gcp, the Helsinki Declaration
and Dutch and Japanese law.
Treatments
All subjects received treatments from the same batch of study medication. 
A single oral administration of Org 30659/ee (1 tablet containing 200 µg Org
30659 and 20 µg ee) was followed by a 72 h pharmacokinetic (pk) sampling
period (sd). The single dose was followed by a washout period of 5 to 7 days,
before the start of the multiple dose period. This consisted of once daily oral
intake of Org 30659/ee (1 tablet containing 200 µg Org 30659 and 20 µg ee)
for 24 days, followed by a 72 h pk sampling period. Treatment administration
was supervised on the first dose and at the multiple doses on days 2, 4, 6, 15
and 24. Additionally, compliance with the dosing regimen was checked on
days 9, 12, 18 and 20. Furthermore, subjects were instructed to record the
exact time of drug administration on a diary provided by the centre. At each
visit to the trial centre, a pill count was performed by the site’s staff.
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Blood Sampling and Measurements
Testing for drugs of abuse (cocaine, morphine and tetrahydrocannabinoid)
was performed during screening and before administration of the single
dose. For all subjects a qualitative, colour immuno- urine pregnancy test was
performed during screening, pre-dose sd period, pre-dose md period and
pre-dose on md days 6, 15 and 24. Upon arrival on Day –1 a breath test to
detect the use of alcohol was performed. 
A 12-lead electrocardiogram was obtained regularly throughout the study
period. At regular time intervals, systolic and diastolic blood pressure (bp,
mm Hg) and pulse rate (pr, bpm) were measured using an automated blood
pressure monitor. Vital signs were recorded before any other procedures,
took place. The subject was sitting or semi-recumbent for at least 5 minutes
prior to start of the measurement.
Blood samples for routine laboratory safety were drawn pre-dose and 24
hours after sd and pre-dose on days 6, 15 and 24 after the start of the md
period and at post study screening. From these samples, Sex Hormone
Binding Globulin (shbg) was also determined. Analysis of the laboratory
safety blood samples was performed at the two centres except for shbg,
which was analysed at the Leiden University Medical Centre using
immunometric assay and luminescentic detection (Immulite, dcp, 
Los Angeles, ca, usa).
Blood was collected and processed to Potassium-EthyleneDiamineTetra-
Acetic acid (k-edta) plasma for the assessment of Org 30659 concentrations
and to serum for the assessment of ee concentrations. Org 30659 concen-
trations were determined at the Department of Drug Metabolism and Kine-
tics, nv Organon, Oss, the Netherlands using a validated gas chromatogra-
phic assay with mass spectrometric detection. The range for the Org 30659
assay was 0.05 - 25 ng/mL plasma. ee concentrations were measured at ppd
Pharmaco, Richmond, Virginia, usa using a validated radioimmunoassay
after high performance liquid chromatography isolation of ee. The range for
the ee assay was 2.25 – 48 pg/mL serum. Blood samples for Org 30659 and
ee determination were drawn pre-dose and B, A, C, 1, 1A, 2, 3, 4, 6, 8, 12,
16, 24, 36, 48 and 72 hours after sd and after the last md. Furthermore, pre-
dose blood samples were taken at days 2, 4, 6 and 15.
Pharmacokinetic analysis
Based on the Org 30659 concentrations in plasma and the ee concentrations
in serum, the following (non-compartmental) pharmacokinetic parameters
ref. 14
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were calculated, both after the first single dose and at steady-state after the
final dose: the peak concentration (Cmax) and its time of occurrence (tmax),
the elimination half-life (tA), the area under the concentration-versus-time
curve (auco-∞ and auco-τ), the apparent clearance (CLapp) and the apparent
volume of distribution (Vz,app). From the steady-state wash-out curve after
the final dose (dosing interval, τ=24h), the following additional pharmaco-
kinetic parameters were calculated: the peak concentration at steady-state
corrected for pre-dose concentration (Cmax,corr), the average concentration 
at steady-state (Cav) and the degree of fluctuation (df). Also weight-
normalised (wn) pharmacokinetic parameters were calculated. Two types 
of accumulation ratios were calculated from the single-dose and steady-
state parameters: R
a1 (=Css,max/Csd,max) and Ra2 (=aucss,o-τ /aucsd,o-τ).
Based on the pre-dose concentrations during the multiple-dose treatment,
the mean pre-dose concentration at steady-state (Css,min,av) and the mean
time of attainment of steady-state (tss) were obtained. All calculations were
performed using sas V6.12 (sas Institute, Inc., Cary, nc).
Statistical analysis
Analysis of Variance (anova) was performed on the pk parameters using a
mixed model with fixed factors ‘Ethnic group’ (Japanese versus Caucasian)
and ‘Regimen’ (steady-state versus single dosing), interaction ‘Ethnic group’-
by-‘Regimen’ and random factor ‘Subject’ nested within ‘Ethnic group’. The
primary pk parameters were (wn-)auc and (wn-)Cmax: for single dose auc0-∞
and Cmax were used and for steady-state auc0-24 and Cmax,corr, respectively.
For the factor ‘Ethnic group’, point estimates and 90% confidence intervals
for the ratio of Japanese over Caucasian means were calculated, both at
steady-state and after single dosing. Similar pharmacokinetics between
Japanese and Caucasian subjects was to be concluded when the 90%
confidence intervals for the primary pk parameters were fully contained
within the acceptance range of 0.70-1.43.
For the factor ‘Regimen’, point estimates and 95% confidence intervals for 
the ratio of steady-state over single-dose means were calculated, both for
Japanese and Caucasian subjects. When the 95% confidence intervals for the
primary pk parameters contained a ratio of one (indicating non-significance
at the 5% level of significance), the absence of a regimen effect on the phar-
macokinetics was to be concluded (i.e. time independent pharmacokinetics).
To study the influence of shbg on the primary pharmacokinetic parameters
of Org 30659 and ee, additional anovas were performed using the same
model extended with pre-dose shbg value as covariate (after logarithmic
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transformation). For the single-dose pk parameters the pre-dose shbg value
from single-dose period day 1 was used and for the steady-state pk parame-
ters the pre-dose shbg value from multiple-dose period day 24 was used.
For all other (supportive) pharmacokinetic parameters, point estimates and
95% confidence intervals for the ratio of ethnic group means and for the 
ratio of regimen means were calculated using the same anova model as 
for the primary pk parameters. Conclusions for these parameters were based
on classical hypothesis testing (at the 5% level of significance).
Log-transformed values of the parameters were used in the anovas except
for tmax for which an anova on ranks was performed.
All analyses were performed using sas V6.12 (sas Institute, Inc., Cary, nc).
Data management
Data from working copies of case report forms, obtained from ProMaSys
(Protocol Management System v3.2, chdr, The Netherlands), were directly
entered into the ProMaSys. The Japanese site had access to this database
system using an Internet connection.
Results
Demographics
In the Netherlands, a total of 19 subjects were included in this trial. One
subject dropped-out due to difficulty in blood sampling immediately after 
the first dose and was subsequently replaced. In Japan, a total of 18 subjects
were included in this trial. Mean (sd) age, weight, height and bmi of the
Caucasian subjects were 25.4 (4.5) years, 69.4 (8.8) kg, 172 (6.4) cm and 
23.4 (2.3) kg/m2, respectively. Mean (sd) age, weight, height and bmi of 
the Japanese subjects were 27.8 (6.1) years, 53.6 (5.4) kg, 158 (5.7) cm and
21.5 (2.3) kg/m2, respectively.
Comparison of single-dose and steady-state
pharmacokinetics
The single-dose and steady-state pharmacokinetic parameters for both
ethnic groups are summarised in Tables 1 and 2. The average time-effect
profiles from 0-8 hours after dosing are displayed in Figure 1. The results of
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the anovas for the statistical comparison of single-dose and steady-state pk
parameters are given in Table 3. For two subjects, both after single dosing and 
at steady-state, several plasma concentrations of Org 30659 around tmax were
unreportable and therefore no pk parameters for Org 30659 were reported for
these subjects.
table 1 Single-dose and steady-state pharmacokinetics of Org 30659 in Caucasian and 
Japanese subjects. Based on n=34 subjects for Org 30659. Presented are median 
(min-max) for tmax; geometric mean (geometric cv%) for other pk parameters 
Org 30659
caucasian women japanese women
Parameter (unit) Single Dose Steady-state Single Dose Steady-state
Cmax (ng/mL) 1.78 (32.8) 3.99 (32.7) 2.85 (34.1) 7.87 (28.8)
tmax (h) 0.75 (0.50-1.02) 0.50 (0.45-1.50) 0.767 (0.75-1.50) 0.583 (0.50-1.00)
tA (h) 10.4 (47.8) 13.3 (26.5) 14.4 (31.9) 12.1 (25.6)
auc* (ng(h/mL) 6.23 (27.4) 13.6 (29.5) 10.9 (31.3) 25.4 (30.1)
wn-CLapp (L/h/kg) 0.469 (28.2) 0.213 (30.3) 0.346 (27.1) 0.149 (29.3)
wn-Vz,app (L/kg) 6.80 (43.8) 4.30 (44.7) 7.22 (47.5) 2.60 (43.4)
Cav (ng/mL) - 0.567 (29.5) - 1.06 (30.1)
df (%) - 674 (23.2) - 713 (18.6)
Cmin,av (ng/mL) - 0.157 (48.7) - 0.319 (43.2)
RA1 - 2.17 (23.1) - 2.76 (34.2)
RA2 - 2.52 (21.9) - 2.93 (36.4)
*: auc0-∞ for single dose and auc0-24 for steady-state; -: not applicable.
Steady-state was reached for Org 30659 after 24 days of multiple dosing and
for ee after 15 days of multiple dosing. The pharmacokinetics of Org 30659
and ee are time-dependent, both in Caucasian and in Japanese women, after
administration of this combination drug. In general, Cmax and auc at steady-
state are higher than would be predicted assuming linear pharmacokinetics
over time.
Assuming linear pharmacokinetics over time for Org 30659 there would have
been no significant differences in Cmax and auc between steady-state and
single dosing. In Table 3 it can be read that the Cmax at steady-state is 111%
higher than after single dosing in Caucasian women (in Japanese women
165%). The daily auc0-24 at steady-state is 115% higher than the total AU0-∞
after single dosing in Caucasian women (in Japanese women 132%).
For ee, the Cmax at steady-state is 37% higher than after single dosing in Cau-
casian women (in Japanese women 53%). The auc0-24 at steady-state is 11%
lower than the total auc0-∞ after single dosing in Caucasian women, whereas in
Japanese women the auc is 24% higher at steady-state than after single dosing.
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table 2 Single-dose and steady-state pharmacokinetics of ee in Caucasian and Japanese 
subjects. Presented are median (min-max) for tmax; geometric mean (geometric 
cv%) for other pk parameters
ee
caucasian women japanese women
Parameter (unit) Single Dose Steady-state Single Dose Steady-state
Cmax (pg/mL) 49.2 (37.7) 80.6 (31.2) 74.5 (34.0) 128 (37.0)
tmax (h) 2.00 (0.75-4.02) 1.50 (0.50-2.02) 1.50 (1.00-2.00) 1.50 (0.50-2.02)
tA (h) 27.9 (48.9) 19.8 (24.2) 19.8 (46.8) 17.4 (25.3)
auc* (pg.h/mL) 747 (42.8) 664 (26.2) 741 (33.5) 912 (25.7)
wn-CLapp (L/h/kg) 0.389 (40.2) 0.438 (26.2) 0.511 (33.2) 0.411 (25.8)
wn-Vz,app (L/kg) 15.7 (38.8) 12.5 (29.4) 14.6 (40.6) 10.3 (25.7)
Cav (pg/mL) - 27.6 (26.2) - 38.0 (25.7)
df (%) - 241 (20.6) - 296 (19.2)
Cmin,av (pg/mL) - 13.2 (42.6) - 15.1 (40.1)
RA1 - 1.64 (23.5) - 1.73 (28.4)
RA2 - 1.70 (28.6) - 1.96 (22.9)
*: auc0-∞ for single dose and auc0-24 for steady-state; -: not applicable.
table 3 Comparison of single-dose and steady-state pharmacokinetic parameters for 
both Caucasian and Japanese subjects. Point estimates are ratios of geometric 
least-squares (ls) means. Based on n=34 subjects for Org 30659 and n=36 
subjects for ee. Time-independent pharmacokinetics if Regimen effect was 
not significant
Compound Ethnic group Parameter Point Estimate 95% Confidence Significance
µ(ss)/µ(sd) Interval
Org 30659 Caucasian Cmax 2.11 1.82-2.45 yes
auc 2.15 1.87-2.47 yes
tA 1.28 1.08-1.52 yes
Japanese Cmax 2.65 2.30-3.05 yes
auc 2.32 2.03-2.65 yes
tA 0.84 0.71-1.00 yes
ee Caucasian Cmax 1.37 1.21-1.54 yes
auc 0.89 0.76-1.04 no
tA 0.71 0.56-0.90 yes
Japanese Cmax 1.53 1.34-1.74 yes
auc 1.24 1.05-1.45 yes
tA 0.88 0.68-1.13 no
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figure 1 Average (+ sd) concentration-time profiles (from 0-8 hours after dosing) of 
Org 30659 and ee after single dose (D) and at steady state (C) for both Caucasian 
and Japanese subjects
Table 3 shows that the elimination half-life of Org 30659 in Caucasian
subjects is significantly longer at steady-state than after single dosing,
whereas in Japanese subjects the half-life is significantly shorter at steady-
state. For ee, the half-life at steady-state in Caucasians is significantly
shorter than after single dosing.
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For Org 30659, the median tmax at steady-state (0.5 h) was found to be
significantly shorter than the median tmax after single dosing (0.75 h). 
Also for ee, the median tmax at steady-state was somewhat shorter than
after single dosing.
Comparison of pharmacokinetics in
Caucasian and Japanese women
The results of the anovas for the statistical comparison of primary pk
parameters between Caucasian and Japanese women are given in Table 4.
table 4 Comparison of Caucasian and Japanese pharmacokinetic parameters after single 
dose and at steady state. Point estimates are ratios of geometric least-squares 
(LS) means. Based on n=34 subjects for Org 30659 and n=36 subjects for ee. 
Similar pharmacokinetics if 90% Confidence Interval contained within 
acceptance range 0.70-1.43
Compound Regimen Parameter Point Estimate 90% Confidence Conclusion 
µ(Jap)/µ(Cauc) Interval kinetics
Org 30659 Single Cmax 1.60 1.33-1.93 not similar
dose wn-Cmax 1.24 1.04-1.48 not similar
auc 1.75 1.48-2.08 not similar
wn-auc 1.36 1.15-1.60 not similar
Steady Cmax 2.01 1.67-2.43 not similar
state wn-Cmax 1.55 1.29-1.86 not similar
auc 1.90 1.60-2.25 not similar
wn-auc 1.46 1.23-1.72 not similar
ee Single Cmax 1.51 1.24-1.84 not similar
dose wn-Cmax 1.17 0.97-1.40 similar
auc 0.99 0.82-1.19 similar
wn-auc 0.76 0.64-0.91 not similar
Steady Cmax 1.69 1.39-2.05 not similar
state wn-Cmax 1.31 1.09-1.57 not similar
auc 1.38 1.15-1.64 not similar
wn-auc 1.07 0.89-1.27 similar
Pharmacokinetics of Org 30659 in Japanese and Caucasian women are not
similar after administration of this combination drug. The Cmax of Org 30659
after single dosing is 60% higher in Japanese women than in Caucasian
women. At steady-state this difference mounts up to 101%. Corrected for
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differences in body weight between Caucasian and Japanese women, the
weight normalised-Cmax of Org 30659 after single dosing is 24% and at
steady-state 55% higher in Japanese women than in Caucasian women. The
auc of Org 30659 after single dosing is 75% higher in Japanese women than
in Caucasian women. At steady-state this difference mounts up to 90%.
Corrected for differences in body weight between Caucasian and Japanese
women, the wn-auc of Org 30659 after single dosing is 36% and at steady-
state 46% higher in Japanese women than in Caucasian women. No overall
significant differences in elimination half-life or tmax were observed between
the two ethnic groups.
The Cmax of ee follows the same pattern as the Cmax of Org 30659. The Cmax
of ee after single dosing is 51 % higher in Japanese women than in Caucasian
women. At steady-state this difference mounts up to 69%. After weight-
normalisation the difference disappears for the single dose (17% higher, but
not significantly different). At steady-state the wn-Cmax is still 31%
(statistically significant) higher in Japanese women. The auc of ee after
single dosing is similar in Caucasian and Japanese women. After weight
normalisation, the wn-auc is 24% lower in Japanese women. The auc of ee
at steady-state is 38% higher in Japanese women than in Caucasian women.
Corrected for differences in body weight, this difference is reduced to 7%.
The mean t1/2 after single dosing for Caucasians was significantly longer than
the t1/2 after single dosing for Japanese women (see Table 2). There were no
significant differences in tmax between Caucasian and Japanese women.
Sex hormone binding globulin
Averaged sex hormone binding globulin (shbg) values are represented in
Figure 2. shbg increased during the trial for all subjects. At follow up all
shbg values had decreased but were still above the baseline values. After
inclusion of shbg into the pk model of Org 30659, the ratio of geometric auc
means for steady-state over single dose decreased from 2.15 to 1.12 for
Caucasian subjects and from 2.32 to 1.20 for Japanese subjects. The
statistical analysis showed that shbg played no significant role in the
comparison of the pharmacokinetics between Caucasian and Japanese
subjects. However, the increase in shbg after multiple dosing provided an
explanation for the observed differences in pharmacokinetics of Org 30659
between single dose and steady-state.
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figure 2 Average (+ sd) Sex Hormone Binding Globulin concentrations for both Caucasian
and Japanese subjects. (Follow-up was performed 7-15 days after last intake of 
study medication)
Safety parameters
There were neither serious adverse events reported nor any deaths. None of
the reported adverse events led to the drop-out of any subject from the trial.
One reported severe adverse event was in fact an exacerbation of pre-existing
shoulder pain. All the other adverse events were of mild or moderate inten-
sity. The most frequently reported drug related adverse events included
bleeding irregularities. Adverse events in this trial were somewhat differently
reported between the two ethnic groups, particularly regarding the repro-
ductive disorder class. Adverse events in the reproductive disorder class were
reported by Caucasian subjects as abdominal pain associated with bleeding
irregularities (n=6 and n=15 respectively) while the Japanese subjects
reported this as dysmenorrhoea with bleeding irregularities (n=3 and n=18
respectively). Breast enlargement (n=5), peripheral oedema (n=9), treatment
related hot flushes, somnolence and malaise (n=4) were reported only by
Japanese. In general more treatment related adverse events were reported by
the Japanese population compared to the Caucasian population (82 and 45
respectively). No clinically relevant abnormalities were found in vital signs,
nor were there any consistent changes observed in ecg parameters and
other safety measures. No other clear difference in any of the safety
measurements was noted between the two ethnic groups.





































The primary objectives of this trial were to compare the pharmacokinetic
parameters and safety of Org 30659 and ee in Caucasian and Japanese
women after single and multiple dose administration and to compare the
single dose and steady-state pharmacokinetics of Org 30659 and ee.
The pharmacokinetics of Org 30659 and to a lesser extent ee were
significantly different between the two ethnic groups following the single
dose administration of the tablet containing both 200 µg Org 30659 and 20
µg ee. This difference in the kinetics was further increased after steady-state
was reached, following multiple administration of these tablets. Weight
normalisation reduced but did not diminish the observed differences. shbg
concentrations could not explain these findings either. Therefore, other
factors like phenotypic differences (including dietary or environmental
factors) and genetic differences in absorption and/or metabolism could
account for the observed kinetic differences between the two ethnic groups.
Ethnic differences in the pharmacokinetics of ee have been reported
previously. ee is extensively metabolised by udp-gluceronosyltransferase
(ugt) 1A1, which also catalyses the glucuronidation of bilirubin and
xenobiotic phenols and some steroids. Mutations of ugt1a1 cause the
unconjugated hyperbilirubinemias known as Crigler-Najjar syndrome and
Gilbert’s syndrome. The frequencies of individual ugt1a1 polymorphisms
show extensive variability across ethnic groups. The incidence of
nonphysiologic neonatal hyperbilirubinemia is twice as high in East Asians as
in whites. Furthermore, consistent inter-individual and ethnic differences
have been reported in the degree of oxidative metabolism of ee that could
attribute to the differences observed in the current study.
Phase ii metabolism, and in particular conjugation with glucuronic acid is
also suggested to be the major metabolic route for Org 30659 in vivo.
ugt2b7 is suggested to play an important role in this conjugation. Large
differences in polymorphism between Asians and Caucasians have been
suggested. It is reported that only 9.4% of the investigated Asian population
are ugt2b7(Y268) homozygous compared with 29.2% of Caucasians. Asians
had a higher prevalence of the homozygous ugt2b7(H268) compared to the
Caucasian population: 56.2% vs 21.8%. The corresponding phenotypical
differences of these polymorphisms have not been determined. The data
from this study suggests that the homozygous ugt2b7(Y268) genotype
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The apparent accumulation of Org 30659 after multiple dosing is probably
related to the strong increase in shbg levels induced by ee. The reduced
clearance at steady-state could be a reflection of the binding of Org 30659 to
proteins or change in metabolism at steady-state. However, the
accumulation of ee cannot be explained by increased shbg levels because
ee binds for 98% to albumin and has no affinity for shbg. The accumulation
of ee is notably less than of Org 30659.
Adverse events in this study were somewhat differently reported between the
two ethnic groups. More treatment related adverse events were reported by
the Japanese population compared to the Caucasian population. The clear
difference in pharmacokinetics between the two groups (higher Org 30659
concentrations and (peak) ee concentrations in the Japanese population)
could contribute to these apparent differences. However, another factor that
may explain these differences could be the number of oc-users before the
start of the trial. None of the Japanese subjects were oc-users, while all but
five of the Caucasian subjects were oc-users. This difference in experience
with the use of coc may have contributed to the difference in ae reporting.
No consistent changes were found in vital signs, ecg and clinical laboratory
data and no clear differences for these safety measures were noted between
the two ethnic groups, supporting that the combination of Org 30659 and ee
was safe.
This study showed that it is possible to adequately perform a bridging study
between Japanese subjects studied in Japan and Caucasian volunteers
studied in the Netherlands using a single protocol and data management
system. This type of study can be performed at an early stage in the drug
development and can provide essential information for the future develop-
ment of western drugs in Japan. There appear to be differences in the
pharmacokinetic handling of both ee and a new synthetic progestagen
between Japanese and Caucasian women. The clinical consequences of these
differences require further investigation.
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Added value of bridging studies
Japanese people are considered a special target patient population by the Japanese
drug registration authorities. Introduction of a western drug on the Japanese market
requires proving efficacy and safety in the Japanese population, which often
requires repetition of most clinical trials in Japan. A way to improve this time and
cost consuming process can be to perform bridging studies between typical
Caucasian and typical Japanese subjects to compare the characteristics that could
potentially differ between the two populations. According to IMS health,
multinational pharmaceutical companies are looking to aggressively expand their
drug sales in Japan. From 1996 to 2000, the proportion of the Japanese market held
by foreign companies increased from around 20% to almost 28%. Some of the
biggest names in the industry, including Pfizer, AstraZeneca, Aventis and Eli Lilly,
have recently made clear their intent to target the world’s second-largest drug
market (www.imshealth.com). Their interest is being driven by the huge potential
gains if they could match their global market shares in the Japanese market. This
expansion could translate into billions of dollars in extra revenues. The task is
becoming more readily achievable, as regulations overseeing drug development are
harmonised between Japan, the usa and Europe, and as changes in healthcare
delivery and finance foster new sales and marketing approaches.
Obviously, racial differences could occur in the pharmacological properties of
investigational new drugs. Therefore, before a new drug is introduced in Japan
sufficient data should be presented on the effects of the drug in a Japanese
population. In some cases a comparison between the ‘western’ population and the
Japanese population can be used to extrapolate the data from ‘western’ studies to
the Japanese (especially when no differences are observed). Extrapolation of data
could save the costs of additional studies in Japan. Therefore, it can be very
rewarding to perform such a comparative (or ‘bridging’) study. Two examples of
comparative studies are presented in this thesis.
The first example shows a study on the effects of nitrazepam, a registered drug for
the treatment of anxiety. This study was first performed in Japan and afterwards
repeated in matched Caucasian subjects in the Netherlands using the same
protocol. The study was designed to explore the possibility and feasibility to perform
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bridging studies in two study centres using one protocol. Once the infrastructure
was established and both study sites’ procedures were harmonised in the
nitrazepam study, a bridging study for a potentially new oral contraceptive was
performed as presented in chapter 10.
The Japanese registration authorities often require repetition of most clinical trials
in Japanese subjects before registration. However, in some cases, a comparative
trial can show that the complete repetition of all the clinical trials is not necessary.
The ‘population’ question should nevertheless be adequately answered. Potential
differences in ethnopharmacological factors would require additional trials in the
Japanese population. Therefore, early comparative studies between Caucasians and
Japanese have intrinsic value to the drug development program.
The comparative trial can be performed early in the development or late in the
development depending on the estimated probability the study will show similar
pharmacokinetics and/or drug effects and the costs associated with the study. 
The study presented in chapter 10 is performed early in the development and
showed significant differences in pharmacokinetics. This finding requires parallel
development in Japan in order to launch the product world-wide. If this study was
performed at a later stage in the development, subsequent development in Japan
would be delayed resulting in a loss of market value due to patent expiry and loss of
revenues. It can be argued that the success probabilities for development in Japan
would be higher in this case because development in the Caucasian population
already produced significant knowledge about the drug.
For the development of a (hypothetical) new drug a bridging scenario is considered.
The drug development team has assumed that the worldwide development of the
drug can be accomplished in three ways;
1 an early bridging study is performed that shows the two ethnic groups are
‘similar’ (this probability is estimated to be 60%)
2 an early bridging study is performed that shows the two ethnic groups are
‘different’ but the drug is developed in parallel in the two groups (this probability
is estimated to be 30%)
3 the drug is developed in parallel in the two groups
In order to decide whether or not it is rewarding to perform the bridging study,
which will introduce additional costs of M¤ 1.5, a decision tree is constructed. 
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The risk adjusted project value after the bridging study is estimated at M¤ 35 for the
first option. The second option is estimated lower because the costs will be doubled
(the drug will have to be developed in both groups in parallel). However, because 
the bridging study will enhance the success probability of the drug, the risk adjusted
project value is not estimated at half the project value of the first option but at 
M¤ 27. Similarly, if the bridging study is not performed but the drug is successfully
developed according to the last option, the ‘risk adjusted’ project value is also set 
at M¤ 27 but obviously, the costs of the bridging study have not been made. 
The constructed decision tree is represented in figure 1.
figure 1 Decision tree for a new drug, which is used to determine the feasibility of a 
bridging study
The decision tree clearly shows that the additional bridging study enhances the
estimated risk adjusted project value with the current input parameters. In order to
find out when the bridging scenario is no longer favourable, sensitivity analysis on
the probability the two ethnic groups are ‘similar’ is performed. The result of this
analysis is shown in Figure 2.
From this graph, it can be concluded that the probability the two ethnic groups are
‘similar’ may be estimated as low as 53% and still the bridging study will produce
additional value despite the introduction of M¤ 1.5. If the probability drops below






















the 53%, it is more sensible to skip the bridging study and immediately start parallel
development in both groups. The latter option produces the estimated risk adjusted
project value of M¤ 27.
figure 2 Sensitivity analysis on the probability that the bridging study will show the 
two ethnic groups are ´similar´
However, the example of the potential oral contraceptive illustrates that it is crucial
to take all questions into account when constructing the drug development
decision tree. Even if one identifies the ‘population’ question as an important
question, the other questions can have more significant impact on the optimal
development strategy. In the presented case, the probability the drug would prove
to have an improved side-effect profile would have to be estimated very low. The
side effects associated with registered oral contraceptives are relatively rare and the
exact mechanism of these effects is unknown and still subject to discussion. It
would require additional evidence on the mechanism leading to these side effects
to convince registration authorities that the new mechanism of action of the drug
will lead to lower incidence of the side effects. Subsequent proof of improved side
effect profile over existing medication would be very difficult (and expensive) due to
the already relatively rare side effects.
Therefore, the probability of successfully answering the ‘clinical’ question would
have to be estimated relatively low and the associated costs very high. Using both
this low probability and high cost for the ‘clinical’ question in the qbd tree yields 
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a negative estimated risk adjusted project value instead of the M¤ 27 used in 
the decision analysis represented in figure 1. As a consequence, the drug was
discontinued after the comparative study presented in chapter 10 was completed.
Adequate estimation of the costs and probabilities of success using the qbd-
approach would have saved at least the presented comparative trial. 
The construction of a decision tree for this drug would have revealed that the
‘clinical’ question far outweighs the ‘population’ question and abandoning 
the development of this drug would have been the best decision.
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aim   This study investigated the effects of two doses (0.5 mg and 1.5 mg) 
of mrla023, which is a gabaA 12,3 subtype selective partial agonist. This
compound mrla023 is expected to result in comparable anxiolytic efficacy 
as clinically used benzodiazepines with an improved tolerability profile. It is
hypothesised to be less sedating because it lacks efficacy at the 11 subtype,
the subtype believed to mediate the sedative effects of benzodiazepines. 
material and methods   Twelve healthy male volunteers partici-
pated in this placebo controlled, double-blind, double-dummy, four-way,
cross-over study. As a positive control, the non-selective benzodiazepine
lorazepam (2mg) was used in a therapeutic anxiolytic dose. The Central
Nervous System (cns) effects of the two doses of mrla023 and lorazepam
were compared with placebo. Saccadic Eye Movements (sem) and Visual
Analogue Scales (vas) were used to assess the sedative properties of
mrla023. The psychomotor and cognitive effects were assessed using 
body sway and a standardised battery of neurophysiological memory tests. 
results   Lorazepam caused sedation (maximum sem reduction of 
89 deg/sec and a vas alertness score maximum effect of 4.5 mm) and
impairment of memory and body stability (three of the four memory tests
studied showed significant memory impairment and body sway with eyes
closed was increased by 28%). mrla023 had significant dose dependent
effects on sem (85 deg/sec maximum reduction at the higher dose, appro-
ximating that of lorazepam) but not on vas score of alertness. No changes
were observed in saccadic latency and saccadic inaccuracy for either doses 
of mrla023, in contrast to significant increases with lorazepam. Contrary to
lorazepam, mrla023 caused no detectable memory impairment or postural
imbalance.
conclusion   These results show that the effect profile of mrla023
differs from that of lorazepam, at doses that were equipotent with regard 
to sem -effects. Therapeutic equipotency cannot be proven at this stage,
because the clinical effects of mrla023 have not yet been determined. 
The differentiation between pharmacodynamic effects for the selective
gabaA agonist mrla023 may be related to selectivity for different gabaA
receptor subtypes. Further studies will show whether this pharmacological
selectivity is associated with an improved side effect profile.
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Introduction
Generalised anxiety disorder (gad) is a severe, chronic, and distressing illness
that often requires long-term management. The lifetime prevalence is
approximately 4 to 6 percent in the general population and is more common
in women than in men. Benzodiazepines are the most frequently prescribed
pharmacological treatment for gad. Benzodiazepines possess several
advantages over other anxiolytics, including rapid action, ease of use and 
a wide margin of safety. Although benzodiazepines are relatively safe drugs
and are widely used in the treatment of anxiety, they may produce untoward
side effects such as sedation, memory impairment and muscle relaxation.
mrla023 is a gabaA 12,3 subtype selective partial agonist, which is expected
to result in comparable anxiolytic efficacy as clinically used benzodiazepines
with an improved tolerability profile based upon pre-clinical animal models.
In particular, mrla023 has the potential to be an effective, non-sedating
anxiolytic. It is believed to be non-sedating because it lacks efficacy at the 
11-subtype, the subtype believed to mediate the sedative effects of
benzodiazepines.
Based on tolerability findings in healthy volunteers, two doses of mrla023
were selected for this study: 0.5 mg and 1.5 mg. The highest dose was chosen
to evaluate the sedative, cognitive, and motor effects that could be expected
with doses at the upper end of the anticipated dose range to be evaluated in
further studies. The lower dose of mrla023 was tested in order to establish
the pharmacodynamic effects expected at a dose that might still demon-
strate anxiolytic efficacy. For lorazepam, a dose of 2 mg was selected, which
is known to be both therapeutically relevant and sedating.
The current study was designed to compare the central nervous system 
(cns) effects of two dose levels of mrla023 with those of placebo and 2 mg
lorazepam in healthy male subjects. Saccadic eye movements and visual
analogue scales were used to assess the sedative properties. According to 
a recent literature review of non-selective benzodiazepine anxiolytics, effects
on saccadic eye movements are also closely correlated with therapeutic
effects. In addition, the psychomotor and cognitive effects of mrla023 were
compared with those of 2 mg lorazepam and placebo, using body sway and 
a standardised psychometric battery. Finally, the plasma levels of mrla023
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Methods
Design
This study was a placebo controlled, randomised, double-blind, double-
dummy, four-way, cross-over, monocentric study in twelve healthy male
volunteers, with a five-day washout period.
Subjects
Twelve healthy non-smoking volunteers were recruited from the chdr
database. All volunteers received a full medical examination and gave written
informed consent before entry to the study. Subjects were asked not to drink
alcohol 48 hours prior to the study, abstain from caffeine-containing
products 8 hours prior to the study and from grapefruit, grapefruit juice and
St. John’s Wort for at least 2 weeks prior to the study until the completion 
of the study. The study was approved by the Medical Ethics Review Board of
Leiden University Medical Center, and performed according to the principles
of the Helsinki Declaration and gcp.
Treatments 
Subjects received each single oral dose mrla023 0.5mg, mrla023 1.5mg,
lorazepam 2 mg or placebo administered with 250 ml of water in a fasting
state at approximately 8 to 9 am on day 1 of each study period. Subjects
always received 3 tablets of mrla023 or matching placebo and 2 capsules of
lorazepam or matching placebo. The treatment sequences were determined
using 4x4 Latin Squares, balanced for 1st order carry-over.
Safety
Adverse events, ecg, blood pressure and heart rate measurements were
assessed throughout the study. ecgs were assessed with a Cardiofax,
equipped with ecaps12 analysis program (Nihon Kohden, Japan). Blood
pressure and heart rate were measured with an automated blood pressure
monitor (mpv1072, Nihon Kohden, Japan), which displays an average value
for two sequential (duplicate) measurements at each time point. All ecg,
blood pressure and heart rate measurements were made after the subject
had been sitting in a semi-recumbent position for at least 5 minutes.
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Pharmacokinetics
Blood samples were drawn on day 1 of each occasion day predose (within 30
minutes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 24 hours post-
dose and were processed to obtain plasma for assay of mrla023 and lorazepam
concentrations. All blood samples were protected from exposure to direct light
throughout the sample handling procedures. Blood samples (5 ml) drawn from
an intravenous catheter were collected into sodium heparinised tubes. Blood
samples were inverted 6 times and immediately centrifuged in a refrigerated
centrifuge at 2000 gs for 10 minutes at 4°C. Plasma was transferred to a 4.5 cc
Nunc cryotube and stored at –20°C within 30 minutes. Plasma samples collec-
ted following each mrla023 dose were assayed for mrla023. Analysis was
accomplished by solid phase extraction of the analyte and an internal standard
from plasma using a 96-well plate format followed by reversed phase hplc
and ms/ms detection. Plasma samples collected following the lorazepam 
dose were assayed for lorazepam. Lorazepam and its stable-isotoped labelled
internal standard were extracted from basified plasma into methyl-t-butyl ether
with an automated procedure using a Tomtec Quadra 96 Model 320. Extracts
were evaporated under nitrogen, reconstituted and analyzed by lc/ms/ms
using positive ion Turbo Ionspray with multiple reaction monitoring. 
Pharmacodynamics
Pharmacodynamic measurements were performed predose (within 30 minu-
tes prior to dosing) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 10 hours postdose.
Pharmacodynamic tests were perfomed in a quiet room with ambient
illumination with only 1 subject in the same room per session. Each session
consisted of the following sequence of tests: saccadic eye movements; body
sway eyes open; body sway eyes closed; vas. Cognitive function tests were
performed in the 1-3 hours-postdose period between the other measurements.
saccadic eye movements   Saccadic eye movements were recor-
ded using a micro-computer-based system for data recording (Cambridge
Electronics Design, Cambridge, uk), Nihon Kohden equipment for stimulus
display, signal collection and amplification (Nihon Kohden Corporation,
Tokyo, Japan), and disposable surface electrodes (Medicotest N-oo-s,
Olstykke, Denmark). Average values of latency (= reaction time), peak
saccadic velocity and inaccuracy (difference between stimulus angle and
corresponding saccade in %) were calculated for all artifact-free saccades.
Saccadic peak velocity has been validated as the most sensitive measure for
the sedative effects of benzodiazepines.
ref. 10
ref. 11-13
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visual analogue scale   Visual analogue scales as originally
described by Norris were previously used to quantify subjective effects of
benzodiazepines. From the set of sixteen scales three composite factors were
derived as described by Bond and Lader, corresponding to alertness, mood
and calmness. These factors were used to quantify subjective drug effects.
body sway   Body sway was measured with an apparatus similar to the
Wright ataxiameter, which integrates the amplitude of unidirectional body
movement transferred through a string attached to the subject’s waist. 
Two-minute measurements were made in the antero-posterior direction
with eyes open and eyes closed, with subjects standing comfortably on a 
firm surface with their feet slightly apart.
cognitive function tests   The neurophysiological memory 
tests were performed using FePsy (The Iron Psyche), an automated system
containing a battery of computerised tests for cognitive (neuropsychological)
functions. The recognition and recall test and the Corsi block tapping task
were included in this study. The Corsi block tapping test was constructed
according the principles of the original Corsi block tapping task. This task
assessed the nonverbal memory span. 
Analysis
pharmacokinetics   The pharmacokinetics of mrla023 was inves-
tigated using non-linear mixed effect modeling as implemented in nonmem
version V software (nonmem Project Group, University of California, San
Francisco, ca), applying the first order conditional estimation (foce) method
with the ‘interaction’ option. A series of pk models was attempted and
compared using the likelihood ratio test. Ultimately, a two-compartment
model with first-order absorption and a lag-time was used to describe the
pharmacokinetics of mrla023. Intra-individual error was modelled using a
constant coefficient of variation error model. No pharmacokinetic
parameters were calculated for lorazepam. 
pharmacokinetic/pharmacodynamic relationships
The observed pharmacodynamic effects were plotted against the predicted
mrla023 concentrations for each individual. Because the average placebo
profile for saccadic peak velocity was not flat, the average placebo profile was
subtracted from all saccadic peak velocity data at corresponding protocol
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was performed using non-linear mixed effect modelling as implemented in
nonmem. Empirical Bayes pharmacokinetics estimates were generated and
used to describe the concentration profile for investigation of the pk/pd
relationship between mrla023 and saccadic peak velocity. A linear con-
centration-effect model was estimated without an effect compartment.
Individual graphs indicated that no improvement could be obtained using
either a more complex concentration-effect model or an effect compartment
and further analysis was not attempted. 
statistics   Treatment response was characterised for continuously
measured variables by calculating the area under the effect curve (auec)
relative to baseline over 6 hours. The pre-values were averaged and set at
time = 0 hr. Change from average pre-value (delta) was calculated. The
auecs were calculated using the linear trapezoidal rule up to 6 hours on 
the basis of protocol (planned) time points and were subsequently divided 
by the corresponding time span resulting in weighted average change from
pre-value. All variables were analysed untransformed except for body sway
because only body sway clearly indicated an increase in variability in respon-
se with an increase in average response. As cognitive function test results
were assessed only once for each treatment, raw scores were analysed.
Statistical analysis was initially performed using analysis of variance with
factors treatment (4 levels) subject (12 levels) occasion (4 levels) and carry-
over (5 levels, coded as the treatment preceding the current treatment,
including ‘no preceding treatment’). If the carry-over effect was found to 
be non-significant, the analysis was rerun without the carry-over factor. 
The four treatments were compared within the anova model using the
following contrasts: placebo - mrla023 0.5mg, placebo - mrla023 1.5mg,
lorazepam 2mg - mrla023 1.5mg and placebo - lorazepam 2mg. Overall 
p-value for the treatment effect was reported along with the specified
contrasts with 95% confidence intervals and p-values. All calculations were
performed using sas for Windows V8.1 (sas Institute, Inc., Cary, nc, usa).
Results
Subjects
Twelve subjects, judged to be in good health on the basis of medical history,
physical examination and routine laboratory data, participated in the study
after giving written informed consent. Two subjects dropped out; one was
repeatedly unable to swallow the capsules and another withdrew after the
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second occasion for personal reasons. These two subjects were replaced by
two other healthy male subjects, using the same randomisation sequence.
Twelve subjects completed study. Subjects were on average 25 years of age
(range 20-29), average weight of 82.3 kg (range 74.6-87.7 kg) and average
height of 184.1 cm (range 177.6-191.9 cm).
Clinical observations
No serious adverse reactions occurred following any of the treatments. 
The most frequently reported adverse event was sedation by eight, five, zero
and two subjects after administration of lorazepam, the high and low doses
of mrla023 and placebo, respectively. Other reported adverse events were
drowsiness after mrla023 0.5mg administration (three subjects), dizziness
after mrla023 1.5mg administration (four subjects), sleepiness and head-
ache after lorazepam 2mg administration (seven and three subjects, respec-
tively) and fatigue and headache after placebo administration (six and five
subjects, respectively). ecg, blood pressure and heart rate measurements
demonstrated no clinically significant effects for both doses of mrla023,
lorazepam and placebo. 
Pharmacokinetics
The average plasma concentration-time curves for both doses of mrla023
and lorazepam are shown in figure 1. Both doses of mrla023 and lorazepam
showed maximum concentrations after approximately 2 hours. The average
pharmacokinetic parameters (with interindividual variation coefficients (cv)
of mrla023 were: clearance/bioavailability of 246 mL min-1 (cv 29%), initial
half-life of 142 min (cv 6%), terminal half-life of 437 min (cv 0%, fixed),
central volume of distribution/bioavailability of 71.1 L (cv 20%), absorption
half-life of 33.6 min (cv 39%) and a lag-time of 27.4 min (cv 19%).
Pharmacodynamics
saccadic eye movements   Saccadic peak velocity (spv), which
was used to assess sedative properties, demonstrated significant effects with
lorazepam and both doses of mrla023 (figure 2 and table 1). There was a
dose-dependent increase of spv with mrla023 0.5 and 1.5 mg (auec0-6hr
decrease of 22 deg/sec and 45 deg/sec). No changes were observed in
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saccadic latency and saccadic inaccuracy for either doses of mrla023, in
contrast to the significant increases with lorazepam. The high dose of
mrla023 and lorazepam caused similar average maximum effects on spv
relative to baseline. However, the effects of lorazepam lasted slightly longer,
leading to a significant difference in time-corrected auec0-6hr (table 1).
figure 1 Average drug concentration profiles (mean + sd) of mrla023 0.5mg (B), 
mrla023 1.5mg (D) and lorazepam 2mg (∆) after oral administration
figure 2 Average time profile (mean + sd) of Saccadic Peak Velocity (change from 
baseline) after oral administration of placebo (C), mrla023 0.5mg (B), 
mrla023 1.5mg (D) and lorazepam 2mg (∆)
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visual analogue scale   The vas score of alertness, which was
used to estimate subjective sedative effects, only showed a significant
average effect after lorazepam (table 1). The average curve for the high dose
of mrla023 was in between the average curves of lorazepam and placebo
(figure 3), and consequently, the auc0-6hr of the high dose of mrla023 did
not differ significantly from either lorazepam or placebo. Subjective calmness
was reduced after the high dose of mrla023, while none of the other
treatments showed any effect. No significant effects were observed for the
vas contentedness subscale.
table 1 Pharmacodynamic measurements auc0-6hr relative to baseline: Saccadic Eye 
Movements, Visual Analogue Scales and Body Sway; anova results (contrast, 
95% ci, p-value)
Variable Overall treat- Placebo Placebo Lorazepam 2mg Placebo
ment effect mrla023 mrla023 mrla023 Lorazepam
(p-value) 0.5mg 1.5mg 1.5mg 2mg
Saccadic Peak <.0001 21.58 45.24 -13.99 59.23
Velocity (deg/sec) (8.40 / 34.76) (32.06 / 58.42) (-27.17 / -0.81) (46.05 / 72.41) 
p = 0.002 p < 0.001 p = 0.038 p < 0.001
Saccadic 0.0003 -0.002 -0.009 0.017 -0.027
Latency (sec) (-0.014 / 0.009) (-0.021 / 0.002) (0.006 / 0.029) (-0.039 /-0.015) 
p = 0.672 p = 0.116 p = 0.005 p < 0.001
Saccadic 0.0008 -0.09 -0.03 2.21 -2.24 
Inaccuracy (%) (-1.27 /  1.08) (-1.21 /  1.14) (1.03 /  3.38) (-3.42 / -1.07) 
p = 0.874 p = 0.954 p < 0.001 p < 0.001
vas Alertness 0.0082 1.35 -0.33 1.47 -1.80
(ln mm) (-0.37 / 3.08) (-2.05 / 1.39) (-0.25 / 3.19) (-3.52 /-0.08) 
p = 0.119 p = 0.698 p = 0.092 p = 0.041
vas 0.2630 -0.25 -0.71 -0.47 -0.24 
Contentedness (-0.97 / 0.48) (-1.44 / 0.02) (-1.20 / 0.25) (-0.96 / 0.49)
(ln mm) p = 0.492 p = 0.055 p = 0.193 p = 0.510
vas Calmness 0.0097 -0.14 -0.53 -0.43 -0.10
(ln mm) (-0.46 / 0.17) (-0.84 /-0.22) (-0.74 /-0.12) (-0.41 / 0.22) 
p = 0.355 p = 0.002 p = 0.009 p = 0.529
Log Body Sway <.0001 0.009 -0.001 0.310 -0.312
Eyes Closed (-0.087 / 0.106) (-0.098 / 0.095) (0.214 / 0.407) (-0.408 /-0.215)
(log mm) p = 0.849 p = 0.976 p < 0.001 p < 0.001
Log Body Sway <.0001 -0.026 -0.021 0.267 -0.288
Eyes Open (-0.102 / 0.050) (-0.097 / 0.055) (0.192 / 0.343) (-0.364 /-0.213)
(log mm) p = 0.487 p = 0.575 p < 0.001 p < 0.001
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figure 3 Average time profile (mean + sd) of vas Alertness (change from baseline) after 
oral administration of placebo (C), mrla023 0.5mg (B), mrla023 1.5mg (D) and 
lorazepam 2mg (∆)
body sway   No body instability was observed after either dose of
mrla023 compared to placebo (figure 4). Lorazepam, however, caused 
a profound and highly significant increase in body sway (table 1). 
figure 4 Average time profile (mean + sd) of log Body Sway Eyes Closed (change from 
baseline) after oral administration of placebo (C), mrla023 0.5mg (B), 
mrla023 1.5mg (D) and lorazepam 2mg (∆)
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cognitive function tests and corsi block tapping
task   Three of the four recognition tests revealed that lorazepam caused
significant memory impairment, compared to placebo (figure 5). In contrast,
neither dose of mrla023 showed any significant effect on memory. Aside
from the effects of lorazepam on the ability to answer correctly, it also signi-
ficantly increased the reaction times to the correct answers of all memory
tests with a range of 0.5-1.3 sec from placebo (figure 5). These significantly
higher reaction times were not found with mrla023. No treatment effects
were observed on the Corsi block tapping task.
figure 5 Effects on cognitive function tests (mean + sd). rfse = Recognition Figures 
Serial; rfsi = Recognition Figures Simultaneous; rwse = Recognition Words 
Serial; rwsi = Recognition Words Simultaneous. †: p<0.05 compared to placebo, 
‡: p<0.05 compared to placebo and mrla023 1.5mg
Pharmacokinetic/pharmacodynamic
relationships (pk/pd)
Concentration-effect-relationships were only determined for statistically
significant pharmacodynamic effects of mrla023 (ie only for spv). The
average pk/pd relationship between the changes in spv from baseline and
the predicted concentration for both doses of mrla023 is represented in
figure 6. A linear concentration-effect model was estimated without an effect
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compartment for both doses of mrla023. Both slope and intercept for spv
did not differ significantly between the two doses of mrla023. There were 
no obvious signs of hysteresis or maximum effects. Individual graphs
indicated that no improvement could be obtained using either a more
complex concentration-effect model or an effect compartment.
figure 6 Concentration-effect profiles for Saccadic Peak Velocity of mrla023 0.5mg (C) 
and mrla023 1.5mg (D)
Discussion
The current placebo-controlled study in healthy male volunteers investigated
the effects of two doses of mrla023, a gabaA 12,3 subtype selective partial
agonist. The benzodiazepine lorazepam was used in a therapeutic anxiolytic
dose as a positive control. As expected, lorazepam caused sedation (shown
by spv-decreases and vas-effects), impairment of memory and body sway.
These effects are typical for benzodiazepines, and are often used as indica-
tors of the drug’s effects. mrla023 caused dose dependent spv-effects of 
a similar magnitude as lorazepam, but mrla023 had no detectable effects 
on vas alertness score, memory or postural stability.
The results from the current study suggest that the clinical effects of
mrla023 may differ from those of lorazepam, but this relies on the
assumption that equipotent therapeutic doses were used. Therapeutic
equipotency cannot be proven at this stage, because the clinical effects 
ref. 12-13
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of mrla023 have not yet been determined in patients with anxiety. However,
lorazepam 2 mg and the highest dose of mrla023 caused similar reductions
in Saccadic Peak Velocity (spv). Although a decrease in spv is usually viewed
as a biomarker for sedation, a recent review showed that the spv-effect is
also closely linked to therapeutic levels of benzodiazepines. If the clear spv-
reductions with mrla023 and lorazepam are indicative of the therapeutic
dose, mrla023 would be expected to have fewer of the adverse effects in
patients that are typically associated with non selective benzodiazepines like
lorazepam. Clinical studies are needed to confirm that mrla023 has similar
efficacy but fewer adverse effects than lorazepam in patients with gene-
ralised anxiety disorder. In any case, the cns-effect profile of the selective
partial gaba-agonist mrla023 in healthy humans differs from that of the
non-selective agonist lorazepam.
Although direct comparative studies are rare, non-selective benzodiazepines,
like diazepam, zopiclone, flurazepam, lormetazepam, triazolam, temazepam
and lorazepam, all show comparable effects on memory, alertness and
postural stability. This suggests that the differentiation between mrla023
and lorazepam, observed in the current study, could be related to the
differences in gaba-subtype (non-) selectivity. It is reported that the effects
of benzodiazepines are mediated by specific gabaA receptor subtypes. 
The 11 sub-unit is believed to primarily mediate the sedative properties and
as a consequence, potentially mediate memory properties of gabaA agonists. 
The selective 11-agonist zolpidem causes clear spv-reductions and is used 
as a hypnotic agent. The current study supports the link between the 11
sub-unit and sedation. mrla023 is a gabaA partial 12,3 agonist devoid of 
11-activity in pre-clinical experiments. mrla023 causes no memory impair-
ment and less subjective sedation than the non-selective full benzodiaze-
pine-agonist lorazepam. However, preclinical evidence also suggests that 
the 12,13 and 15 sub-units mediate the therapeutic, myorelaxation and
motor impairment properties of gabaA agonists. In view of this, mrla023
shows a surprising lack of motor impairment. There are several explanations.
It could reflect the partial agonist character of the mrla023. The purported
12,13-effect of mrla023 may become more apparent at higher doses, not
evaluated in this study. Finally, the pre-clinical subselectivity may not always
show the same pattern in humans. 
Previous studies with other partial gabaA agonists showed less differentia-
ting effects than mrla023. However, these agents show no subtype selec-
tivity. Bretazenil, for example, showed differences from placebo in saccadic
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the difference in selectivity for different subtypes compared with mrla023,
because bretazenil is generally less potent on all 1-subtypes than a full
agonist like diazepam. Ro 41-3696, reported to be a partial agonist, induced
fewer effects on psychomotor performance and memory than 10 mg
zolpidem at 1.5 h after intake but the effects were still significantly greater
than placebo. Moreover, it is unknown whether these doses were equipotent,
an important requisite for comparison of partial agonism and subtype
selectivity.
In conclusion, this study showed a clear differentiation in pharmacodynamic
effects for the selective gabaA agonist mrla023, which was not found for the
non-selective benzodiazepine lorazepam. This differentiation may be related
to selectivity for different gabaA receptor subtypes, which may be associated
with fewer side effects at therapeutically effective doses in patients.
ref. 28
ref. 29
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The value of determining critical
questions early
This section presents a study in the development of a potential new drug for the
treatment of generalised anxiety disorder (gad). The development of a partially
selective gaba-a agonist could have a therapeutic advantage over existing anxio-
lytics (existing benzodiazepines in particular). The main issue for these kinds of 
new drugs is that, after reaching the site of action (i.e. it must pass the blood-brain-
barrier), the proposed mechanism of action points to a differentiation of the effects.
The presented study indeed showed differentiation of effects.
The input parameters for the question-based development tree of this compound
are presented in table 1. These input parameters are based on a classic drug
development program of this type of compound (i.e. the parameters are estimated
without the impact of the presented study).
table 1 Input parameters for the question based development plan of mrla023 without 
the presented study
Parameter Value
Success action site 75%
Success pharmacological effect 65%
Success clinical efficacy 80%
Success therapeutic window 85%
Success population 90%
Costs action site M¤ 25
Costs Pharmacological effect M¤ 25
Costs Clinical effect M¤ 60
Costs Clinical window M¤ 30
Costs Population M¤ 35
Estimated market value M¤ 400
Similar to the value estimation of section 1, an optimal question sequence is
determined by decision analysis. This priority list is represented in table 2. 
The estimated risk adjusted project value of this optimal sequence is M¤ 27.
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According to the priority list presented in table 2, the two most important questions
for this novel drug are ‘pharmacology’ and ‘site’. In the classic npv approach, per-
formance of an additional cross-over study to determine the pharmacodynamic
effects on sedation, body stability and memory compared to the existing market
leader introduces extra development costs and maybe extra time. However,
because of the early evaluation, a less sedative dose can be selected to examine the
efficacy in patients. This maximum dose with a differential effect profile is crucial
because it is the core of the market advantage over the existing benzodiazepines.
Furthermore, the study prevents late failure created by an unwitting selection of 
a dose set too high. With this study, a maximum dose can be selected that is less
sedating without any effects on memory, therewith providing important informa-
tion regarding the ‘window’ question. Furthermore, the pharmacokinetic para-
meters of the drug, as estimated in the presented study, provide a first indication of
what the optimal dosing regimen could be. The ‘site’ question is not fully answered,
but the effects observed in the presented study are indicative of cns penetration.
In order to estimate the impact of the additional study presented in this section, 
a new set of input parameters can be estimated that incorporate the knowledge 
and costs obtained in the presented study. Since an important part of the ‘window’
question is resolved, the probability of success on ‘window’ is now at least 86%. 
The probability of successfully answering the ‘pharmacology’ question is raised to 
at least 66% because of the demonstrated differential profile on the pharmaco-
dynamic measures in the presented study. It remains uncertain if the differential
profile is observed in patients. The indications for central activity observed in this
study enhance the probability of success on ‘site’ to at least 76%. The costs of the
study are added by elevating both ‘window’ and ‘pharmacology’ costs with M¤ 1
(this includes the introduction of preparatory expenses, sponsor resources/time
etc.). These updated input parameters are listed in table 3.
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table 3 Input parameters for the question based development plan of mrla023 after 
the presented study
Parameter Value
Success action site 76%
Success pharmacological effect 66%
Success clinical efficacy 80%
Success therapeutic window 86%
Success population 90%
Costs action site M¤ 25
Costs Pharmacological effect M¤ 26
Costs Clinical effect M¤ 60
Costs Clinical window M¤ 31
Costs Population M¤ 35
Estimated market value M¤ 400
With this new set of parameters the estimated risk-adjusted project value is esti-
mated at M¤ 28.2. With the npv approach, the inclusion of this additional early
pharmacology study would decrease the project value because it increases the 
costs of development without increasing the value of the drug. In other words, 
the knowledge obtained in this relatively inexpensive study is less likely to be
adequately valued using npv analysis. Question-based development shows that 
the introduction of extra costs can increase the project value by increasing the
probabilities of success at a later stage in the development of this drug.
The negative impact of the additional study presented in this section could have 
led to a more classical approach to the development of this drug. This ‘classical
approach’ could consist of a single ascending dose study in healthy volunteers 
to investigate safety and tolerability, followed by a multiple dose study and a food
interaction study. Thereafter, the drug would enter phase II where in small groups 
of patients the efficacy would have to be established and the less sedating dose
selected. This approach introduces substantially more costs.
The investigation of new centrally active drugs in patients is severely hampered by
several factors. The heterogeneity of the clinical population, the differences in drug
responses, and the methodology available to investigate sedative effects in patients
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would require a substantial increase in the number of patients needed to show a
statistically significant effect. Furthermore, the costs of investigating patients
instead of healthy volunteers would further increase the costs of the development.
Combined, a study in more patients than the twelve healthy volunteers used in this
study would have a considerable impact on the project value.
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Summary and
Conclusions
245 section 4 – developping a new formulation
Introduction
The development of new medicines is an expensive and time-consuming
process. It takes an average of 12-15 years to discover and develop a new
medicine. Most of that time is spent testing the safety of the drug. The ave-
rage cost of bringing one new medicine to market in 1990 was estimated at
$500 million. The Tufts University Center for the Study of Drug Development
found that the time from synthesis of a new drug to marketing approval has
increased over time. While in the 1960s the approximate time from first
synthesis to approval was about 8 years, this time period has increased to
14.2 years in the 1990s. Most of this increase in time is due to the prolonged
period from first administration to humans to submission for registration,
which increased from 3.1 to 8.6 years.
The exact costs of drug development today are difficult to determine. 
Over $500 million is supposedly spent to introduce one single new drug on
the market. About 30% of these costs ($150 million) are spent on the clinical
development phases i to iii. Therefore, stopping as soon as possible the
development of drugs that will fail to reach registration is highly rewarding.
Growing research & development (r&d) expenditures have fuelled the
development of hundreds of new medicines over the past half-century by 
the pharmaceutical industry. As illustrated before, drug development is 
both high-cost and high-risk. It was, for instance, estimated that in the
period between 1980 and 1984 only three of every 10 nce’s had returns
higher than average after-tax R&D costs. Many attempts have been made 
to optimise the development of new medicines, both by improving the drug
target and the process of development.
Target optimisation
Computer aided drug design has made it possible to identify many com-
pounds that adequately bind or fit onto the target site. The synthesis of new
biologically active compounds has been facilitated by the use of combina-
torial chemistry. The most active compound on receptor level is selected
from the wide range of new compounds by comparing hundreds of com-
pounds at once using high throughput screening. By sequencing the human
genome, many new potential targets for new drugs have been identified.
Unfortunately, the relationship between a modification of a certain biological
target and the improvement of a clinical endpoint is often unknown, particu-
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with the potential of a breast cancer to metastasise but it remains unknown
which one(s) or which combination to block yet. Developing an inhibitor for
each target is prohibitively expensive, so biological knowledge will have to
precede chemical synthesis.
Process optimisation
The cost of development and the increased number of lead compounds 
have made adequate selection of compounds to enter the clinical phase
crucial. Mergers and take-overs of pharmaceutical companies to form bigger
companies with larger pipelines reflect attempts of procedural optimisation.
The obvious goal is to have more investigational compounds so that more
drugs will be successful and spread the risk of failure. Because the selection
of compounds has become so important, more efforts are aimed at early
discontinuation of failures (i.e. compounds that will not reach registration).
Therefore, there is a growing pressure on the drug development process to
enhance the relevance of studies at all stages. Traditionally, phase 1 studies
were mainly concerned with kinetics and tolerability of a new compound in
healthy volunteers, but efforts are now made to include potential biomarkers
of clinical endpoints.
In order to compare and select the compounds that will enter the clinical
phase of the drug development process, the Net Present Value (npv) is often
used. npv is commonly used because of its ability to discount present and
future cash flows and to provide an estimate of the total (financial) value of 
a project. npv uses a discount rate to convert a stream of future cash flows 
to a single value today. In the calculation of a project’s npv, a comparison 
is made between the situations that arise if the project is continued or
abandoned. npvs greater than zero indicate the amount the organisation 
will earn in excess of traditional financial investment of the outgoing cash
flow. The npv can then be used to compare different projects using the same
factors. The value of future cash flows is predominantly dependent on the
factor time (spending money as late as possible and generating revenues 
as early as possible). Therefore, the most influential parameters for npv
calculations of a drug development project are costs of development (as low
as possible), revenues (as high as possible) and time to introduction on the
market (as early as possible).
The difficulty of development of useful treatments is not solved by the
described target -and process optimisation efforts. A structured approachref. 5-6
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that combines and optimises both knowledge and procedural aspects of 
drug development may improve success rates and/or reduce some of the
expensive failures of development.
Classic development phases
Classically, the clinical development program of a drug is divided in four
phases:
• Phase I: Research using small groups of healthy volunteers. Traditionally, 
this phase mainly focuses on if the human body tolerates the new drug 
and on finding a dose where the level of tolerance is acceptable. 
Furthermore, it examines how the drug enters and leaves the human 
body. In general, this phase takes about 1 to 2 years.
• Phase ii: Research on a group of patients where the first proof for efficacy 
is established. More characteristics of the nce are determined and a safe 
and well-tolerated dose is determined where the drug is efficacious.
• Phase iii: The potential new drug is tested on thousands of patients in 
multi-centre research projects to investigate the side effects of the drug 
at a set dose in more detail. Furthermore, the efficacy of the drug at the 
determined dose is compared to existing medication. Further research is 
conducted to investigate possible side effects after long-term treatment 
and development of the drug for different indications is investigated.
• Phase iv: The registered drug is monitored closely to examine the 
occurrence of unexpected side-effects and interactions with other drugs.
The different phases of the research and development process are represen-
ted in figure 1. The description of these phases is typically process oriented
and contains very little information about which scientific aspects are
actually covered during the development.
Generic question groups
During these phases a number of generic questions are generally answered.
Posing these questions throughout the development of a drug is in
agreement with the learn-confirm view described by Sheiner. The main
generic question groups are:
• Does the biologically active compound/active metabolites get to the site
of action? 
ref. 7
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Related issues: Absorption, route of administration, bioavailability,
distribution, tissue distribution, accumulation, action site penetration,
metabolism, active metabolites, metabolic routes, excretion:
hepatic/renal, clearance, half-life
• Does the compound cause its intended pharmacological/functional
effect(s)? 
Related issues: Effects related to mechanism of action, additional effects
of primary pharmacological activity, effects of secondary pharmacological
activity, other, undesirable effects
• Does the compound have beneficial effects on the disease or its clinical
pathophysiology? 
Related issues: Effects on relevant physiological systems, effects on
disease, undesirable clinical effects
• What is the therapeutic window of the new drug? 
Relevant issues: Clinical effects at tolerated dose, dose
regimens/intervals, controlled drug delivery, forgiveness
• How do the sources of variability in drug response in the target population
affect the development of the product?
Relevant issues: Compliance, pharmacogenomics, ethnic differences,
concomitant medication, variability in pharmacokinetics,
pharmacodynamics and disease state
figure 1 Pharmaceutical research and development process for a new product 
(http://www.fda.gov/cder/)
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Each of these questions has a probability to be successfully answered but
answering these questions will introduce development costs. The set of
probabilities and costs varies from drug to drug and is therefore unique. For
one drug it can be very difficult to successfully answer the ‘site’ question
whereas it can be relatively easy for another compound. The unique set of
probabilities and costs defines the optimal development strategy for each
compound. Addressing a question with low probability of success at an early
phase can be highly rewarding. npv analysis merely shows that these type of
additional studies only introduce additional costs and development time and
the npv of the project will decrease. Therefore, the npv of development
projects does not adequately reflect the value of additional knowledge on a
compound, which requires a different value estimation method. The option-
based theory takes into consideration the fact that projects can also be
discontinued at various stages of the development program. The early
discontinuation of drugs that will be unsuccessful is desirable and the value
of early evaluation studies on relevant questions can be incorporated in the
option-based theory. However, the option -based method is rarely used and
is often defined using the classical phase I-iii description of the process as
decision knots in the decision tree. These phases are not relevant as targets
in the development process but merely a classification based on the type of
study and the number of patients involved in the trial.
This thesis introduces a question-based approach to drug development
which uses decision knots that are relevant for the development of new
drugs: generic questions that are really answered throughout the
development program. The resulting question-based decision tree reflects
the true risks and uncertainties that are faced in the development of an
individual drug. Furthermore, the question-based approach shows how the
project value can increase by performing an additional early phase evaluation
study that helps to adequately answer a question later on. These studies can
help in preventing unsuccessful compounds to enter late stages of
development after substantial costs have been incurred. The early
discontinuation can substantially reduce the costs of drug development. By
defining the costs and probabilities of success and constructing the decision
tree for a new compound, the bottleneck in the development of each
individual drug will be identified. In four sections, several examples are
presented to illustrate the use and impact of the question-based
development plan.
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Value of research on biomarkers
In Section 1, three methodological reviews on potential biomarkers for the
effects of drugs in healthy volunteers are presented. The proposed generic
questions can be answered in several studies (e.g. the FTIH can provide an
indication of ‘pharmacology’ and ‘clinical’). To adequately answer questions,
appropriate methodology to show effects is needed. For some
questions/drugs this selection of the appropriate methodology is easy: e.g.
‘site’ or ‘pharmacology’ for a peripherally acting antihypertensive agent
(plasma levels of the drug and blood pressure, respectively). But for drugs
indicated for diseases such as depression, schizophrenia and anxiety this
selection of the appropriate methodology is more difficult. The probability 
of successfully answering the question is therefore linked to the available
methodology. Increased knowledge about the specificity and selectivity of
the available methodology allows better selection of methods in clinical
trials, and therefore, the probability of successfully answering the question
will grow. The added value can be obtained by an increased probability of
success but also on an increased probability a failure will be discontinued
early (reduced costs). So knowledge of methodology (and research on
methodology) has intrinsic value which should be included in the project
value of a new drug.
npv shows that additional research costs money (including time) and there-
fore, the npv will drop if research on biomarkers is included in the project
value of a drug. However, the question-based approach assumes the method
factor to be incorporated in the probability factor of the compounds potential
to successfully answer the relevant question. The reviews presented in
section 1 all address the available methods for answering the ‘pharmacology’
and ‘clinical’ questions.
Currently, no validated biomarkers for the effects of antipsychotics, benzo-
diazepines or antidepressants in healthy volunteers are available, but a useful
marker should meet the following requirements:
1 a clear, consistent response across studies (from different groups) and 
drugs
2 a clear response of the biomarker to a therapeutic dose of the drug
3 a dose (concentration)-response relationship
4 a plausible relationship between the biomarker, the pharmacology of the 
drug and the pathogenesis of the disease.
If these basic requirements are used as a filter on all described methodology
in healthy volunteers, most methods are not very useful biomarkers. Chapter
2 describes that only prolactin response to antipsychotic agents fulfils the
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requirements of a useful biomarker. The same goes for saccadic peak velocity
as biomarker for the effects of benzodiazepines in healthy volunteers, as des-
cribed in Chapter 3. Chapter 4 shows that rem sleep characteristics are of
limited value as biomarkers for antidepressant effects in healthy volunteers,
but this observation can be caused by inadequate modelling of the complex
structure of human sleep. Sensitivity analyses on the probability of success
on ‘pharmacology’ versus project value according to the question-based
development approach allows construction of a ‘break-even’ table. This table
shows how much project value is gained by increasing the method factor for
each percent. The question-based development approach using historical
data input (probabilities and costs) shows that every % increase in success
probability of the ‘pharmacology’ question (by increased knowledge on the
available methods) causes an increase in project value of M¤ 0.8. A similar
analysis of the ‘clinical’ question shows an increase in project value of M¤ 1.4
for each % increase in success probability. Furthermore, the probability a
method will be selected that will not show an effect at a therapeutically
relevant dose of an efficacious drug will be reduced thereby preventing
useless studies and the use of volunteers/resources.
The value of timing additional studies
Section 2 showed that with a relatively small number of volunteers the
question “Can a new formulation improve the therapeutic window and
clinical effects of an existing drug?” could be answered. Using blood pressure
and the most sensitive marker for the side effect of sedation (saccadic peak
velocity), it was possible to identify the optimal therapeutic window of a 
drug. Furthermore, it was possible to correlate the in vivo with the in vitro
dissolution of the new formulation. Combined, these studies helped in
designing a sustained release formulation for an existing drug with adequate
clinical effects at tolerated levels. Because the drug has been on the market
for quite some time, the development of the original formulation apparently
did not optimally answer these questions. Now additional studies were
performed at a post-registration stage. The followed strategy was apparently
to bring the original product to the market as soon as possible and use
additional market-experience to consider a different (hopefully patentable)
formulation. Additional useful information was obtained from market
experience. This approach has also been adopted in the nifedipine case,
where after introduction of the original product, an improved formulation
was successfully developed based on the discovery of a novel pharmaco-
dynamic property of the drug. The improved product after the launch of the
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original product is sometimes referred to as a 2nd-cycle product. Another
possible strategy could have been early inclusion of additional studies to
evaluate the effects of a different formulation. The inclusion of these studies
at an early stage in the original development of rilmenidine would have
allowed the introduction of the sustained release formulation for rilmenidine
and thereby reducing the additional costs of having to introduce a new for-
mulation. The npv of such a hypothetical development plan would probably
have been lower than the one actually used, but the result would be a
formulation that would meet a larger market demand and the revenues
could therefore have been higher. These studies increased the knowledge on
rilmenidine which would not be adequately valued using npv, in contrast
with the question-based approach. The rating of the success probabilities
would yield a suggested policy to examine the ‘window’ and ‘clinical’
questions early in the development.
Added value of bridging studies
Two comparative studies between Japanese and Caucasian subjects are
presented in Section 3. The introduction of new drugs in Japan is increasingly
interesting for western pharmaceutical companies. Japan has a large popu-
lation and the availability of western drugs is rare. The Japanese registration
authorities often require repetition of most clinical trials in Japanese subjects
before registration. However, in some cases, a comparative trial can show
that the complete repetition of all the clinical trials is not necessary. The
‘population’ question should nevertheless be adequately answered. If there 
is a difference in ethnopharmacological factors, additional trials in the
Japanese population are required. Therefore, early comparative studies
between Caucasians and Japanese have intrinsic value to the drug develop-
ment program. The added value can be caused by two options: one option is
that the comparative studies show that there are no differences in drug
response that affect dose. Similar drug responses in both groups would allow
extrapolation of the western data to the Japanese population and hence
prevent additional trials in Japan. Another option would be the timing of
these comparative studies. If the probability the drug response is similar is
high, the qbd tree shows that one should decide to answer the ‘population’
question late in development (there are more important questions to ask).
But especially if there is a real probability the drug response will be different
between the ethnic groups, an early evaluation study can add substantially 
to the project value of the new drug. The example in Chapter 10 of the
potential oral contraceptive illustrates that it is important to take all
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questions into account when constructing the drug development decision
tree. Even if one identifies the ‘population’ question as tangible, the other
questions can have more significant impact on the optimal development
strategy. In the presented case, the probability the drug would prove to have
an improved side-effect profile would have to be estimated very low. As a
consequence, the drug was discontinued after the comparative study
presented in this thesis had been completed. Adequate estimation of the
probabilities of success using the qbd-approach would have saved at least
the presented comparative trial. The construction of a decision tree for the
oral contraceptive would have revealed that the ‘clinical’ question far
outweighs the ‘population’ question.
The value of determining critical
questions early
In Section 4, a study in the development of a potential new drug for the
treatment of generalised anxiety disorder (gad) is presented. The develop-
ment of a selective gaba-a partial agonist could have a therapeutic advan-
tage over existing anxiolytics. The main issue for these kinds of new drugs 
is that the proposed mechanism of action indeed shows a differentiation of
the effects. Also, the drug or active metabolites must reach the site of action
(i.e. it must pass the blood-brain-barrier). Therefore, the two most important
questions for the novel drug are ‘pharmacology’ and ‘site’. In the classic npv
approach, performance of an additional cross-over study to determine the
pharmacodynamic effects on sedation, body stability and memory compared
to the existing market leader introduces extra development costs and maybe
time. However, because of the early evaluation, the study showed indications
that there are in vivo differentiation of effects and a less sedative dose can be
selected to examine the efficacy in patients. The maximum dose is crucial
because it is the core of the market advantage over the existing drugs.
Therewith, the study attempts to prevents late failure because of relative over
dosage. The ‘site’ question is not fully answered but the effects observed in
the presented study are indicative for central penetration.
Conclusions
The use of npv analysis in drug development does not adequately reflect 
the additional value of knowledge. Similar to other efforts, npv analysis is
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an attempt to deal with the uncertainties and risks of drug development 
in a procedural approach. A question-based approach to drug development
seems more rational and better incorporates the alteration of success pro-
babilities. Furthermore, the question-based approach has implications for
the execution of the drug development project and the selection of new
biologically active compounds. It is beyond the scope of this thesis to present
a universal model for drug selection and development. Based on several
examples this thesis illustrates that the combination of success probabilities
and accompanying costs to answer the questions are a unique data set that
can vary with different compounds. Even if the overall probability of success
and the overall costs are the same, these unique sets dictate an optimal
development strategy. The sequence of relevant questions should serve 
as a priority list in the development of new drugs throughout the program.
Regular updates of all probabilities and costs will optimally direct the
development process. Another advantage of the question-based approach 
is that experts of different company departments all involved in the develop-
ment of new drugs discuss and agree on the chances and threats in the
development of new drugs.
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Samenvatting 
en Conclusies
259 section 4 – developping a new formulation
Inleiding
De ontwikkeling van nieuwe geneesmiddelen is een duur en tijdrovend 
proces. Het duurt gemiddeld 12-15 jaar om een potentieel geneesmiddel 
te ontwikkelen nadat het molecuul ontdekt is. De meeste tijd hiervan wordt
besteed aan het testen van de veiligheid van het middel. De gemiddelde kos-
ten die gemaakt worden om één geneesmiddel op de markt te brengen werd
in 1990 geschat op $500 miljoen. De Tufts University Center for the Study of
Drug Development heeft gevonden dat de tijd van synthese van het middel
tot de goedkeuring van het middel voor de markt toegenomen is in de loop
der tijd. Terwijl in de zestiger jaren de tijd van synthese tot goedkeuring nog
ongeveer 8 jaar was, is deze periode geschat op 14.2 jaar in de jaren negentig.
Het merendeel van deze toename in tijd is te wijten aan een toename in tijd
van eerste toediening aan de mens tot indiening van het dossier voor goed-
keuring (de klinische fase van het geneesmiddel ontwikkelingsproces). Deze
periode nam in de bestudeerde periode toe van 3.1 tot 8.6 jaar.
De exacte kosten van het huidige geneesmiddel ontwikkelingsproces zijn
moeilijk vast te stellen. Er wordt verondersteld dat meer dan $500 miljoen
wordt uitgegeven om een nieuw geneesmiddel te kunnen introduceren op de
markt. Ongeveer 30% van deze kosten ($150 miljoen) wordt uitgegeven aan
de klinische ontwikkelingsfasen i tot iii. Het is dan ook lonend om zo snel
mogelijk te stoppen met de ontwikkeling van middelen die uiteindelijk niet
geregistreerd zullen worden. Toenemende investeringen in onderzoek en
ontwikkeling hebben geleid tot de ontwikkeling van honderden nieuwe
geneesmiddelen in de laatste 50 jaar. Zoals eerder beschreven is genees-
middel ontwikkeling zowel een duur als riskant proces. Het is bijvoorbeeld
geschat dat in de periode tussen 1980 en 1984 maar 3 van de 10 potentiële
geneesmiddelen hogere opbrengsten hadden dan gemiddelde onderzoek– 
en ontwikkelingskosten. Er zijn vele pogingen gedaan om de ontwikkeling
van geneesmiddelen te optimaliseren, zowel door het verbeteren van de 
aangrijpingspunten van stoffen als het proces van ontwikkelen.
Optimalisatie van het aangrijpingspunt
Door het in kaart brengen van het menselijk genoom zijn vele nieuwe poten-
tiële aangrijpingspunten voor nieuwe geneesmiddelen geïdentificeerd. 
Met behulp van computersimulatie kunnen stoffen worden ontworpen die in
theorie effectief zijn op de geïdentificeerde moleculaire aangrijpingspunten
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(ligand) voor de receptor wordt vergemakkelijkt door gebruik te maken van
‘combinatorial chemistry’ (een techniek waarbij verschillende biologisch
actieve delen van het molecuul op alle mogelijke manieren aan elkaar wor-
den gezet). De daarna noodzakelijke selectie van het beste ligand wordt
geoptimaliseerd door gebruik te maken van ‘high throughput screening’ op
receptor niveau. Hierbij wordt gebruik gemaakt van cellen die de betreffende
receptor tot expressie brengen en waarbij receptor activiteit bijvoorbeeld
gepaard gaat met het aanmaken van een fluorescerende marker. Helaas is 
de relatie tussen het modificeren van een bepaald biologisch aangrijpings-
punt en de verbetering van een klinisch eindpunt vaak onbekend, vooral voor
multifactoriële ziekten.
Proces optimalisatie
De selectie van potentiële geneesmiddelen is steeds belangrijker geworden
waardoor de farmaceutische industrie vaak overgaat tot schaalvergroting. 
De fusies en overnames binnen deze industrie hebben vaak tot doel meer
potentiële geneesmiddelen in de portfolio te krijgen waardoor de risico’s
zoveel mogelijk gespreid worden. Verder heeft deze schaalvergroting vaak
optimalisatie van personeel en investeringen tot doel. Doordat de selectie
van potentiële geneesmiddelen steeds belangrijker is wordt er ook gepro-
beerd zo vroeg mogelijk in de ontwikkeling te stoppen met stoffen die niet
succesvol zullen zijn. Daartoe wordt steeds vaker geprobeerd biomarkers 
voor effecten bij patiënten al te meten in de vroege fase van het geneesmid-
del ontwikkelingsproces. Waar vroeger studies naar de effecten van nieuwe
stoffen in gezonde vrijwilligers vaak gericht waren op de veiligheid en ver-
draagzaamheid van de nieuwe stoffen, wordt tegenwoordig steeds meer
geprobeerd om te voorspellen wat de effecten van geneesmiddelen in
patiënten zal zijn. 
Om te selecteren welke stoffen in ontwikkeling zullen worden genomen
wordt vaak gebruik gemaakt van een bedrijfskundige maat: de netto contante
waarde, of ‘Net Present Value’ (npv). De npv van een project kan worden
bepaald door de huidige waarde van de verwachte toekomstige opbrengsten
te berekenen en ze vervolgens op te tellen waarna van het gevonden getal de
initiële investering wordt afgetrokken. Bij de berekening van de npv van een
project wordt een vergelijk gemaakt tussen de situatie die ontstaat als het
project wel en niet wordt uitgevoerd. De waarde van toekomstige geld stro-
men is voornamelijk afhankelijk van de factor tijd (zo laat mogelijk geld uitge-
ven en zo snel mogelijk geld binnen krijgen). Hierdoor zijn de belangrijkste
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parameters die gebruikt worden om de npv van een project te optimaliseren:
lage ontwikkelingskosten, hoge opbrengsten bij introductie op de markt en
korte tijd tot introductie op de markt.
De moeilijkheid om bruikbare therapieën te ontwikkelen wordt niet opgelost
door de beschreven pogingen tot optimalisatie van aangrijpingspunt en het
ontwikkelingsproces. Daarom zou een structurele aanpak waarbij zowel
inhoud als procedures geoptimaliseerd worden mogelijk de succes kans kun-
nen vergroten en/of de kosten van niet-succesvolle stoffen kunnen reduce-
ren.
figure 1 Ontwikkelings proces van een nieuw geneesmiddel (http://www.fda.gov/cder/)
Traditionele ontwikkelingsfases
Het klinische ontwikkelingsprogramma van een geneesmiddel wordt traditio-
neel ingedeeld in 4 fases;
• Fase i: onderzoek in kleine groepen gezonde vrijwilligers. Traditioneel 
wordt in deze fase onderzocht bij welke dosering het geneesmiddel goed 
verdragen wordt en hoe het geneesmiddel wordt opgenomen in het 
lichaam en weer uitgescheiden wordt.
ref. 5-6
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• Fase ii: in deze fase wordt in beperkte patiënten groepen het eerste bewijs
geleverd voor de effectiviteit van het middel. Hierna wordt een dosis gese-
lecteerd die zowel veilig als effectief is.
• Fase iii: de dosering van het geneesmiddel zoals geselecteerd in de fase ii
studies wordt in detail getest op bijwerkingen en effectiviteit in duizenden
patiënten in grote onderzoeksprojecten waar meerdere ziekenhuizen en 
instellingen aan meewerken. Verder wordt in deze fase de effectiviteit van 
het middel vaak vergeleken met die van bestaande geneesmiddelen. 
Het betreft hier langdurige projecten en de effecten van het middel 
worden onderzocht na langdurige behandeling. Als deze fase afgerond 
is wordt het geneesmiddel geregistreerd en op de markt gebracht.
• Fase iv: van het geregistreerde geneesmiddel wordt bijgehouden of er 
onverwachte bijwerkingen of onverwachte interacties met andere genees-
middelen optreden.
De verschillende fases van het ontwikkelingsproces zijn weergegeven in
figuur 1. De beschrijving van deze fasen is typisch proces georiënteerd en
bevat weinig informatie over de wetenschappelijke aspecten van het middel
die eigenlijk worden onderzocht tijdens de ontwikkeling
Generieke hoofdvragen
Tijdens deze fasen moet eigenlijk een aantal generieke vragen worden beant-
woord. Het stellen van deze vragen gedurende de ontwikkeling van een mid-
del kom overeen met de Leer-Bevestig theorie zoals beschreven door
Sheiner. De belangrijkste generieke hoofdvragen zijn:
• Komt het middel op de plaats waar het zijn activiteit heeft?
Gerelateerde onderwerpen: absorptie, administratie route, biologische 
beschikbaarheid, distributie, weefsel distributie, accumulatie, action site 
penetratie, metabolisme, actieve metabolieten, metabolisme routes, 
excretie: hepatisch/renaal, klaring, halfwaarde tijd.
• Veroorzaakt het middel het bedoelde farmacologisch / functioneel effect?
Gerelateerde onderwerpen: effecten gerelateerd aan het werkingsme-
chanisme, additionele effecten van de primaire farmacologische activiteit,
effecten van de secondaire farmacologische activiteit, andere, ongewens-
te effecten.
• Heeft het geneesmiddel gunstige effecten op de klinische patofysiologie 
van de ziekte?
Gerelateerde onderwerpen: effecten op relevante fysiologische systemen, 
effecten op de ziekte, ongewenste klinische effecten.
ref. 7
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• Wat zijn de therapeutische grenzen van het middel?
Gerelateerde onderwerpen: klinische effecten bij een tolereerbare dose-
ring, doseringschema/interval, gecontroleerde geneesmiddel afgifte, 
effecten van het vergeten van medicatie binnen het doseringschema.
• Hoe beïnvloeden de bronnen van variabiliteit in geneesmiddel respons 
in de patiënt populatie de ontwikkeling van het product?
Gerelateerde onderwerpen: Therapietrouw, farmacogenetica, etnische 
verschillen, co-medicatie, variabiliteit in farmacokinetiek, farmacodyna-
miek en ziekte status.
Elk van deze vragen heeft een bepaalde kans om succesvol beantwoord te
worden, maar het beantwoorden van elk van deze vragen zal gepaard gaan
met bepaalde kosten. Deze set van kansen en kosten kan variëren per mid-
del. Wat voor het ene middel een moeilijk te beantwoorde vraag is kan rela-
tief eenvoudig zijn voor een ander geneesmiddel. Hierdoor heeft elk middel
een optimale ontwikkel strategie. Het in een vroeg stadium adequaat beant-
woorden van de meest relevante vragen is dus erg lucratief. npv analyse laat
zien dat het doen van deze additionele vroege fase studies naar de meest
relevante vragen alleen maar meer tijd en kosten introduceren waardoor de
totale npv van het project daalt. De npv van geneesmiddel ontwikkelings-
projecten reflecteert dus niet de waarde van toegevoegde kennis van het
middel. Een andere waardebepaling zou eigenlijk gebruikt moeten worden.
De optie gebaseerde theorie gaat uit van het feit dat een project in de ver-
schillende fases ook gestopt kan worden waardoor het belangrijk is zo vroeg
mogelijk te stoppen met de ontwikkeling van niet-succesvolle middelen.
Hierdoor worden de additionele waarde van vroege evaluatie studies en de
kansen adequaat geïncorporeerd in de waarde van het project. Deze metho-
de wordt echter zelden gebruikt in de praktijk en opties worden meestal
gedefinieerd als de klassieke beschrijving van het ontwikkelingstraject: de
fasen I, ii en iii worden weergegeven als beslispunten in een beslisboom.
Deze fasen zijn echter niet relevant als doel op zich in het ontwikkelingspro-
ces maar slechts een classificatie gebaseerd op het type studie en het aantal
patiënten dat betrokken is bij de studies. 
In dit proefschrift wordt een vraag gebaseerde aanpak van geneesmiddelont-
wikkeling gepostuleerd dat gebruik maakt van beslispunten die relevant zijn
voor de ontwikkeling van het geneesmiddel namelijk de vragen die eerder zijn
gedefinieerd. Deze vraag gebaseerde aanpak reflecteert de werkelijke onze-
kerheden en risico’s die genomen worden bij de ontwikkeling van een nieuw
middel. Verder kan deze methode aantonen dat de waarde van een project
toe kan nemen door het uitvoeren van een extra vroege fase studie die de
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relevante vragen helpt op te helderen. Deze studies kunnen voorkomen dat
niet-succesvolle middelen pas laat in de ontwikkeling worden gediscontinu-
eerd en daardoor aanzienlijk bijdragen aan de kosten van geneesmiddel ont-
wikkeling. Als de kansen en kosten behorend bij de verschillende ontwikke-
lingsvragen worden gedefinieerd kan met behulp van beslisboom analyse
worden aangetoond waar de knelpunten zitten in de ontwikkeling van het
betreffende middel. In vier secties worden in dit proefschrift voorbeelden van
het gebruik en de impact van de vraag gebaseerde aanpak gegeven.
Waarde van biomarker onderzoek
In Sectie 1 worden drie methodologische reviews over mogelijke biomarkers
voor de effecten van geneesmiddelen in gezonde vrijwilligers beschreven. 
De kans dat een vraag adequaat kan worden beantwoord is afhankelijk van
het middel en de beschikbare methoden om de vraag te kunnen beantwoor-
den. De npv analyse laat zien dat onderzoek naar en reviewen van biomar-
kers en methoden additionele kosten (en wellicht extra tijd) met zich mee
brengt. Daarmee wordt de totale projectwaarde lager. De vraag gebaseerde
aanpak laat juist zien dat de kennis van de beschikbare methode toegevoeg-
de waarde heeft voor de projectwaarde. De toegevoegde waarde kan behaald
worden doordat de kans dat de vraag succesvol wordt beantwoord vergroot
wordt of doordat een niet succesvol geneesmiddel vroeg uit ontwikkeling 
kan worden genomen. Er zijn momenteel geen gevalideerde biomarkers voor
antipsychotica in gezonde vrijwilligers. Een bruikbare biomarker moet in ieder
geval:
• Een consistente respons geven na toediening van verschillende middelen 
die hetzelfde therapeutisch effect hebben
• Een consistente respons geven bij therapeutische doseringen van het 
middel
• Een relatie tussen de dosering en de respons hebben
• Een plausibel verband hebben tussen de biomarker, de farmacologie van 
het middel en/of de pathofysiologie van de ziekte
Wanneer deze vereisten als filter worden toegepast op alle beschreven
methoden, dan blijkt dat er vele methoden niet erg bruikbaar zijn als biomar-
ker. In hoofdstuk 2 wordt beschreven dat alleen prolactine respons na anti-
psychotische middelen aan alle vereisten van bruikbare biomarkers voldoet.
In hoofdstuk 3 geldt hetzelfde voor maximale saccadische oogsnelheid als
biomarker voor de effecten van benzodiazepines in gezonde vrijwilligers.
Hoofdstuk 4 laat zien dat rem slaap als biomarker voor antidepressiva
momenteel van beperkte waarde is maar dat dit mogelijk komt door de
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inadequate modelering van de complexe structuur van de slaap. De review
gepresenteerd in deze sectie hebben allemaal invloed op de ‘pharmacology’
vraag. Sensitiviteitsanalyse van de kans op succesvol beantwoording van
deze vraag op de totale projectwaarde laat zien hoeveel de impact van deze
reviews is op de projectwaarde van een gemiddeld nieuw middel. Voorts
wordt aangetoond dat kennis over de beschikbare methoden de kans ver-
mindert dat een methode wordt geselecteerd dat geen effect laat zien van
therapeutisch relevante doseringen van een effectief middel. Daarmee kan
worden voorkomen dat er onnodige studies worden uitgevoerd bij mensen
en resources bespaard kunnen worden.
Waarde van timing additionele studies
Sectie 2 beschrijft een aantal studies bij een relatief kleine groep vrijwilligers
die gecombineerd adequaat antwoord geven op de vraag of een nieuwe
formulering van een bestaand middel het therapeutisch window en de klini-
sche effecten kan verbeteren. Gebruikmakend van bloeddruk en de meest
gevoelige biomarker voor de bijwerking sedatie (saccadische topsnelheid)
bleek het mogelijk om het therapeutisch window van de nieuwe formulering
te bepalen. Het uiteenvallen van de vertraagd afgifte tablet in vitro (in een
bekerglas) kon worden gecorreleerd aan de situatie in vivo (in het menselijk
lichaam). Gecombineerd bepaalden deze studies het optimale profiel van een
nieuwe formulering met betrekking tot therapeutische klinische werking bij
verdraagbare concentraties van het middel. Aangezien dit middel reeds een
poos op de markt is bleek de oorspronkelijke ontwikkeling geen adequaat
antwoord te hebben gegeven op deze vraag. Daarom zijn deze additionele
studies na registratie nodig geweest. De inclusie van deze studies in een
vroeg stadium van de oorspronkelijke ontwikkeling van rilmenidine zou heb-
ben geleid tot introductie van de optimale vertraagd afgifte tablet. Daarmee
zouden de extra kosten die gepaard gaan met de introductie van de nieuwe
formulering bespaard kunnen worden. De npv van dit hypothetisch ontwik-
kelingsplan zou waarschijnlijk lager zijn dan degene die daadwerkelijk is
gebruikt, maar het resultaat zou een formulering zijn die een groter markt-
segment zou kunnen bereiken. De waarde van de vergrootte kennis van het
middel door middel van deze studies zijn niet adequaat weer te geven in een
npv analyse in tegenstelling tot de vraag gebaseerde aanpak. Het inschatten
van de kansen op succesvolle beantwoording van de ‘window’ en ‘clinical’
vragen zou resulteren in een ontwikkelingsplan waarbij deze vragen vroeg 
in de ontwikkeling opgehelderd zouden moeten worden.
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Waarde van brug studies 
De introductie van nieuwe geneesmiddelen in Japan is steeds interessanter
voor westerse farmaceutische industrieën. Japan heeft een grote populatie
en de beschikbaarheid van westerse geneesmiddelen is relatief schaars. 
De Japanse registratie autoriteiten eisen vaak dat de klinische ontwikkelings
studies worden herhaald in Japanse vrijwilligers. In sommige gevallen zou
een vergelijkende studie tussen Japanse en westerse (Caucasische) vrijwilli-
gers / patiënten de noodzaak voor volledige herhaling van het ontwikkelings-
programma kunnen voorkomen. Deze Sectie 3 beschrijft twee vergelijkende
studies tussen de beide etnische groepen. De ‘population’ vraag zal niette-
min adequaat beantwoord moeten worden. Als er een verschil is in etnofar-
macologische factoren tussen Japanners en Caucasiërs, zal dit extra studies
in de Japanse populatie noodzakelijk maken. Daarom hebben vergelijkende
studies tussen de beide etnische groepen intrinsieke waarde. Deze toege-
voegde waarde kan tot uiting komen in twee opties: één optie is dat uit de
vergelijkende studie blijkt dat geen verschillen bestaan die doseringsaanpas-
sing nodig maken. Dit zou extrapolatie van de westerse data naar de Japanse
populatie mogelijk maken en daarmee extra studies in Japan voorkomen. Een
andere optie is de timing van de vergelijkende studies. Als de kans groot is
dat reactie op het middel vergelijkbaar is dan zal de vraag gebaseerde beslis-
boom laten zien dat het wijs is deze vraag laat in de ontwikkeling aan bod te
laten komen (er zijn immers meer cruciale vragen voor een dergelijk middel).
Als daarentegen de kans groot is dat een doseringsaanpassing nodig is in de
Japanse populatie dan zal de vroege vergelijkende studie aanzienlijk bijdragen
in de projectwaarde van het nieuwe geneesmiddel. Het voorbeeld in deze
sectie van het nieuwe anticonceptiemiddel illustreert dat het belangrijk is 
alle vragen in ogenschouw te nemen bij het ontwerpen van het geneesmid-
del ontwikkelingsprogramma. Ook al wordt de ‘population’ vraag belangrijk
ingeschat, dan nog kan het zijn dat andere vragen belangrijker zijn en daar-
mee meer impact op de ontwikkeling hebben. In dit voorbeeld zou de kans
dat aangetoond kan worden dat het middel een verbeterd bijwerkingsprofiel
heeft ten opzichte van bestaande middelen uit dezelfde klasse laag ingeschat
moeten worden. Daarmee is deze vraag belangrijker geworden dan de ‘popu-
lation’ vraag. Het middel uit het voorbeeld is dan ook gediscontinueerd om
deze reden. Het inschatten van de kansen volgens de vraag gebaseerde aan-
pak zou er toe hebben geleid dat dit van tevoren aan het licht was gekomen
en zou hebben voorkomen dat de vergelijkende studie uitgevoerd werd.
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Waarde van vroeg beantwoorden 
kritische vragen
In de laatste Sectie 4 staat de ontwikkeling van een nieuw middel tegen
angststoornissen met een nieuw werkingsmechanisme centraal. Het idee
achter het nieuwe werkingsmechanisme is dat, in tegenstelling tot bestaan-
de middelen uit deze klasse, een differentiatie van de klinische effecten kan
worden bereikt. Bestaande middelen zijn weliswaar effectief, maar veroorza-
ken ook bijwerkingen met name slaperigheid, vermindering van het geheu-
gen en duizeligheid. Het nieuwe werkingsmechanisme veronderstelt dat het
middel even effectief kan zijn met weinig of geen van de genoemde bijwer-
kingen. Om deze differentiatie te weeg te kunnen brengen moet het middel
uiteraard eerst op de plaats komen waar het zijn werking heeft; het brein.
Hierdoor zijn ‘pharmacology’ en ‘site’ de belangrijkste vragen voor dit nieuwe
middel. De gepresenteerde studie waarin de effecten op sedatie, geheugen
en lichaamsstabiliteit worden vergeleken met de marktleider uit deze klasse
zou in de npv analyse extra ontwikkelingskosten en wellicht tijd introduce-
ren. De studie toonde aan dat de differentiatie in effecten van het middel ook
in proefpersonen waarneembaar is. Op basis van deze studie kon een minder
sederende dosering kon geselecteerd worden om de effectiviteit in patiënten
te onderzoeken. Deze maximale dosering is cruciaal want het betreft de kern
van het marktvoordeel dat het middel kan hebben boven de bestaande mid-
delen. Door deze studie werd voorkomen dat de ontwikkeling van het middel
gestaakt wordt in een laat stadium omdat de verkeerde dosering was geko-
zen. De ‘site’ vraag is niet volledig beantwoord maar de effecten geobser-
veerd in deze studie zijn indicatief voor penetratie van het middel in het
brein.
Conclusies
Het gebruik van Net Present Value berekeningen geeft niet adequaat de toe-
gevoegde waarde van kennis weer. Het is, net als diverse andere benaderin-
gen, een poging om procedureel optimaliserend om te gaan met de onzeker-
heid die vast zit aan het ontwikkelen van nieuwe geneesmiddelen voor
complexe ziekten. Een vraag gebaseerde aanpak van dit probleem lijkt ratio-
neler en tot beter inzicht te leiden in de inhoudelijke kant van het genees-
middel ontwikkelingsproces. Daarnaast heeft deze aanpak implicaties voor
de uitvoering van het project en de selectie van de mogelijke nieuwe biolo-
gisch actieve stoffen. Het valt buiten het doel van dit proefschrift een een-
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duidig allesomvattend model te presenteren. Aan de hand van diverse voor-
beelden wordt geïllustreerd dat de combinatie van kansen op succes en bij-
behorende kosten een unieke set oplevert die per middel kan verschillen.
Daarnaast wordt aangetoond dat, zelfs bij gelijk blijvende overall kansen en
kosten, deze unieke set een optimale volgorde dicteert. Deze volgorde zou
dan ook moeten dienen als prioriteitenlijst door het gehele ontwikkelingspro-
gramma. Voorts heeft de vraag gebaseerde aanpak als voordeel dat experts
van de verschillende afdelingen die betrokken zijn bij de geneesmiddelont-
wikkeling samen overeenstemming krijgen over de kansen en bedreigingen
van hun nieuwe middel en daarmee mogelijke hiaten in kennis over de stof
tijdig kunnen aanvullen.
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